


A Multi-Omics Epidemiologic Study of Alzheimer's Disease



Shahzad Ahmad

A Multi-Omics Epidemiologic Study of Alzheimer's disease

SHAHZAD AHMAD

The work described in this thesis was conducted at the Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands.

The Erasmus Rucphen Family study as a part of EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947) and also received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/ grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme "Quality of Life and Management of the Living Resources" of 5th Framework Programme (no. QLG2-CT-2002-01254). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. All study participants, general practitioners, specialists, researchers, institutions and funders of all other studies from this thesis are appreciatively acknowledged.

The work presented in this thesis was supported by funded by the Defining Genetic, Polygenic and Environmental Risk for Alzheimer's Disease, using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics (PERADES) Programme (Project No. 733051021), the European Union Innovative Medicine Initiative (IMI) programme: the Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development (ADAPTED, Project No. 115975) and the Alzheimer's disease sequencing project (ADSP). Other support includes Horizon 2020 programme: CoSTREAM (Project No. 667375-2) and the Gut Liver Brain Biochemical Axis in Alzheimer's Disease (Project No. 1RF1AG058942-01) and AMP-AD project (U01-AG061359 NIA).

The publication and printing of this thesis was financially supported by the department of Epidemiology, Erasmus Medical Center, Rotterdam, Erasmus University Rotterdam, and Alzheimer Nederland.



Cover design: Shahzad Ahmad and Erwin Timmerman Optima.nl, postermywall.com

Layout: Marian Sloot Printing: ProefschriftMaken

ISBN/EAN: 978-94-6380-939-9

For articles published or accepted for publication, the copyright has been transferred to the respective publisher. No part of this thesis may be reproduced, stored in a retrieval system or transmitted in any form or by any means without the permission of the author, or, when appropriate, from the publishers of the manuscript.

A Multi-Omics Epidemiologic Study of Alzheimer's disease

Een multi-omics epidemiologische studie van de ziekte van Alzheimer

Thesis

to obtain the degree of Doctor from the
Erasmus University Rotterdam
by command of the
rector magnificus

Prof. dr. R.C.M.E. Engels

and in accordance with the decision of the Doctorate Board.
The public defence shall be held on

Thursday 1 October 2020 at 11:30 hours

by

Shahzad Ahmad

born in Kasur, Pakistan

Erasmus University Rotterdam

The Erasmus University logo, featuring the word "Erasmus" in a stylized, cursive script.

Doctoral Committee:

Promotor: Prof. dr.ir. C.M. Van Duijn

Other members: Prof. dr. T. Hankemeier
Prof. dr. M.A. Ikram
Prof. dr. F. Rivadeneira

Copromotor: Dr. N. Amin

Paranymphs: Hata Karamujić-Čomić
Ivana Prokić



قَالُوا سُبْحَانَكَ لَا عِلْمَ لَنَا إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ الْعَلِيمُ الْحَكِيمُ ❁

Dedicated to my parents, Ramzano Noor, and Noor Muhammad;

to my wife, Noreen, and my daughter, Minha;

to my teachers and mentors

Table of Contents

Chapter 1	General Introduction	13
Chapter 2	Genetics of Alzheimer's disease	35
2.1	Variation in cadherin genes in the 5p14.3 genomic region is implicated in Alzheimer's disease in an extended ADSP pedigree	37
Chapter 3	Pathways implicated in Alzheimer's disease and lifestyle factors	59
3.1	Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study	61
3.2	Genetic predisposition, modifiable risk factor profile and long-term dementia risk in the general population	81
Chapter 4	Proteomics and metabolomics of Alzheimer's disease	101
4.1	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in <i>APOE</i> ϵ 4 carriers	103
4.2	Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease	129
Chapter 5	Gut-Liver-Brain axis	153
5.1	Association of altered liver enzymes with Alzheimer's disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers	155
5.2	Altered bile acid profile associates with cognitive impairment in Alzheimer's disease – An emerging role for gut microbiome	179
5.3	The Alzheimer's disease genetic risk variant in <i>ABCA7</i> is associated to the gut microbiome	209
Chapter 6	General Discussion	225
Chapter 7	Summary / Samenvatting	245
Chapter 8	Appendix	251
8.1	Acknowledgements	253
8.2	PhD Portfolio	261
8.3	About the author	269

Publications and manuscripts in this thesis

Chapter 2

Shahzad Ahmad, Rafael A. Nafikov, Elizabeth Blue, Patrick A. Navas, Hata Karamujić-Čomić, Dina Vojinovic, Sven Van der Lee, Ashley van der Spek, Bowen Wang, Andrea R. Horimoto, Alejandro Q. Nato Jr, Harkirat K. Sohi, Mohamad Saad, Michael O. Dorschner, Debby Tsuang, Li-San Wang, CHARGE, ADSP Data Flow Work Group, ADSP Family Analysis Work Group, Lindsay A. Farrer, Jonathan L. Haines, Margaret Pericak-Vance, Gerard Schellenberg, Eric Boerwinkle, Richard P. Mayeux, M. Arfan Ikram, Anita DeStefano, Sudha Seshadri, Najaf Amin, Ellen M. Wijsman*, Cornelia M. Van Duijn* from the Alzheimer's disease sequencing project (ADSP). Variation in cadherin genes in the 5p14.3 genomic region is implicated in Alzheimer's disease in an extended ADSP pedigree. (Submitted)

*Senior authors contributed equally to the work

Chapter 3.1

Shahzad Ahmad, Christian Bannister, Sven J. van der Lee, Dina Vojinovic, Hieab H.H. Adams, Alfredo Ramirez, Valentina Escott-Price, Rebecca Sims, Emily Baker, Julie Williams, Peter Holmans, Meike W. Vernooij, M. Arfan Ikram, Najaf Amin, Cornelia M. van Duijn. Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. *The Alzheimer's and dementia: The Journal of the Alzheimer's Association*. 2018 July;14(7): 848–857

Chapter 3.2

Silvan Licher, Shahzad Ahmad, Hata Karamujić-Čomić, Trudy Voortman, Maarten J.G. Leening, M. Arfan Ikram and M. Kamran Ikram. Genetic predisposition, modifiable risk factor profile and long-term dementia risk in the general population. *Nature Medicine*. 2019 August; 25:1364–1369

Chapter 4.1

Shahzad Ahmad, Marta del Campo Milan, Oskar Hansson, Ayse Demirkan, Ruiz Agustin, Maria E Sáez, Nikolaos Giagtzoglou, Alfredo Cabrera-Socorro, Margot H.M. Bakker, Alfredo Ramirez, Thomas Hankemeier, Erik Stomrud, Niklas Mattsson-Carlgren, Philip Scheltens, Wiesje van der Flier, M. Arfan Ikram, Anders Malarstig, Charlotte E Teunissen, Najaf Amin, Cornelia M. van Duijn. CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in *APOE* ε4 carriers. *Scientific Reports*. 2020 May; 10:8233

Chapter 4.2

Shahzad Ahmad, Adelina Orellana, Isabelle Kohler, Lutz Frölich, Itziar de Rojas, Silvia Gil, Mercè Boada, Isabel Hernández, Lucrezia Hausner, Margot H.M. Bakker, Alfredo Cabrera-Socorro, Najaf Amin, Alfredo Ramírez, Agustín Ruiz, Thomas Hankemeier*, Cornelia M. Van Duijn*. Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. (Under revised submission in *Alzheimer's research and Therapy*)

*Senior authors contributed equally to the work

Chapter 5.1

Kwangsik Nho*, Alexandra Kueider-Paisley*, Shahzad Ahmad*, Siamak Mahmoudian Dehkordi, Matthias Arnold, Shannon L. Risacher, Gregory Louie, Colette Blach, Rebecca Baillie, Xianlin Han, Gabi Kastenmüller, John Q. Trojanowski, Leslie M. Shaw, Michael W. Weiner, P. Murali Doraiswamy, Cornelia van Duijn, Andrew J. Saykin#, Rima Kaddurah-Daouk#, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium.. Association of altered liver enzymes with Alzheimer's disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers. *JAMA Network Open*. 2019 Jul 3;2(7): e197978

*First authors contributed equally to the work

#Senior authors contributed equally to the work

Chapter 5.2

Siamak MahmoudianDehkordi*, Matthias Arnold*, Kwangsik Nho*, Shahzad Ahmad, Wei Jia, Guoxiang Xie, Gregory Louie, Alexandra Kueider-Paisley, M. Arthur Moseley, J. Will Thompson, Lisa St John Williams, Jessica D. Tenenbaum, Colette Blach, Rebecca Baillie, Xianlin Han, Sudeepa Bhattacharyya, Jon B. Toledo, Simon Schafferer, Sebastian Klein, Therese Koal, Shannon L. Risacher, Mitchel Allan Kling, Alison Motsinger-Reif, Daniel M. Rotroff, John Jack, Thomas Hankemeier, David A. Bennett, Philip L. De Jager, John Q. Trojanowski, Leslie M. Shaw, Michael W. Weiner, P. Murali Doraiswamy, Cornelia M. van Duijn, Andrew J. Saykin#, Gabi Kastenmüller#, Rima Kaddurah-Daouk#, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease – An emerging role for gut microbiome. *the Alzheimer's and dementia: The Journal of the Alzheimer's Association*. 2019 January;15(1): 76–92


*First authors contributed equally to the work

#Senior authors contributed equally to the work

Chapter 5.3


Shahzad Ahmad*, Hata Karamujić-Čomić*, Djawad Radjabzadeh*, Bruno Bonnechere, Dina Vojinovic, Thomas Hankemier, M. Arfan Ikram, Andre G. Uitterlinden, Rima Kaddurah-Daouk, Robert Kraaij, Najaf Amin, Cornelia M. van Duijn. The Alzheimer's disease genetic risk variant in *ABCA7* is associated to the gut microbiome. (In preparation)

*First authors contributed equally to the work



Chapter 1

General Introduction



Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for 50-70% of the worldwide dementia cases in elderly people^{1,2}. Almost 47 million individuals are reported to suffer from dementia worldwide, and this number is expected to double every 20 years^{1,3}. AD is characterized by progressive loss of memory, problems in executive functioning and daily life activities⁴. The prevalence of AD is rising sharply in aging populations⁵. The increasing disease burden is posing serious health and economic challenge in modern society.

Pathologically, AD is characterized by two hallmarks, amyloid-beta ($A\beta$) plaques and neurofibrillary tangles (NFTs). Plaques and tangles are primarily observed in brain regions involved in memory, learning and emotional behaviors, such as the hippocampus, entorhinal cortex, and amygdala⁶. Plaques are generated due to improper cleavage of amyloid precursor protein (*APP*), resulting in the formation of $A\beta$ monomers. These monomeric peptides aggregate to form the amyloid plaques that may damage the synapses and neurites. The *APP* gene is implicated in the causal pathway of at least a subgroup of patients because mutation carriers of the *APP* gene develop early-onset AD. NFTs are formed as a result of hyperphosphorylation of the microtubule-associated protein tau, leading to the disruption of axonal transport and neuronal damage^{7,8}. Alongside the two hallmarks of AD pathology, it has been recognized for long that AD pathology is accompanied by neuro-inflammation^{9,10}. Recent genetic studies have implicated the microglia and astrocytes as key players in the AD pathophysiology¹¹. Despite extensive research about the role of these core pathologies, unraveling the underpinning mechanism of AD pathology which contributes to the onset and progression of AD remains a challenge in achieving a suitable treatment and prevention of AD.

For decades, the diagnosis of AD was based on the criteria of Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV-TR)¹² and the National Institute of Neurological Disorders and Stroke–Alzheimer Disease and Related Disorders (NINCDS-ADRDA)¹³ working group, which were and are still commonly used in clinical research. These criteria rely on the initial identification of dementia symptoms followed by the assessment of clinical features of AD phenotype¹⁴. Clinically, these criteria support the diagnosis of a probable and possible AD, but definitive AD diagnosis relies on the histopathological confirmation of the clinical diagnosis¹⁵. However, advances in biomarker research have paved the way for a more accurate and reliable diagnosis of AD using structural magnetic resonance imaging (MRI) features, neuroimaging with positron emission topography (PET) and cerebrospinal fluid (CSF) pathology biomarkers and thus have forced a reconsideration of the established clinical diagnostic criteria¹⁴.

Recently, the National Institute on Aging and Alzheimer's Association (NIA-AA) Research Framework proposed A/T/N biomarker criteria to identify high-risk AD subjects. Where "A" indicates the $A\beta$ biomarker (CSF $A\beta$ -42 or cortical amyloid positron emission tomography [PET]); "T" refers to tau biomarker (CSF levels of phosphorylated tau or tau PET); and "N" represents the biomarker values of neuronal injury or neurodegeneration (structural MRI,

[¹⁸F]-fluorodeoxyglucose–PET, or CSF total tau)¹⁶. Although A/T/N biomarkers may assist to identify the high-risk subjects during the prodromal stage or even the preclinical phase of AD, CSF and MRI biomarkers are costly and invasive, and therefore not suitable for screening large populations. Discovery of less invasive blood-based biomarkers is needed which would allow screening of high-risk populations. A/T/N biomarkers are also increasingly being used to evaluate the relevance of new molecular pathways in AD pathophysiology.

Technological advancement has fueled multi-omics research in AD to unravel the underlying etiology of AD to enable treatment and early diagnosis of disease. AD is determined by a complex interplay of genetic and environmental risk factors¹⁷. Mounting evidence suggests the co-occurrence of cardiovascular risk factors (e.g., diabetes, hypertension and obesity) and classic AD neuropathology¹⁸⁻²⁰. Smoking, obesity, low education attainment, physical activity, and diet may contribute to an increased risk of AD²¹. A report from the *Lancet commission* acknowledged the epidemiological findings and suggested that 35% of the dementia risk can be reduced by modifying these cardiovascular and lifestyle-related risk factors²².

Preclinical and prodromal phase of AD

The AD pathogenesis can be conceptualized as a trajectory including the preclinical stage (presymptomatic), mild cognitive impairment (MCI) (early symptomatic or predementia), and AD dementia²³. The early preclinical stage of AD starts decades before the symptomatic phase²⁴ and it can be characterized by altered levels of biomarkers^{25,26} (Figure 1). Biomarkers may include both structural brain features at neuroimaging and biochemical changes in blood, and CSF^{27,28}. With regard to neuroimaging, MRI is employed to detect volumetric and structural changes to brain morphology and vascular features²⁹. MRI measures such as global cortical atrophy, hippocampal atrophy, and white matter hyperintensities are shown to be associated with cognitive measures and risk of dementia³⁰ and have increasingly been applied in healthy populations as biomarkers of AD diagnosis and its progression³¹. A recent development in PET tracers has allowed *in vivo* detection of A β abnormalities (imaging radiotracer: [¹⁸F]-florbetaben) and tau accumulations (¹⁸F-THK5351 and ¹⁸F-AV-1451) with high accuracy^{32,33}. Earlier studies have shown the association of tau PET binding with an increased amyloid pathology³⁴, brain structural atrophy³⁵, and glucose hypometabolism in preclinical AD individuals. Ongoing progress in tau PET scanning further holds the potential to monitor tau deposition during the early stages of neurodegeneration^{36,37}. The preclinical stage is regarded as the best stage for evaluating the genetic and metabolic risk factors involved in disease progression to AD. Advances in CSF and blood-based biomarkers detection made it possible to monitor pathophysiological processes in the preclinical stage of AD (Figure 1) but higher costs of MRI or PET scanning and invasive nature of CSF based methods make them less attractive for high-throughput population screening. There have been recent developments in research of blood-based markers³⁸. Future




Figure 1: Biomarkers of AD trajectory over time, presenting three stages of AD, presymptomatic stage, MCI and eventually AD dementia. Reprinted from Leclerc *et al.*²⁸ Abbreviations: MCI, mild cognitive impairment; MRI, magnetic resonance imaging; CSF, cerebrospinal fluid.

research should focus blood-based methods to discover biomarkers of preclinical stage which are relatively less invasive and cost-effective.

The second stage of AD is described by MCI due to AD, which is an early symptomatic prodementia phase²³ (Figure 1). Although there is an ongoing discussion, it is of note that 32% of the MCI patients progress into AD within five years; therefore, MCI is often viewed as a prodromal phase of AD dementia^{27,39}. Due to the high prevalence of MCI in the general population and the higher risk of MCI patient progression into AD compared with cognitively normal people^{40,41}, understanding the genetic and biochemical risk factors of MCI may unravel molecular pathways that are relevant for preventive intervention. MCI patients exhibit a 20% to 30% higher prevalence of cerebral amyloid pathology compared with cognitively normal subjects, which is two to three times higher in *APOE* ϵ 4 carriers compared to the noncarriers⁴². Multiple evidence suggests that CSF levels of A β -42, p-tau and total tau can be used to identify MCI patients who are at higher risk of developing into AD⁴³. Prediction sensitivity of CSF levels of A β -42 is 79% and specificity of 65%. P-tau has a sensitivity of 84% and specificity of 47%, while total-tau predicts AD conversion with a sensitivity of 86% and specificity of 56%⁴³. A recent study has reiterated the generalizability and robustness of CSF biomarker-based models for prediction of dementia in MCI patients (A β -42, p-tau and hippocampal volume)⁴⁴. The study basically constructed and tested various CSF biomarker-based models in multiple cohorts and shown the potential clinical implications of these models in predicting MCI to AD progression⁴⁴.

Omics research of Alzheimer's disease

Omics approaches refer to high-throughput technologies aiming to assess the molecular components of biological systems⁴⁵. Several layers of omics including genomics, epigenomics, proteomics, metabolomics, and microbiomics, are used to improve the understanding of etiology and pathophysiology of disease at the molecular level (Figure 2)⁴⁶. The aim of this thesis is to use a multi-omics approach to decipher the molecular pathways of AD.




Figure 2: Multi-omics layers and their interaction with environmental factors in biological systems.
Source: Adapted from Siroux *et al*⁴⁷.

Genetics

In the last decade, substantial advances in the discovery of genetic determinants of AD have been made. The genetic component of AD constitutes a major driving force of AD pathophysiology, and genetic discoveries over the years played a pivotal role in our current understanding of disease molecular mechanism. Based on the age at onset, AD patients who develop dementia before 65 years of age are classified as early-onset AD⁴⁸, of which almost half is contributed by mutations in three genes i.e., *PSEN1*⁴⁹, *PSEN2*⁵⁰ and *APP*⁵¹. Early-onset AD accounts for only 1-5 % of the total AD cases, of which 10-15 % cases follow autosomal dominant inheritance⁵². Most of the AD cases are sporadic in nature and often develop dementia after 65 years of age⁴⁸. The genetic

etiology of the late-onset AD patients is more complex and heritability is estimated to vary from 60% to 80%⁵³. To date, the $\epsilon 4$ allele of the *APOE* gene is the strongest common genetic risk variant for late-onset AD⁵⁴ and it confers AD risk in a dose-dependent manner. The *APOE* gene has three allelic variants $\epsilon 4$, $\epsilon 3$, and $\epsilon 2$, of which homozygote carriers of *APOE* $\epsilon 4$ allele have 50% higher lifetime risk of AD compared with 10% for non-carriers by age 85, while *APOE* $\epsilon 2$ allele is considered protective for AD^{55,56}. Although *APOE* $\epsilon 4$ allele has a frequency of nearly 25% in the general population⁵⁷, it is neither necessary nor sufficient to develop AD therefore not used alone for AD diagnosis^{58,59}. It is of note that at least one-third of the AD patients are *APOE* $\epsilon 4$ non-carriers, and nearly 50% homozygotes of *APOE* $\epsilon 4$ do not develop AD by age 80⁵⁷. In the Rotterdam Study, van der Lee *et al.*,⁶⁰ have shown that the other common genetic variants may also affect the risk of dementia, particularly in the *APOE* $\epsilon 4$ carriers. Despite the discovery of the *APOE* gene a two decades ago, its role in AD pathology remains unclear as there is a wide range of mechanisms of action of *APOE* in AD, and many questions remain to be answered. A recent study has suggested that *APOE* may contribute to the amyloid disposition in preclinical subjects whereas other common genetic factors may drive the progression of AD in amyloid positive individuals⁶¹. Disentangling the complex interaction of the *APOE* gene with lifestyle and systemic risk factors would provide new insights into the *APOE* molecular mechanism, and pathophysiology and risk of AD (see Chapter 3.2).

Technical and methodological advances in genotyping and genetic imputations have paved the way for genome-wide association studies (GWAS), which test the association of millions of single nucleotide polymorphism (SNPs) in the whole genome to disease status in individuals. In parallel, several international groups including the Alzheimer's Disease Genetics Consortium (ADGC), Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), and the Genetic and Environmental Risk in Alzheimer's Disease (GERAD) have joined their efforts under the umbrella of the International Genomics of Alzheimer's Project (IGAP) to push forward the growth in the genetics of AD. IGAP reported 11 novel loci in addition to replicating eight previously known genetic loci from earlier GWAS studies⁶²⁻⁶⁷. More recently, in January 2019, IGAP published the largest GWAS to date and reported five novel AD risk variants⁶⁸ (Figure 3). Moreover, Jansen *et al.*, conducted a GWAS largely based on the UK Biobank data (~635,000) using the family history of AD as 'proxy AD' and identified nine genetic variants, in addition to replicating few already existing risk loci⁶⁹. Together, various meta-analyses of GWAS studies have identified more than 39 risk loci for late-onset AD⁷⁰.

One of the major contributions of GWAS is providing insights into the biological pathways involved in AD. Pathway enrichment analysis based on data integration of ribonucleic acid (RNA) expression with AD GWAS meta-analysis results, identified eight gene pathways implicated in AD⁷¹ including *immune response*, *endocytosis*, *cholesterol transport*, *hematopoietic cell lineage*, *protein ubiquitination*, *hemostasis*, *clathrin/AP2 adaptor complex* and *protein folding*⁷². These diverse biological pathways may be involved in the clinically heterogeneous manifestation




Figure 3: Alzheimer's disease implicated genetic variants with respect to population frequency, effect size and implicated biological pathways. Modified reprint from Scheltens *et al.*³.

of MRI endophenotypes⁷³⁻⁷⁵, and may also modulate the prodromal stages of AD⁷⁶⁻⁷⁸. More recently Kunkle *et al.*,⁶⁸ is the first one to report the enrichment of the tau binding proteins and *APP* metabolism-related pathways in late-onset AD using GWAS data. Disentangling the role of AD implicated biological pathways in early AD pathology may help to improve our understanding of the pathogenesis of AD during the prodromal stage. In chapter 3.1 of this thesis, I have addressed several unanswered questions, including whether AD-related pathways are associated with brain structural and volumetric changes during the prodromal stage of AD, the incidence of MCI in the Rotterdam Study.

All known common SNPs explain only 16% of the variation in the clinical manifestation and 31% of the genetic variance of AD^{68,70,79}, leaving nearly 60% of the genetic risk uncharacterized⁸⁰. It is likely that rare variants missed out in imputation based GWAS may explain the remaining clinical and genetic variance of AD⁸¹, which reiterates the need to detect these rare variants using advanced genome sequencing techniques. Recently reported rare variant discoveries in *PLD3*, *APP*, *AB13*, *PLCG2*, and *TREM2* genes⁸²⁻⁸⁵ strengthen the notion that rare variants may fill the space of missing heritability of late-onset AD⁸⁶. Moreover, Alzheimer's disease sequencing project

(ADSP) has reported the association of three novel rare genetic variants in *IGHG3*, *AC099552.4* and in *ZNF655* genes⁸⁷. Advances in next-generation sequencing techniques made it possible to couple genetic linkage analysis with deep genetic information to identify rare genetic variants using family-based data⁸¹. Genetic linkage analysis is a classic approach to genetic discovery to identify genomic regions segregating with disease status in families with multiple affected individuals. Genetic linkage is based on the principle that genes that are located physically close to each other on the chromosome, also segregate together during meiosis⁸⁸. The availability of suitable multigenerational families of AD cases is one of the major shortcomings in the discovery of rare variants using linkage analysis⁸⁹. Extended pedigrees with multiple AD cases are expected to harbor highly penetrant variants, therefore they are ideally suited to identify disease loci⁹⁰. In chapter 2 of this thesis, I have studied the genetics of AD in complex multi-generation families of the highly inbred Genetic Research in Isolated Population (GRIP).

Proteomics

Unlike genes, protein levels can be influenced by several factors such as environment, disease stage, medication use, diet patterns. Since disease-related molecular changes are reflected at transcriptome and proteome level, proteomics can be exploited to discover disease biomarkers, targets for treatment, and to understand the disease pathophysiology⁹¹. One of the major contributions of the genomic studies is to provide insight into the protein functions⁹². Evidence suggests that the majority of AD implicated genes are expressed in blood-derived macrophages^{68,93,94} and can modulate the protein expression levels in the blood circulation. Moreover, the interaction of *APOE* with common genetic pathways⁶⁰ and its impact on blood-brain barrier integrity⁹⁵ can lead to altered blood protein levels which may represent AD brain pathophysiology⁹⁶. Large scale proteomic studies are now emerging in AD research⁹⁷⁻¹⁰² and already have identified altered levels of proteins in the circulation, representing signaling, synaptic and oxidative stress-related pathophysiology^{103,104}. There is an increasing interest in the relationship between altered levels of proteins and AD in the presymptomatic stage. Prospective studies targeting various protein pathways and their interaction with genetic risk factors such as *APOE* would provide new insight into biomarkers and pathways altered prior to the onset of AD. In this thesis (Chapter 4.1), I studied the association of plasma levels of proteins profiled during the predementia stage of AD and their interaction with *APOE* in the Rotterdam Study.

Metabolomics

Advances in high-throughput metabolomics allowed the detection of hundreds of biochemical compounds (metabolites) in blood, CSF, urine and brain tissues¹⁰⁵. Metabolic imprints represent complex interactions of genes, proteins, and environmental factors, thus helping to provide deep

insight into disease pathophysiology^{105,106}. Metabolomics may provide promising biomarkers for disease progression due to the complex and dynamic nature of the AD continuum, and because blood metabolic repertoire usually reflects CSF and brain biochemical changes^{107,108}. Metabolomic studies on tissue samples of MCI and AD patients have suggested altered metabolic function in the preclinical¹⁰⁹⁻¹¹¹ and clinical stages of AD¹¹¹⁻¹¹³. Increasing evidence suggests the role of altered levels of metabolites in several key AD related pathways including lipid metabolism, amino acid metabolism, energy metabolism oxidative stress, synaptic function, cell signaling, and inflammation^{114,115}. Until now, among all pathways identified by metabolomic studies, lipid-related metabolites provide the strongest and most consistent evidence of association with AD which is also supported by the role of *APOE* in lipid uptake and transport¹¹¹. Several lipid classes have been linked to dementia so far, such as phospholipids, sphingolipids, sterols, sphingomyelins, and phosphatidylcholines^{4,108,111,115-117}. Due to the huge risk attributed by *APOE* and its role in lipid transport, the interaction of *APOE* with lipid metabolites need special attention. Moreover, studies are needed that address the role of signaling lipids in AD pathophysiology and in AD progression. In chapter 4.2 of this thesis, I performed an investigation which evaluate the role of signaling lipids (lysophosphatidic acids) in AD. This study was conducted in cohorts participating in the Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development (ADAPTED) consortium including the Barcelona-based memory clinic Fundació ACE and the Department of Geriatric Psychiatry at the Medical Faculty Mannheim, University of Heidelberg.

Gut-liver-brain axis

Evidence of metabolic dysfunction in AD trajectory¹¹⁸ and increased risk of AD contributed by metabolic disorders (diabetics, hypertension, and obesity), strengthen the notion that AD metabolic disorders play a key role in either etiology or progression of disease¹¹⁹⁻¹²². Disturbed energy metabolism^{123,124} and altered gut microbiota in AD animal models¹²⁵⁻¹²⁷, all point to the complex interplay of liver and gut in AD pathophysiology. Studies addressing the determinants of the liver, gut microbiome, and brain biochemical communication and their relationship to AD pathogenesis could help to understand the unknown role of the Gut-Liver-Brain axis in AD. The liver being a major metabolic organ can directly influence the metabolic milieu of circulation^{128,129} or indirectly via the production of bile acids which can modulate the gut microbiota composition^{130,131} (Figure 4). Although several studies suggest the association of liver disease with brain structural features, cognition and dementia¹³²⁻¹³⁴, there are many questions to answer on the role of liver function biomarkers in AD pathophysiology. In this thesis (chapter 5.1), I describe the association of liver function biomarkers with biomarkers of AD pathophysiology in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.

Another integral component of gut-liver brain axis is the gut microbiota, which makes up to 95% of the total human microbiota¹³⁵. The gut microbiota can regulate the levels of metabolites, cytokines, immunological and neuronal signals¹³⁵⁻¹³⁸, thus physiologically connecting the gut, the




Figure 4: Gut-liver-brain axis. Abbreviations: BBB, blood-brain barrier; SCFA, Short-chain fatty acids; ASAT, Aspartate aminotransferase; ALAT, Alanine aminotransferase. Source: Adapted from Tripathi *et al*¹⁴⁸.

brain, and liver¹³⁹ (Figure 4). Secondary bile acids represent an important microbial-derived class of metabolites¹⁴⁰ which can cross blood-brain barrier¹⁴¹ and act as signaling molecules to regulate the molecular processes in the central nervous system including the energy homeostasis¹⁴². In Chapter 5.2 of this thesis, I have studied the role of bile acid metabolites in AD in the ADNI and the Rotterdam Study cohorts. Gut microbial diversity is also known to affect levels of short-chain fatty acids such as butyrate, acetate, and propionate in circulation, which may affect inflammatory, *immune response* and the blood-brain barrier function^{143,144} (Figure 4). Moreover, increasing evidence from genetic studies implicate *immune response* and brain resident microglia in early phase of AD^{145,146}. Function of microglial cells can also be modulated by signaling molecules originating from the gut microbiota, thus, microglia can act at the junction of the gut brain-axis in AD^{146,147}. The complex relationship between AD genes, microglia, and microbiota poses another unanswered question i.e., whether, AD risk genes can modify human gut microbial abundance in a non-demented population. Answering this question would help to identify bacterial taxa involved in AD pathophysiology.

Scope of this thesis

The aim of this thesis is to identify the genetic, metabolic and proteomic determinants of AD and to evaluate the interaction of lifestyle factors with the genetic risk of AD.

In **chapter 2**, I present a genetic linkage analysis to identify the genomic regions linked with AD in complex inbred Dutch families and subsequently used whole-genome sequencing to identify the rare genetic variants in the identified linkage region.

Chapter 3 explores the role of AD pathways in the prodementia phase of AD and the interaction of lifestyle factors in AD genetic risk. In **chapter 3.1**, I study the association of AD implicated biological pathways with MCI and brain structural features in a healthy population. **Chapter 3.2** provides insight into the role of modifiable lifestyle factors in the genetic risk of dementia in the Rotterdam Study.

Chapter 4 studies the metabolic and proteomic determinants of AD. **Chapter 4.1** explores the altered levels of brain-specific proteins in the blood prior to the onset of AD in a prospective manner and whether *APOE* can influence this association. I studied the role of lysophosphatidic acids in AD pathophysiology in the MCI population and their role in progression to AD in **Chapter 4.2**.

Chapter 5 studies the determinants of the liver-gut-brain axis in AD. **Chapter 5.1** highlights the role of liver function in AD pathology and their relationship with various endophenotypes of AD. **Chapter 5.2** focusses on the relationship of bile acids with AD, cognition and AD genetic variants. In **chapter 5.3**, I study the impact of AD genetic risk factors on the abundance of various gut microbiota in the healthy population.

The findings are integrated and discussed in general discussion (**Chapter 6**)

References

1. Winblad, B. *et al.* Defeating Alzheimer's disease and other dementias: a priority for European science and society. *Lancet Neurol* **15**, 455-532 (2016).
2. Rosenthal, S.L. & Kamboh, M.I. Late-Onset Alzheimer's Disease Genes and the Potentially Implicated Pathways. *Curr Genet Med Rep* **2**, 85-101 (2014).
3. Scheltens, P. *et al.* Alzheimer's disease. *Lancet* (2016).
4. Tochel, C. *et al.* What outcomes are important to patients with mild cognitive impairment or Alzheimer's disease, their caregivers, and health-care professionals? A systematic review. *Alzheimers Dement (Amst)* **11**, 231-247 (2019).
5. Guerreiro, R. & Bras, J. The age factor in Alzheimer's disease. *Genome Med* **7**, 106 (2015).
6. Mattson, M.P. Pathways towards and away from Alzheimer's disease. *Nature* **430**, 631 (2004).
7. Iqbal, K., Liu, F., Gong, C.-X. & Grundke-Iqbal, I. Tau in Alzheimer disease and related tauopathies. *Current Alzheimer Research* **7**, 656-664 (2010).
8. Eid, A., Mhatre, I. & Richardson, J.R. Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. *Pharmacology & therapeutics* **199**, 173-187 (2019).
9. Heneka, M.T. *et al.* Neuroinflammation in Alzheimer's disease. *The Lancet Neurology* **14**, 388-405 (2015).
10. Bradburn, S., Murgatroyd, C. & Ray, N. Neuroinflammation in mild cognitive impairment and Alzheimer's disease: A meta-analysis. *Ageing research reviews* (2019).
11. Morales, I., Jiménez, J.M., Mancilla, M. & Maccioni, R.B. Tau oligomers and fibrils induce activation of microglial cells. *Journal of Alzheimer's Disease* **37**, 849-856 (2013).
12. Association, A.P. *Diagnostic criteria from dsM-iV-tr*, (American Psychiatric Pub, 2000).
13. McKhann, G.M. *et al.* The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's & dementia* **7**, 263-269 (2011).
14. Dubois, B. *et al.* Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. *The Lancet Neurology* **6**, 734-746 (2007).
15. Morris, E. *et al.* Diagnostic accuracy of 18 F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *European journal of nuclear medicine and molecular imaging* **43**, 374-385 (2016).
16. Jack, C.R., Jr. *et al.* NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement* **14**, 535-562 (2018).
17. Borenstein, A.R., Copenhagen, C.I. & Mortimer, J.A. Early-life risk factors for Alzheimer disease. *Alzheimer Dis Assoc Disord* **20**, 63-72 (2006).
18. Qiu, C., Xu, W. & Fratiglioni, L. Vascular and psychosocial factors in Alzheimer's disease: epidemiological evidence toward intervention. *J Alzheimers Dis* **20**, 689-97 (2010).
19. Barnes, D.E. & Yaffe, K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. *Lancet Neurol* **10**, 819-28 (2011).

20. Attems, J. & Jellinger, K.A. The overlap between vascular disease and Alzheimer's disease—lessons from pathology. *BMC medicine* **12**, 206 (2014).
21. Scheltens, P. *et al.* Alzheimer's disease. *Lancet* **388**, 505-17 (2016).
22. Broce, I.J. *et al.* Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer's disease. *Acta Neuropathologica* **137**, 209-226 (2019).
23. Sperling, R.A. *et al.* Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 280-92 (2011).
24. Morris, J. Early-stage and preclinical Alzheimer disease. *Alzheimer disease and associated disorders* **19**, 163 (2005).
25. Jack Jr, C.R. *et al.* Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *The Lancet Neurology* **9**, 119-128 (2010).
26. Godbolt, A.K. *et al.* A decade of pre-diagnostic assessment in a case of familial Alzheimer's disease: tracking progression from asymptomatic to MCI and dementia. *Neurocase* **11**, 56-64 (2005).
27. Jack, C.R., Jr. *et al.* Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *Lancet Neurol* **9**, 119-28 (2010).
28. Leclerc, B. & Abulrob, A. Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. *ScientificWorldJournal* **2013**, 589308 (2013).
29. Lockhart, S.N. & DeCarli, C. Structural imaging measures of brain aging. *Neuropsychology review* **24**, 271-289 (2014).
30. Dettre, S. *et al.* Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. *Stroke* **41**, 600-606 (2010).
31. Frisoni, G.B., Fox, N.C., Jack Jr, C.R., Scheltens, P. & Thompson, P.M. The clinical use of structural MRI in Alzheimer disease. *Nature Reviews Neurology* **6**, 67 (2010).
32. Presotto, L. *et al.* Low-dose CT for the spatial normalization of PET images: A validation procedure for amyloid-PET semi-quantification. *NeuroImage: Clinical* **20**, 153-160 (2018).
33. Jang, Y.K. *et al.* Head to head comparison of [(18)F] AV-1451 and [(18)F] THK5351 for tau imaging in Alzheimer's disease and frontotemporal dementia. *Eur J Nucl Med Mol Imaging* **45**, 432-442 (2018).
34. Mishra, S. *et al.* AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure. *Neuroimage* **161**, 171-178 (2017).
35. LaPoint, M.R. *et al.* The association between tau PET and retrospective cortical thinning in clinically normal elderly. *Neuroimage* **157**, 612-622 (2017).
36. Leuzy, A. *et al.* Tau PET imaging in neurodegenerative tauopathies—still a challenge. *Molecular psychiatry* **24**, 1112-1134 (2019).
37. Saint-Aubert, L. *et al.* Tau PET imaging: present and future directions. *Molecular neurodegeneration* **12**, 19 (2017).
38. Nakamura, A. *et al.* High performance plasma amyloid- β biomarkers for Alzheimer's disease. *Nature* **554**, 249 (2018).

39. Ward, A., Tardiff, S., Dye, C. & Arrighi, H.M. Rate of conversion from prodromal Alzheimer's disease to Alzheimer's dementia: a systematic review of the literature. *Dementia and geriatric cognitive disorders extra* **3**, 320-332 (2013).
40. Taragano, F.E., Allegri, R.F. & Lyketsos, C. Mild behavioral impairment: A prodromal stage of dementia. *Dement Neuropsychol* **2**, 256-260 (2008).
41. Wilson, R.S., Leurgans, S.E., Boyle, P.A. & Bennett, D.A. Cognitive decline in prodromal Alzheimer disease and mild cognitive impairment. *Arch Neurol* **68**, 351-6 (2011).
42. Jansen, W.J. *et al.* Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA* **313**, 1924-38 (2015).
43. Mattsson, N. *et al.* CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA* **302**, 385-93 (2009).
44. van Maurik, I.S. *et al.* Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *The Lancet Neurology* **18**, 1034-1044 (2019).
45. Bersanelli, M. *et al.* Methods for the integration of multi-omics data: mathematical aspects. *BMC bioinformatics* **17**, S15 (2016).
46. Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. *Genome biology* **18**, 83 (2017).
47. Siroux, V., Agier, L. & Slama, R. The exposome concept: a challenge and a potential driver for environmental health research. *Eur Respir Rev* **25**, 124-9 (2016).
48. Rossor, M.N., Fox, N.C., Mummery, C.J., Schott, J.M. & Warren, J.D. The diagnosis of young-onset dementia. *The Lancet Neurology* **9**, 793-806 (2010).
49. Sherrington, R. *et al.* Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. *Nature* **375**, 754 (1995).
50. Levy-Lahad, E. *et al.* Candidate gene for the chromosome 1 familial Alzheimer's disease locus. *Science* **269**, 973-977 (1995).
51. Goate, A. *et al.* Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* **349**, 704 (1991).
52. Jarmolowicz, A.I., Chen, H.Y. & Panegyres, P.K. The patterns of inheritance in early-onset dementia: Alzheimer's disease and frontotemporal dementia. *Am J Alzheimers Dis Other Demen* **30**, 299-306 (2015).
53. Alzheimer's, A. 2015 Alzheimer's disease facts and figures. *Alzheimer's & dementia: the journal of the Alzheimer's Association* **11**, 332 (2015).
54. Corder, E.H. *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-3 (1993).
55. Corder, E.H. *et al.* Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* **7**, 180-4 (1994).
56. Seshadri, S., Drachman, D.A. & Lippa, C.F. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. *Arch Neurol* **52**, 1074-9 (1995).
57. Farrer, L.A. *et al.* Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis. *Jama* **278**, 1349-1356 (1997).


58. Meyer, M.R. *et al.* APOE genotype predicts when—not whether—one is predisposed to develop Alzheimer disease. *Nature genetics* **19**, 321 (1998).
59. Verghese, P.B., Castellano, J.M. & Holtzman, D.M. Apolipoprotein E in Alzheimer's disease and other neurological disorders. *The Lancet Neurology* **10**, 241-252 (2011).
60. van der Lee, S.J. *et al.* The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *The Lancet Neurology* **17**, 434-444 (2018).
61. Leonenko, G. *et al.* Genetic risk for Alzheimer's disease is distinct from genetic risk for amyloid deposition. *Annals of neurology* (2019).
62. Lambert, J.C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-8 (2013).
63. Lambert, J.C. *et al.* Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* **41**, 1094-9 (2009).
64. Genin, E. *et al.* APOE and Alzheimer disease: a major gene with semi-dominant inheritance. *Mol Psychiatry* **16**, 903-7 (2011).
65. Seshadri, S. *et al.* Genome-wide analysis of genetic loci associated with Alzheimer disease. *JAMA* **303**, 1832-40 (2010).
66. Hollingworth, P. *et al.* Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* **43**, 429-35 (2011).
67. Naj, A.C. *et al.* Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* **43**, 436-41 (2011).
68. Kunkle, B.W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430 (2019).
69. Jansen, I.E. *et al.* Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. (2019).
70. Kamboh, M.I. A brief synopsis on the genetics of Alzheimer's disease. *Current genetic medicine reports* **6**, 133-135 (2018).
71. Karch, C.M. & Goate, A.M. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biol Psychiatry* **77**, 43-51 (2015).
72. International Genomics of Alzheimer's Disease, C. Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimers Dement* **11**, 658-71 (2015).
73. Van der Flier, W.M. Clinical heterogeneity in familial Alzheimer's disease. *Lancet Neurol* **15**, 1296-1298 (2016).
74. Becker, J.T., Huff, F.J., Nebes, R.D., Holland, A. & Boller, F. Neuropsychological function in Alzheimer's disease. Pattern of impairment and rates of progression. *Arch Neurol* **45**, 263-8 (1988).
75. Mann, U.M., Mohr, E., Gearing, M. & Chase, T.N. Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. *J Neurol Neurosurg Psychiatry* **55**, 956-9 (1992).
76. Petersen, R.C. *et al.* Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* **56**, 303-8 (1999).

77. Gauthier, S. *et al.* Mild cognitive impairment. *Lancet* **367**, 1262-70 (2006).
78. Petersen, R.C. Mild cognitive impairment as a diagnostic entity. *Journal of internal medicine* **256**, 183-194 (2004).
79. Ridge, P.G. *et al.* Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiology of aging* **41**, 200. e13-200. e20 (2016).
80. Grozeva, D., Saad, S., Menzies, G.E. & Sims, R. Benefits and Challenges of Rare Genetic Variation in Alzheimer's Disease. *Current Genetic Medicine Reports* **7**, 53-62 (2019).
81. Ott, J., Wang, J. & Leal, S.M. Genetic linkage analysis in the age of whole-genome sequencing. *Nat Rev Genet* **16**, 275-84 (2015).
82. Guerreiro, R. *et al.* TREM2 variants in Alzheimer's disease. *N Engl J Med* **368**, 117-27 (2013).
83. Jonsson, T. *et al.* Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med* **368**, 107-16 (2013).
84. Cruchaga, C. *et al.* Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature* **505**, 550-4 (2014).
85. Sims, R. *et al.* Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature genetics* **49**, 1373 (2017).
86. Kunkle, B.W. *et al.* Genome-wide linkage analyses of non-Hispanic white families identify novel loci for familial late-onset Alzheimer's disease. *Alzheimers Dement* (2015).
87. Bis, J.C. *et al.* Whole exome sequencing study identifies novel rare and common Alzheimer's-associated variants involved in immune response and transcriptional regulation. *Molecular psychiatry*, 1 (2018).
88. Pulst, S.M. Genetic linkage analysis. *Archives of neurology* **56**, 667-672 (1999).
89. Liu, F. *et al.* A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. *Am J Hum Genet* **81**, 17-31 (2007).
90. Jun, G. *et al.* Evaluating the contribution of rare variants to type 2 diabetes and related traits using pedigrees. *Proc Natl Acad Sci U S A* **115**, 379-384 (2018).
91. Lovestone, S. *et al.* Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers. *Expert review of proteomics* **4**, 227-238 (2007).
92. Braun, P. & LaBaer, J. High throughput protein production for functional proteomics. *Trends in biotechnology* **21**, 383-388 (2003).
93. Henstridge, C.M., Hyman, B.T. & Spires-Jones, T.L. Beyond the neuron–cellular interactions early in Alzheimer disease pathogenesis. *Nature Reviews Neuroscience*, 1 (2019).
94. Colonna, M. TREMs in the immune system and beyond. *Nat Rev Immunol* **3**, 445-53 (2003).
95. Bell, R.D. *et al.* Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* **485**, 512-6 (2012).
96. Zipser, B.D. *et al.* Microvascular injury and blood–brain barrier leakage in Alzheimer's disease. *Neurobiology of aging* **28**, 977-986 (2007).
97. Ray, S. *et al.* Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. *Nature medicine* **13**, 1359 (2007).

98. Soares, H.D. *et al.* Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. *Archives of neurology* **69**, 1310-1317 (2012).
99. Ringman, J.M. *et al.* Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. *Archives of neurology* **69**, 757-764 (2012).
100. Hu, W.T. *et al.* Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology* **79**, 897-905 (2012).
101. Llano, D.A., Devanarayan, V., Simon, A.J. & Alzheimer's Disease Neuroimaging, I. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. *Alzheimer Disease & Associated Disorders* **27**, 233-243 (2013).
102. Hye, A. *et al.* Proteome-based plasma biomarkers for Alzheimer's disease. *Brain* **129**, 3042-50 (2006).
103. Swomley, A.M. *et al.* Abeta, oxidative stress in Alzheimer disease: evidence based on proteomics studies. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* **1842**, 1248-1257 (2014).
104. Schonberger, S.J., Edgar, P.F., Kydd, R., Faull, R.L. & Cooper, G.J. Proteomic analysis of the brain in Alzheimer's disease: molecular phenotype of a complex disease process. *PROTEOMICS: International Edition* **1**, 1519-1528 (2001).
105. Johnson, C.H., Ivanisevic, J. & Siuzdak, G. Metabolomics: beyond biomarkers and towards mechanisms. *Nature reviews Molecular cell biology* **17**, 451-459 (2016).
106. Menni, C., Zierer, J., Valdes, A.M. & Spector, T.D. Mixing omics: combining genetics and metabolomics to study rheumatic diseases. *Nature Reviews Rheumatology* **13**, 174 (2017).
107. Fiandaca, M.S. *et al.* Plasma 24-metabolite panel predicts preclinical transition to clinical stages of Alzheimer's disease. *Frontiers in neurology* **6**, 237 (2015).
108. Varma, V.R. *et al.* Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. *PLoS medicine* **15**, e1002482 (2018).
109. Koal, T., Klavins, K., Seppi, D., Kemmler, G. & Humpel, C. Sphingomyelin SM (d18: 1/18: 0) is Significantly Enhanced in Cerebrospinal Fluid Samples Dichotomized by Pathological Amyloid- β 42, Tau, and Phospho-Tau-181 Levels. *Journal of Alzheimer's Disease* **44**, 1193-1201 (2015).
110. Snowden, S.G. *et al.* Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study. *PLoS medicine* **14**, e1002266 (2017).
111. Toledo, J.B. *et al.* Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimer's & Dementia* **13**, 965-984 (2017).
112. Paglia, G. *et al.* Unbiased metabolomic investigation of Alzheimer's disease brain points to dysregulation of mitochondrial aspartate metabolism. *Journal of proteome research* **15**, 608-618 (2016).
113. Graham, S.F. *et al.* Untargeted metabolomic analysis of human plasma indicates differentially affected polyamine and L-arginine metabolism in mild cognitive impairment subjects converting to Alzheimer's disease. *PLoS One* **10**, e0119452 (2015).


114. Wilkins, J.M. & Trushina, E. Application of metabolomics in Alzheimer's disease. *Frontiers in neurology* **8**, 719 (2018).
115. Jiang, Y. *et al.* Metabolomics in the development and progression of dementia: A systematic review. *Frontiers in Neuroscience* **13**, 343 (2019).
116. van der Lee, S.J. *et al.* Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. *Alzheimer's & Dementia* **14**, 707-722 (2018).
117. Tynkkynen, J. *et al.* Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts. *Alzheimer's & Dementia* **14**, 723-733 (2018).
118. Willette, A. Does metabolic syndrome impact cognition and emotion in Alzheimer's disease? *European journal of neurology* **23**, 237-238 (2016).
119. Craft, S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. *Archives of neurology* **66**, 300-305 (2009).
120. Wang, X.-F. *et al.* Linking Alzheimer's disease and type 2 diabetes: Novel shared susceptibility genes detected by cFDR approach. *Journal of the neurological sciences* **380**, 262-272 (2017).
121. Rios, J.A., Cisternas, P., Arrese, M., Barja, S. & Inestrosa, N.C. Is Alzheimer's disease related to metabolic syndrome? A Wnt signaling conundrum. *Progress in neurobiology* **121**, 125-146 (2014).
122. Demetrius, L.A. & Driver, J. Alzheimer's as a metabolic disease. *Biogerontology* **14**, 641-649 (2013).
123. Kapogiannis, D. & Mattson, M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. *The Lancet Neurology* **10**, 187-198 (2011).
124. Clarke, J.R., Ribeiro, F.C., Frozza, R.L., De Felice, F.G. & Lourenco, M.V. Metabolic dysfunction in Alzheimer's disease: from basic neurobiology to clinical approaches. *Journal of Alzheimer's Disease* **64**, S405-S426 (2018).
125. Harach, T. *et al.* Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. *Scientific reports* **7**, 41802 (2017).
126. Harach, T. *et al.* Reduction of Alzheimer's disease beta-amyloid pathology in the absence of gut microbiota. *arXiv preprint arXiv:1509.02273* (2015).
127. Bäuerl, C., Collado, M.C., Diaz Cuevas, A., Viña, J. & Pérez Martínez, G. Shifts in gut microbiota composition in an APP/PSS 1 transgenic mouse model of Alzheimer's disease during lifespan. *Letters in applied microbiology* **66**, 464-471 (2018).
128. Jin, R. *et al.* Amino acid metabolism is altered in adolescents with nonalcoholic fatty liver disease—An untargeted, high resolution metabolomics study. *The Journal of pediatrics* **172**, 14-19. e5 (2016).
129. Kalhan, S.C. *et al.* Plasma metabolomic profile in nonalcoholic fatty liver disease. *Metabolism* **60**, 404-413 (2011).
130. Kakiyama, G. *et al.* Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. *Journal of hepatology* **58**, 949-955 (2013).
131. Frimmer, M. & Ziegler, K. The transport of bile acids in liver cells. *Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes* **947**, 75-99 (1988).
132. Bertolotti, M. *et al.* Nonalcoholic fatty liver disease and aging: epidemiology to management. *World journal of gastroenterology: WJG* **20**, 14185 (2014).


133. Yilmaz, Y. & Ozdogan, O. Liver disease as a risk factor for cognitive decline and dementia: An Under-recognized issue. *Hepatology* **49**, 698-698 (2009).
134. Weinstein, G. *et al.* Association of nonalcoholic fatty liver disease with lower brain volume in healthy middle-aged adults in the Framingham study. *JAMA neurology* **75**, 97-104 (2018).
135. Sochocka, M. *et al.* The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer's disease—a critical review. *Molecular neurobiology* **56**, 1841-1851 (2019).
136. Le Chatelier, E. *et al.* Richness of human gut microbiome correlates with metabolic markers. *Nature* **500**, 541 (2013).
137. Foster, J.A. & McVey Neufeld, K.A. Gut-brain axis: how the microbiome influences anxiety and depression. *Trends Neurosci* **36**, 305-12 (2013).
138. Eid, A., Mhatre, I. & Richardson, J.R. Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine. *Pharmacol Ther* **199**, 173-187 (2019).
139. Nicholson, J.K. *et al.* Host-gut microbiota metabolic interactions. *Science* **336**, 1262-1267 (2012).
140. Shea, H.C., Head, D.D., Setchell, K.D. & Russell, D.W. Analysis of HSD3B7 knockout mice reveals that a 3 α -hydroxyl stereochemistry is required for bile acid function. *Proceedings of the National Academy of Sciences* **104**, 11526-11533 (2007).
141. Ackerman, H.D. & Gerhard, G.S. Bile Acids in Neurodegenerative Disorders. *Front Aging Neurosci* **8**, 263 (2016).
142. Chiang, J.Y. Bile acid metabolism and signaling. *Compr Physiol* **3**, 1191-212 (2013).
143. Correa-Oliveira, R., Fachi, J.L., Vieira, A., Sato, F.T. & Vinolo, M.A. Regulation of immune cell function by short-chain fatty acids. *Clin Transl Immunology* **5**, e73 (2016).
144. Stanley, C.A. New genetic defects in mitochondrial fatty acid oxidation and carnitine deficiency. *Adv Pediatr* **34**, 59-88 (1987).
145. McQuade, A. & Blurton-Jones, M. Microglia in Alzheimer's Disease: Exploring How Genetics and Phenotype Influence Risk. *J Mol Biol* **431**, 1805-1817 (2019).
146. Katsumoto, A., Takeuchi, H., Takahashi, K. & Tanaka, F. Microglia in Alzheimer's Disease: Risk Factors and Inflammation. *Front Neurol* **9**, 978 (2018).
147. Abdel-Haq, R., Schlachetzki, J.C.M., Glass, C.K. & Mazmanian, S.K. Microbiome-microglia connections via the gut-brain axis. *J Exp Med* **216**, 41-59 (2019).
148. Tripathi, A. *et al.* The gut-liver axis and the intersection with the microbiome. *Nat Rev Gastroenterol Hepatol* **15**, 397-411 (2018).



Chapter 2

Genetics of Alzheimer's disease





Chapter 3

Pathways implicated in Alzheimer's disease and lifestyle factors



Chapter 3.1

Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study

Shahzad Ahmad, Christian Bannister, Sven J. van der Lee, Dina Vojinovic, Hieab H.H. Adams, Alfredo Ramirez, Valentina Escott-Price, Rebecca Sims, Emily Baker, Julie Williams, Peter Holmans, Meike W. Vernooij, M. Arfan Ikram, Najaf Amin, Cornelia M. van Duijn

This chapter is published in the *Alzheimer's and dementia: The Journal of the Alzheimer's Association*. 2018 July;14(7): 848–857

Supplementary information for this chapter is available at:
<https://doi.org/10.1016/j.jalz.2018.01.005>

Abstract

Introduction: Exploring the role of Alzheimer's disease (AD) implicated pathways in prodementia phase may provide new insight for preventive and clinical trials targeting disease specific pathways.

Methods: We constructed weighted Genetic risk scores, first based on 20 genome-wide significant AD risk variants and second clustering these variants within pathways. Risk scores were investigated for their association with AD, mild cognitive impairment and brain magnetic resonance imaging phenotypes including white matter lesions, hippocampal volume, and brain volume.

Results: The risk score capturing *endocytosis* pathway was significantly associated with mild cognitive impairment ($P = 1.44 \times 10^{-4}$). *Immune response* ($P = 0.016$) and *clathrin/AP2 adaptor complex* pathway ($P = 3.55 \times 10^{-3}$) excluding apolipoprotein E (*APOE*) also showed modest association with white matter lesions but did not sustain Bonferroni correction ($P = 9.09 \times 10^{-4}$).

Discussion: Our study suggests that the clinical spectrum of early AD pathology is explained by different biological pathways, in particular, the *endocytosis*, *clathrin/AP2 adaptor complex* and *immune response* pathways that are independent of *APOE*.

Introduction

Alzheimer's disease (AD) is a heterogeneous and genetically complex disease with high heritability (56-79 %)¹. It has been known since the end of the previous century that a polymorphism in the apolipoprotein E (*APOE*) gene is the strongest common genetic risk factor²⁴. This finding fueled speculations on the role of *lipid metabolism* and *cholesterol transport* pathway in AD in addition to the amyloid cascade and tau phosphorylation mechanism⁵,⁶. Furthermore, large-scale genome-wide association studies (GWAS) have discovered more than 20 novel common genetic variants that influence the risk of late-onset AD⁷-¹³. These common genetic variants have been mapped to eight biological pathways including *immune response*, *endocytosis*, *cholesterol transport*, *hematopoietic cell lineage*, *protein ubiquitination*, *hemostasis*, *clathrin/AP2 adaptor complex* and *protein folding*, each having a distinct biological function¹⁴-¹⁶. These eight pathways are not independent in a way that genes may be part of more than one biological pathway. For instance, *APOE* is part of four of the eight pathways namely *cholesterol transport*, *hematopoietic cell lineage*, *clathrin/AP2 adaptor complex* and *protein folding* pathways; clusterin (*CLU*) encoding for apolipoprotein J is involved in six pathways; phosphatidylinositol binding clathrin assembly protein (*PICALM*) and complement factor 1 (*CRI*) are involved in two pathways¹⁴-¹⁶.

These diverse biological pathways may be responsible for the clinically heterogeneous manifestation of AD¹⁷-¹⁹, which include endophenotypes such as changes in structural and functional magnetic resonance imaging (MRI) phenotypes, most notably hippocampal volume, total brain volume, and white matter lesions²⁰-²³. Furthermore, these biological pathways may also modulate the prodromal stages of AD such as mild cognitive impairment (MCI)²⁴-²⁶. Owing to heterogeneity during the prodementia phase, one important unanswered question is whether the different biological pathways that are implicated in AD relate to the pleiotropy of clinical endophenotypes. We hypothesized that some biological pathways are involved in distinct clinical endophenotypes whereas others may be involved in multiple or even all. Disentangling the connection of biological pathways to various aspects of AD-related early pathology may be a crucial step towards improving our understanding of the pathogenesis of AD during the prodementia stage and the first step toward a more informative and powerful readout for preventive and therapeutic trials targeting specific pathways.

The present study aims to capture the different biological pathways involved in AD using genetic risk scores to evaluate their role in AD and prodementia endophenotypes including MCI, white matter lesions, total brain, and hippocampal volume.

Methodology

Study population

This study included samples from the Rotterdam Study (RS). The RS is a prospective population-based study²⁷ designed to investigate the etiology of age-related disorders. At the baseline examination in 1990-1993, study recruited 7983 subjects ≥ 55 years of age from the Ommoord district of Rotterdam (RS-I). At the baseline entry and after every 3 to 4 years, all the study participants were extensively interviewed and physically examined at the dedicated research center. During 2000 to 2001, the baseline cohort (RS-I) was expanded by adding 3011 subjects ≥ 55 years of age, who were not yet part of RS-I (RS-II). Second expansion of RS was performed by recruiting 3932 persons having ≥ 45 years of age during 2006 to 2008 (RS-III). The study has been approved by the Medical Ethical Committee of Erasmus Medical Center and by the Ministry of Health, Welfare and Sport of the Netherlands. Written informed consent was also obtained from each study participant to participate and to collect information from their treating physicians. Details of AD, dementia and MCI diagnosis are provided in the supplementary information. In the present study for AD cross-sectional analysis, we included in total 1270 late-onset AD cases and 7623 controls (age at last follow-up ≥ 65 years and dementia-free) whose follow-up information is complete until 2009-2013 in RS-I, RS-II and RS-III cohorts. This AD sample includes 1057 incident and 213 prevalent AD cases. For prospective AD analysis, 10370 dementia-free (normal) participants were also included in the study from all three RS cohorts at their baseline and were subsequently followed until 2009-2013, to analyze their progression into AD (average 11 years of follow-up). In the MCI data set, we included 360 MCI cases and 3245 cognitively normal controls from the first extensive cognitive assessment conducted between 2002 and 2005 in RS-I and RS-II cohorts. MRI was implemented in 2005 in RS cohorts and 5899 persons came for MRI scanning until 2015. After excluding subjects with stroke and/or dementia ($n = 251$) at time of scanning, poor imaging quality ($n = 313$) and missing genotyping information ($n = 814$), we retained 4521 cognitively normal individuals in the MRI sample (Table 1).

Genotyping

Blood was drawn for genotyping from participants of RS cohorts during their first visit and DNA genotyping was performed at the internal genotyping facility of the Erasmus Medical Center, Rotterdam. All samples were genotyped with the 550K, 550K duo, or 610K Illumina arrays. Genotyping quality control criteria include, call rate $< 95\%$, Hardy-Weinberg equilibrium $P < 1.0 \times 10^{-6}$ and minor allele frequency (MAF) $< 1\%$. Moreover, study samples with excess autosomal heterozygosity, call rate $< 97.5\%$, ethnic outliers, and duplicate or family relationships were excluded during quality control analysis. Genetic variants were imputed from the Haplotype Reference Consortium reference panel (version 1.0)²⁸, using the Michigan imputation server²⁹. The server uses SHAPEIT2 (v2.r790)³⁰ to phase the genotype data and performs imputation

Table 1: Cohort characteristics

Characteristics	RS-I	RS-II	RS-III	Total
AD data set (N)	5854	2062	977	8893
Late-onset AD	1118	134	18	1270
AD free controls	4736	1928	959	7623
Age-at-onset (SD), years	84.58 (6.8)	82.75 (6.7)	78.54 (9.5)	84.30 (6.8)
Age of controls (SD), years	82.87 (6.9)	76.52 (6.4)	69.15 (5.7)	79.53 (8.2)
Female (%)	3526 (60%)	1133 (55%)	569 (58%)	5228 (59%)
MCI data set (N)	2178	1427		3605
MCI cases	235	125	-	360
Controls	1943	1302	-	3245
Age (SD), years	74.79(5.7)	67.53(6.9)	-	71.9 (7.2)
Female (%)	1271(58.4)	786(55.1)	-	2057 (57%)
MRI data set (N)	968	1068	2485	4521
Age (SD), years	78.89 (4.9)	69.34 (5.9)	57.21 (6.4)	64.72 (10.8)
Female (%)	556 (58%)	565 (53%)	1390 (56%)	2511 (56%)

Abbreviation: RS, Rotterdam Study (Cohort I, II, II); AD, Alzheimer's disease; MCI, Mild cognitive impairment; MRI, Magnetic resonance imaging; SD, Standard deviation.

with Minimac 3 software³¹. For this study, we used genetic variants that had imputation quality (R^2) > 0.5.

MRI scanning

Image acquisition

MRI scanning is assessed on a 1.5-T MRI unit with a dedicated eight-channel head coil (Signa HD platform, GE Healthcare, Milwaukee, USA) since the induction of a dedicated MRI machine in the RS. The MRI protocol was based on several high-resolution axial sequences, including a T1-weighted (slice thickness 0.8 mm), T2-weighted (1.6 mm), and fluid-attenuated inversion recovery sequence (2.5 mm). A detailed description of the MRI protocol is described previously³².

Image processing

We excluded 251 persons with stroke and/or dementia from the total 5899 subjects, because this may affect image processing. All T1 images were segmented into the supratentorial gray matter, white matter and cerebrospinal fluid using a k-nearest neighbor algorithm³³. White matter lesions were segmented based on T1 tissue maps and an automatically detected threshold for the intensity of fluid-attenuated inversion recovery scans³⁴. The hippocampus was segmented using a fully automated method, as described previously³⁵. Semiquantitative MRI postprocessing software was used to measure intracranial volume and brain volume which included Elastix

and custom-built software³⁶. To calculate intracranial volume, non-brain tissues (skull, eyes and dura) were removed by nonlinearly registering all brain scans to a manually created template in which non-brain tissues were masked^{133,36,37}. In all MRI scans, after visual inspection of all segmentations, additional 313 subjects were excluded because of poor quality.

Statistical analysis

Genetic risk score computation

To construct the risk score, we selected late-onset AD-associated single nucleotide polymorphisms (SNPs) reaching genome-wide significance level ($P < 5.0 \times 10^{-8}$; Supplementary Table 1), including one rare *TREM2* variant^{7,38}. In common variants, we considered only variants identified by the International Genomics of Alzheimer's Project (IGAP) meta-analyses. In addition, we considered *APOE ε4* (rs429358) variant for risk score construction. From a total of 21 SNPs, the *HLA-DRB1-HLA-DRB5* (rs9271192) variant was excluded from risk score calculation because of its low imputation quality ($R^2 = 0.31$) in the RS. This led to a final selection of 20 independent genome-wide significant AD-associated variants. Weighted genetic risk score was constructed using the effect sizes (log of odds ratio) of the genome-wide significant variants from the IGAP meta-analysis⁷ as weights and their respective allele dosages from imputed genotype data of our study cohorts. Risk score was constructed as the sum of the products of SNP dosages and their corresponding weights in R software (<https://www.R-project.org/>). We constructed genetic risk score in two ways: (1) combining all 20 selected variants and (2) clustering the variants into their respective pathways.

Combined genetic risk score

Combined genetic risk score (GRS1) was constructed in two ways, that is, (1) using all the 20 selected SNPs and (2) excluding the *APOE ε4* variant to identify the joint independent effect of all other genome-wide significant SNPs.

Pathway-specific genetic risk score

For pathway-specific genetic risk score (GRS2), the genome-wide significant AD SNPs were divided into pathways (*immune response, endocytosis, cholesterol transport, hematopoietic cell lineage, protein ubiquitination, hemostasis, clathrin/AP2 adaptor complex and protein folding pathway*) identified by Jones *et al.*¹⁶ (Supplementary Table 2). Classifying genome-wide significant AD SNPs into pathways, we also used information from Guerreiro *et al.*,¹⁴ in which the authors reviewed the possible division of known AD-associated genes into biological pathways¹⁴. Further, the GeneNetwork database (<http://genenetwork.nl/>) was used to confirm the allocated pathways. Of the 20 SNPs, 14 could be clustered into seven nonmutually exclusive pathways (Supplementary Table 2). Similar to GRS1, we also constructed GRS2 with and without the *APOE ε4* variant. *APOE ε4* variant was grouped under four pathways including *cholesterol transport*¹⁴, *hematopoietic cell lineage, clathrin/AP2 adaptor complex* and *protein folding*¹⁶. GRS2 was constructed for only those pathways, which could be assigned at least two SNPs, therefore *protein ubiquitination*

pathway, which contained only one SNP, was excluded from all analyses, while *hematopoietic cell lineage and protein folding* pathways were also not considered in the analyses excluding the *APOE* $\epsilon 4$ variant.

Association analyses of *GRS1*, and *GRS2*

To test the association of AD and MCI with the risk scores, we used logistic regression analysis in R software (www.R-project.org), using disease status as the outcome, risk scores as predictor and age and sex as covariates. To assess the possible inflation of association results between AD and risk scores, we repeated the association analysis excluding 625 AD cases who were part of the IGAP meta-analysis⁷ from total 1,270 AD cases of the RS cohort. Furthermore, we performed prospective analysis using the Cox-proportional hazards model (N=1057 incident AD cases) in R software using 'survival' package³⁹ and reported results as hazard ratio (HR) per 1 standard deviation increase in risk score and 95% confidence interval. The association of single variants with AD and MCI was assessed using a logistic regression model adjusted for age and sex. Results of association analyses were reported as unstandardized regression coefficient and *P* values.

To test the association of MRI phenotypes including total brain volume, white matter lesions and hippocampal volume with the risk scores we used linear regression adjusted for age, sex, and intracranial volume in MRI scans. Single variant association analysis was also performed for MRI phenotypes. Bonferroni correction ($0.05/(11 \text{ risk scores} \times 5 \text{ phenotypes})$; $P = 9.09 \times 10^{-4}$) was used to correct for multiple testing.

Results

Association of the *GRS1* with AD, MCI, and MRI endophenotypes

The risk score containing all SNPs, this is, *GRS1* both including *APOE* $\epsilon 4$ (effect = 0.73, $P = 6.53 \times 10^{-74}$) and excluding *APOE* $\epsilon 4$ (effect = 0.69, $P = 1.12 \times 10^{-11}$) was significantly associated with an increased risk of AD (Table 2). This association remained significant (*APOE* excluding; effect = 0.66, $P = 8.47 \times 10^{-7}$) after removing the patients who were included in the IGAP meta-analysis⁷ (Supplementary Table 3). *GRS1* was also significantly associated with progression from normal subjects into AD patients both including (HR = 1.69, $P = 6.64 \times 10^{-83}$) and excluding *APOE* $\epsilon 4$ (HR = 1.27, $P = 4.88 \times 10^{-15}$; Supplementary Table 4). *GRS1* was associated with MCI when *APOE* $\epsilon 4$ was included (effect = 0.19, $P = 0.012$) but the association was stronger when *APOE* $\epsilon 4$ was excluded from the analysis (effect = 0.59, $P = 9.51 \times 10^{-4}$; Table 3) however, these associations did not pass multiple testing correction. No association of *GRS1* was observed with any of the MRI phenotypes: white matter lesions, hippocampal volume, and total brain volume (Table 4).

Table 2: Results of association of Alzheimer's disease with risk scores

SNP Cluster [†]	Including <i>APOE</i>			Excluding <i>APOE</i>		
	β	SE	<i>P</i> -value	β	SE	<i>P</i> -value
GRS1 (Combined)	0.73	0.040	6.53x10 ⁻⁷⁴	0.69	0.101	1.12x10 ⁻¹¹
Immune response	-	-	-	0.69	0.166	3.20x10 ⁻⁵
Endocytosis	-	-	-	0.75	0.171	1.28x10 ⁻⁵
Cholesterol Transport	0.71	0.042	3.22x10 ⁻⁶⁴	0.39	0.219	0.077
Hematopoietic cell lineage[†]	0.73	0.042	5.16x10 ⁻⁶⁶	-	-	-
Hemostasis			-	0.50	0.292	0.090
Clathrin/AP2 Adaptor complex	0.72	0.042	4.68x10 ⁻⁶⁵	0.50	0.236	0.036
Protein folding[†]	0.72	0.042	2.96x10 ⁻⁶⁴	-	-	-

Abbreviations: GRS1, Combined genetic risk score; SNP, Single nucleotide polymorphism; β , Regression coefficient; SE, Standard error

Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); $P < 9.09 \times 10^{-4}$ was considered significant

* Logistic regression model adjusted for age and sex in RS (N=1270 cases)

† Only one SNP available in excluding *APOE* GRS2

Association of the GRS2 with AD

Among GRS2 of which *APOE* $\epsilon 4$ is a part, *cholesterol transport*, *hematopoietic cell lineage*, *clathrin/AP2 adaptor complex*, and *protein folding* were significantly associated with AD (effect ≥ 0.71 , $P < 3.22 \times 10^{-64}$) only when *APOE* $\epsilon 4$ was included in the risk scores. Among the non-*APOE* pathways, AD was significantly associated with GRS2 capturing *immune response* (effect = 0.69, $P = 3.20 \times 10^{-5}$) and *endocytosis pathway* (effect = 0.75, $P = 1.28 \times 10^{-5}$; Table 2) and association sustained (*Immune response*; effect = 0.68, $P = 2.22 \times 10^{-3}$ and *endocytosis*; effect = 0.79, $P = 5.37 \times 10^{-4}$) even after removing the patients who were included in the IGAP meta-analysis⁷ (Supplementary Table 3). GRS2 capturing *immune response* (HR = 1.14, $P = 1.19 \times 10^{-5}$), *endocytosis* (HR = 1.19, $P = 5.16 \times 10^{-8}$) and *APOE* $\epsilon 4$ excluded *clathrin/AP2 adaptor complex* (HR = 1.09, $P = 5.98 \times 10^{-3}$) pathway showed association with progression from normal into AD. Both *Immune response* and *endocytosis* pathways were significant after correcting for multiple testing. GRS2 including *APOE* $\epsilon 4$ were also significantly associated with normal to AD progression (HR ≥ 1.60 , $P \leq 1.44 \times 10^{-69}$; Supplementary Table 4). Comparatively, except for *APOE* $\epsilon 4$, and the variants in *CRI* and *BINI* genes, no single variant showed significant evidence of association with AD (Supplementary Table 5). The variant rs6733839 in the *BINI* gene partially explains the association between the *endocytosis* pathway and AD, whereas *APOE* $\epsilon 4$ mainly explains the association of all pathways of which *APOE* $\epsilon 4$ is a part.

Association of the GRS2 with MCI

In GRS2, only the *endocytosis* pathway showed significant evidence for association (effect = 1.16, $P = 1.44 \times 10^{-4}$; Table 3) with MCI. Although the significance of the association is similar to that of

Table 3: Results of association of mild cognitive impairment with risk scores

SNP Cluster [†]	Including <i>APOE</i>			Excluding <i>APOE</i>		
	β	SE	<i>P</i> -value	β	SE	<i>P</i> -value
GRS1 (combined)	0.19	0.075	0.012	0.59	0.179	9.51x10 ⁻⁴
Immune response	-	-	-	0.46	0.295	0.116
Endocytosis	-	-	-	1.16	0.305	1.44x10 ⁻⁴
Cholesterol Transport	0.11	0.082	0.164	0.39	0.392	0.322
Hematopoietic cell lineage[†]	0.09	0.084	0.269	-	-	-
Hemostasis	-	-	-	-0.08	0.524	0.872
Clathrin/AP2 Adaptor complex	0.12	0.082	0.128	0.72	0.423	0.089
Protein folding[†]	0.10	0.083	0.218	-	-	-

Abbreviations: GRS1, Combined genetic risk score; SNP, Single nucleotide polymorphism; β , Regression coefficient; SE, Standard error.

Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); $P < 9.09 \times 10^{-4}$ was considered significant

* Logistic regression model adjusted for age and sex in RS (N=360 cases)

† Only one SNP available in excluding *APOE* pathway-based GRS2

the overall risk score (GRS1), the effect estimate is considerably higher (1.16 vs. 0.59 overall). In the single variant analysis, the strongest association of MCI was observed with rs6733839 in the *BIN1* gene (effect = 0.262, $P = 1.12 \times 10^{-3}$; Supplementary Table 5). Although this association was not significant after correcting for multiple testing, however, it partially explains the association between MCI and GRS2 capturing *endocytosis*.

Association of the GRS2 with MRI phenotypes

White matter lesions were associated with GRS2 capturing *immune response* (effect = 0.15, $P = 0.016$) and *clathrin/AP2 adaptor complex* excluding *APOE* $\epsilon 4$ (effect = 0.26, $P = 3.55 \times 10^{-3}$). If we consider multiple testing, both these associations lose significance after accounting for all tested phenotypes and risk scores. Of note is that no association of white matter lesions with the GRS2 capturing the *clathrin/AP2 adaptor complex* is observed when *APOE* $\epsilon 4$ is included in the GRS2 (effect = 0.011, $P = 0.507$; Table 4). We did not observe association of GRS2 with hippocampal volume and total brain volume. In the single variant analysis association of white matter lesions are seen with variants in *PICALM*, *CLU* genes ($P \leq 0.05$). Hippocampal volume shows association with variants in *BIN1* and *CELF1* genes ($P < 0.05$; Supplementary Table 6). None of the single variant association sustained Bonferroni correction for multiple testing.

Table 4: Results for association of risk scores with magnetic resonance imaging phenotypes

SNP cluster*	Including <i>APOE</i>						Excluding <i>APOE</i>											
	White matter lesions		Brain volume		White matter lesions		Hippocampal volume		Hippocampal volume		Brain volume							
	β	SE	P	β	SE	P	β	SE	P	β	SE	P						
GRS1 (combined)	0.012	0.016	0.4448	-0.001	0.016	0.929	0.002	0.007	0.806	0.059	0.037	0.114	-0.009	0.038	0.810	-0.006	0.016	0.724
Immune response	-	-	-	-	-	-	-	-	-	0.149	0.062	0.016	-0.024	0.062	0.706	-0.010	0.026	0.692
Endocytosis	-	-	-	-	-	-	-	-	-	0.071	0.062	0.254	-0.046	0.063	0.462	0.004	0.026	0.865
Cholesterol	0.005	0.017	0.785	0.001	0.017	0.964	0.004	0.007	0.574	0.063	0.080	0.434	0.013	0.080	0.875	0.023	0.033	0.497
Transport																		
Hematopoietic cell lineage†	0.002	0.017	0.901	0.001	0.017	0.976	0.004	0.007	0.556	-	-	-	-	-	-	-	-	-
Hemostasis	-	-	-	-	-	-	-	-	-	0.228	0.108	0.034	-0.077	0.109	0.479	-0.009	0.045	0.835
Clathrin/AP2	0.011	0.017	0.507	-0.002	0.017	0.924	0.003	0.007	0.658	0.258	0.088	3.55x10 ⁻³	-0.077	0.109	0.479	-0.009	0.045	0.835
Adaptor complex																		
Protein folding†	0.007	0.017	0.700	-0.001	0.017	0.970	0.004	0.007	0.619	-	-	-	-	-	-	-	-	-

Abbreviations: GRS1, Combined genetic risk score; SNP, Single nucleotide polymorphism; β , Regression coefficient; SE, Standard error; P , P-value

Note: Multiple testing correction by Bonferroni 0.05/ (5 phenotypes x 11 risk scores); $P < 9.09 \times 10^{-4}$ was considered significant

* Linear regression model with MRI phenotype as outcome and risk score as predictor, adjusted for age at MRI scan, sex in RS (N=4521)

† Only one SNP available in excluding *APOE* pathway-based GRS2

Discussion

Combined risk score is significantly associated with AD and normal to AD progression but not with any of the early features of AD tested in our study including MCI and MRI markers. However, our pathway-based risk score analysis shows that the *endocytosis* pathway significantly associates with MCI in addition to AD and normal to AD progression (Supplementary Figure 1).

The association of GRS1 with AD is consistent with other similar studies on AD⁴⁰⁻⁴². However, while others observed significant association of combined risk score with MCI^{43,44}, in our study the association of GRS1 with MCI was not significant after correcting for multiple testing. We did not find association of GRS1 with any of the studied MRI endophenotypes. These findings are consistent with those of Mormino *et al.*,⁴⁵ and Lupton *et al.*,⁴⁶; both studies did not find association of hippocampal volume with combined GRS1 based on genome-wide significant AD variants, but Mormino *et al.*,⁴⁵ observed this association only with risk score based on non-genome wide significant AD variants. The largest study so far that included RS, however, reported significant evidence of association of risk score based on all genome-wide significant AD variants with hippocampal volume and total brain volume⁴⁷.

This is the first study that addressed the role of specific pathways in AD and its early clinical manifestations, that is., MCI and MRI phenotypes. Our study shows that GRS2 based on the *immune response* pathway was significantly associated with AD and normal to AD progression. Furthermore, we observed association of *immune response* with white matter lesions at MRI but this association did not survive Bonferroni correction. The genes clustered in the *immune response* pathway (*CLU*, *CRI*, *INPP5D*, *MS4A6A*, *TREM2*, *MEF2C*, *EPHA1*) are mainly expressed in microglial cells and play a part in the innate *immune response* in central nervous system⁴⁸⁻⁵². Microglial cells are also thought to play a role in amyloid plaque clearance^{53,54}. It has been hypothesized that the activation of the immune system and the subsequent inflammatory response are involved in neuronal damage including axonal loss and white matter pathology due to demyelination⁵⁵. White matter lesions are associated with increased risk of cognitive decline, developing dementia²¹ and AD^{22,56}. White matter lesions are also more frequently observed in AD patients than controls^{57,58}.

The most interesting finding of the present study is that the genes capturing the *endocytosis* pathway significantly associate with MCI, AD and with progression from normal (dementia-free) to AD. This pathway is independent of *APOE* and includes the *BIN1*, *PICALM*, *CD2AP*, and *SORL1* genes. We show that the association of GRS1 with MCI status is mainly attributed to the genes involved in the *endocytosis* pathway. Omitting the AD genes not related to the *endocytosis* pathway makes the association of the pathway with MCI even stronger. This suggests that the *endocytosis* pathway plays a critical role in an early prodromal phase of AD. Our findings are in line with previous studies suggesting the activation of the *endocytic* pathway is the earliest reported

intracellular manifestation of AD⁵⁹⁻⁶¹. Furthermore, the effect estimate of the *endocytosis* pathway was larger for MCI (1.16) compared with AD (0.75) suggesting a stronger association with MCI; however, this difference in effect estimates was not significant ($P = 0.12$). The *endocytosis* pathway is involved in neuronal uptake of macromolecules and secretory vesicles during synaptic transmission. As efficient uptake of extracellular cholesterol is critical for neuronal functions such as repair, synapse formation and exon elongation⁶², normal neuronal work needs smooth functioning of *endocytosis* pathway⁶³. Postmortem studies have also demonstrated reduced brain cholesterol levels in the brain areas responsible for memory and learning, among late-onset AD cases and age-matched controls⁶⁴. These facts suggest that defects in *endocytosis*, which derive the cholesterol uptake, could lead to impaired neurotransmitter release and synaptic function⁶⁵. Dysfunction in *endocytosis* can also contribute to the accumulation of abnormal A β peptide⁶⁶. Based on this finding, we can suggest that the *endocytosis* pathway is a common molecular mechanism between MCI and AD that starts manifesting at early stages of disease. Risk contributed by variants clustered in this pathway at various stages of AD progression can possibly provide clue about disease trajectory.

Our study further shows association of the *clathrin/AP2 adaptor complex* pathway with white matter lesions. Although the association failed to pass the multiple testing, it is interesting to note that no association was detected with the combined risk score either in our study or a larger study performed earlier by Chauhan *et al.*,⁴⁷ that included up to 11550 individuals. This suggests that pathway-based risk scores may be more sensitive in picking association signals that may be relevant for specific AD pathologies. Two variants tagging *PICALM* and *CLU* genes cluster in the *clathrin/AP2 adaptor complex* pathway. Each variant independently shows nominal association with white matter lesions in our analyses but combining their effects are additive and improve the strength of association. There is strong evidence that the two proteins encoded by the genes interact at molecular level^{67,68}. *PICALM* is involved in VAMP2 trafficking that is a crucial process to maintain functional integrity of synapses which are crucial to cognitive function^{69,70}. *PICALM* is also found to be expressed in the white matter and, immunolabeling of human brain tissue shows that *PICALM* is mainly found in blood vessel walls⁷¹. *CLU* clustered in the *clathrin/AP2 adaptor* is involved in efflux of free insoluble A β peptides through blood-brain barrier⁷². Increased plasma levels of *CLU* were associated with increased burden of A β peptide in healthy elderly population and brain atrophy in AD^{73,74} and decreased integrity of white matter in young adults⁷⁵. Demyelination of white matter is reported to occur even before the accumulation of A β plaques and neurofibrillary tangles⁷⁶. The findings of the present study suggest that the increased genetic burden of risk variants in the *clathrin/AP2 adaptor complex* (*clathrin-mediated endocytosis*) and *immune response* pathway may play a role in early pathogenesis of AD through white matter pathology.

Among pathways including *APOE* (*Cholesterol transport, hematopoietic cell lineage, clathrin/AP2 adaptor complex and protein folding*), significant association with AD and normal to AD progression suggest that *APOE* $\epsilon 4$ appears to be the driving genetic factor for these associations.

Our study provides a readout of pathway-based risk score association with AD and its prodromal endophenotypes. Our findings are important from a clinical perspective as these will aid in determining whether a certain biological pathway is involved in a patient. This will permit targeted interventions based on predicted pathological pathways. Similar to the case of cardiovascular diseases⁷⁷, a heterogeneous disease treatment can be followed based on pathway biomarkers (e.g., glucose level, total cholesterol and high-density lipid levels, and liver enzymes in case of cardiovascular disease)⁷⁸ but rather on genetic basis. This requires reference pathways and treatment portfolio. In the meantime, the pathway-based genetic risk score will allow stratification of patients in clinical trials based on causal pathways involved in patients. This may improve both the power and efficiency of future clinical and preventive trials.

Our study is a step forward to use known genetic and pathway information for disentangling the mechanisms of AD but it has one major limitation that pathway information is based on known AD variants identified so far. This will further improve in future with improved genetic risk information that can better capture the underlying pathways. Another possible limitation of our study is that 625 cases of RS-I were a part of the meta-analysis performed by the IGAP⁷ which can contribute to possible inflation in our results of association of risk score with AD. However, excluding these patients, the results of this study largely remained unchanged.

To conclude, our study provides strong evidence that the *endocytosis* pathway is relevant in the prodromal phase of AD, that is., in subjects with MCI. Furthermore, the pathways including *immune response* and *clathrin/AP2 adaptor complex* pathways may be relevant for brain-related early endophenotypes of AD, such as white matter lesions; this, however, needs further investigation in larger samples. Interestingly, all the observed associations with early AD pathology are shown by *APOE* excluding pathways. Future findings from genomic research will improve the quality of the pathway-specific genetic scores.

Acknowledgments

This study was funded by the Netherlands Organisation for Health Research and Development (ZonMw) as part of the Joint Programming for Neurological Disease (JPND) as part of the PERADES Program (Defining Genetic, Polygenic, and Environmental Risk for Alzheimer's disease, using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics), Project number 733051021. This work was funded also by the European Union Innovative Medicine Initiative (IMI) programme under grant agreement No. 115975 as part of the Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development (ADAPTED, <https://www.imi-adapted.eu>); and the European Union's Horizon 2020 research and innovation programme as part of the Common mechanisms and pathways in Stroke and Alzheimer's disease CoSTREAM project (www.costream.eu, grant agreement No. 667375); European Union's Horizon 2020 research and innovation programme Marie Skłodowska-Curie Research and Innovation Staff Exchange (RISE) under the grant agreement No. 645740 as part of the Personalized pREvention of Chronic DIseases (PRECeDI) project. This study was also supported by MRC Dementias Platform UK (DPUK) and the UK Dementia Research Institute (UK DRI). The Rotterdam Study is funded by the Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture, and Science; the Ministry for Health, Welfare and Sports; the European Commission (DG XII); and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study, and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS-I, RS-II, RS-III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS data sets are supported by the Netherlands Organization of Scientific Research NWO Investments (Project number 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), and the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project number 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn Verkerk, Lizbeth Herrera, and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data. I would like to thank Alzheimer Nederland for providing me travel grant to present my research at AAIC2017

References

1. Gatz, M. *et al.* Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry* **63**, 168-74 (2006).
2. Corder, E.H. *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-3 (1993).
3. Bu, G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. *Nat Rev Neurosci* **10**, 333-44 (2009).
4. Huang, Y. & Mucke, L. Alzheimer mechanisms and therapeutic strategies. *Cell* **148**, 1204-22 (2012).
5. Kopke, E. *et al.* Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. *J Biol Chem* **268**, 24374-84 (1993).
6. Hardy, J.A. & Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. *Science* **256**, 184-5 (1992).
7. Lambert, J.C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-8 (2013).
8. Genin, E. *et al.* APOE and Alzheimer disease: a major gene with semi-dominant inheritance. *Mol Psychiatry* **16**, 903-7 (2011).
9. Lambert, J.C. *et al.* Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. *Nat Genet* **41**, 1094-9 (2009).
10. Seshadri, S. *et al.* Genome-wide analysis of genetic loci associated with Alzheimer disease. *JAMA* **303**, 1832-40 (2010).
11. Hollingworth, P. *et al.* Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* **43**, 429-35 (2011).
12. Naj, A.C. *et al.* Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* **43**, 436-41 (2011).
13. Desikan, R.S. *et al.* Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. *Circulation* **131**, 2061-9 (2015).
14. Guerreiro, R., Bras, J. & Hardy, J. SnapShot: genetics of Alzheimer's disease. *Cell* **155**, 968-968 e1 (2013).
15. Medway, C. & Morgan, K. Review: The genetics of Alzheimer's disease; putting flesh on the bones. *Neuropathol Appl Neurobiol* **40**, 97-105 (2014).
16. International Genomics of Alzheimer's Disease, C. Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimers Dement* **11**, 658-71 (2015).
17. Van der Flier, W.M. Clinical heterogeneity in familial Alzheimer's disease. *Lancet Neurol* **15**, 1296-1298 (2016).
18. Becker, J.T., Huff, F.J., Nebes, R.D., Holland, A. & Boller, F. Neuropsychological function in Alzheimer's disease. Pattern of impairment and rates of progression. *Arch Neurol* **45**, 263-8 (1988).

19. Mann, U.M., Mohr, E., Gearing, M. & Chase, T.N. Heterogeneity in Alzheimer's disease: progression rate segregated by distinct neuropsychological and cerebral metabolic profiles. *J Neurol Neurosurg Psychiatry* **55**, 956-9 (1992).
20. Dubois, B. *et al.* Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement* **12**, 292-323 (2016).
21. DeBette, S. *et al.* Association of MRI markers of vascular brain injury with incident stroke, mild cognitive impairment, dementia, and mortality: the Framingham Offspring Study. *Stroke* **41**, 600-6 (2010).
22. DeBette, S. & Markus, H.S. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. *BMJ* **341**, c3666 (2010).
23. Kaye, J.A. *et al.* Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. *Neurology* **48**, 1297-304 (1997).
24. Petersen, R.C. *et al.* Mild cognitive impairment: clinical characterization and outcome. *Arch Neurol* **56**, 303-8 (1999).
25. Gauthier, S. *et al.* Mild cognitive impairment. *Lancet* **367**, 1262-70 (2006).
26. Petersen, R.C. Mild cognitive impairment as a diagnostic entity. *Journal of internal medicine* **256**, 183-194 (2004).
27. Hofman, A. *et al.* The Rotterdam Study: 2016 objectives and design update. *Eur J Epidemiol* **30**, 661-708 (2015).
28. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279-83 (2016).
29. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-7 (2016).
30. Delaneau, O., Marchini, J., Genomes Project, C. & Genomes Project, C. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. *Nat Commun* **5**, 3934 (2014).
31. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet* **44**, 955-9 (2012).
32. Ikram, M.A. *et al.* The Rotterdam Scan Study: design update 2016 and main findings. *European journal of epidemiology* **30**, 1299-1315 (2015).
33. Vrooman, H.A. *et al.* Multi-spectral brain tissue segmentation using automatically trained k-Nearest-Neighbor classification. *Neuroimage* **37**, 71-81 (2007).
34. De Boer, R. *et al.* White matter lesion extension to automatic brain tissue segmentation on MRI. *Neuroimage* **45**, 1151-1161 (2009).
35. Fischl, B. FreeSurfer. *Neuroimage* **62**, 774-81 (2012).
36. Klein, S., Staring, M. & Pluim, J.P.W. Comparison of gradient approximation techniques for optimisation of mutual information in nonrigid registration. Vol. 5747 192-203 (2005).
37. Ikram, M.A. *et al.* Common variants at 6q22 and 17q21 are associated with intracranial volume. *Nat Genet* **44**, 539-44 (2012).
38. Guerreiro, R. *et al.* TREM2 variants in Alzheimer's disease. *N Engl J Med* **368**, 117-27 (2013).

39. Therneau, T. A Package for Survival Analysis in S. R package version 2.37-7. 2014. URL <http://CRAN.R-project.org/package=survival> (2015).
40. Chouraki, V. *et al.* Evaluation of a Genetic Risk Score to Improve Risk Prediction for Alzheimer's Disease. *J Alzheimers Dis* **53**, 921-32 (2016).
41. Escott-Price, V., Shoai, M., Pither, R., Williams, J. & Hardy, J. Polygenic score prediction captures nearly all common genetic risk for Alzheimer's disease. *Neurobiol Aging* (2016).
42. Sleegers, K. *et al.* A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Abeta42. *Alzheimers Dement* **11**, 1452-60 (2015).
43. Adams, H.H. *et al.* Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. *Alzheimers Dement* **11**, 1277-85 (2015).
44. Lacour, A. *et al.* Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment. *Mol Psychiatry* **22**, 153-160 (2017).
45. Mormino, E.C. *et al.* Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology* **87**, 481-8 (2016).
46. Lupton, M.K. *et al.* The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. *Neurobiol Aging* **40**, 68-77 (2016).
47. Chauhan, G. *et al.* Association of Alzheimer's disease GWAS loci with MRI markers of brain aging. *Neurobiol Aging* **36**, 1765 e7-16 (2015).
48. Zhang, Y. *et al.* An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. *J Neurosci* **34**, 11929-47 (2014).
49. Kofler, J., Bissel, S., Wiley, C., Stauffer, M. & Murdoch, G. Differential microglial expression of new Alzheimer's disease associated genes MS4A4A and MS4A6A. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* **8**, P253.
50. Colonna, M. TREMs in the immune system and beyond. *Nat Rev Immunol* **3**, 445-53 (2003).
51. Crehan, H., Hardy, J. & Pocock, J. Blockage of CR1 prevents activation of rodent microglia. *Neurobiol Dis* **54**, 139-49 (2013).
52. Zhang, B. *et al.* Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell* **153**, 707-20 (2013).
53. Lee, C.Y. & Landreth, G.E. The role of microglia in amyloid clearance from the AD brain. *J Neural Transm (Vienna)* **117**, 949-60 (2010).
54. Heneka, M.T. *et al.* Neuroinflammation in Alzheimer's disease. *Lancet Neurol* **14**, 388-405 (2015).
55. Heppner, F.L., Ransohoff, R.M. & Becher, B. Immune attack: the role of inflammation in Alzheimer disease. *Nat Rev Neurosci* **16**, 358-72 (2015).
56. Jeong, H. *et al.* Age, hypertension, and genetic polymorphisms and their relative associations with white matter hyperintensities in Korean patients with Alzheimer's disease. *Neurology Asia* **20**, 35-41 (2015).
57. Smith, E.E. *et al.* Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. *Arch Neurol* **65**, 94-100 (2008).

58. Wolf, H., Ecke, G.M., Bettin, S., Dietrich, J. & Gertz, H.J. Do white matter changes contribute to the subsequent development of dementia in patients with mild cognitive impairment? A longitudinal study. *Int J Geriatr Psychiatry* **15**, 803-12 (2000).
59. Funderburk, S.F., Marcellino, B.K. & Yue, Z. Cell “self-eating” (autophagy) mechanism in Alzheimer’s disease. *Mt Sinai J Med* **77**, 59-68 (2010).
60. Ginsberg, S.D. *et al.* Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer’s disease. *J Chem Neuroanat* **42**, 102-110 (2011).
61. Cataldo, A.M. *et al.* Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer’s disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. *Am J Pathol* **157**, 277-86 (2000).
62. Vance, J.E., Campenot, R.B. & Vance, D.E. The synthesis and transport of lipids for axonal growth and nerve regeneration. *Biochim Biophys Acta* **1486**, 84-96 (2000).
63. Keating, D.J., Chen, C. & Pritchard, M.A. Alzheimer’s disease and endocytic dysfunction: clues from the Down syndrome-related proteins, DSCR1 and ITSN1. *Ageing Res Rev* **5**, 388-401 (2006).
64. Svennerholm, L. & Gottfries, C.G. Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). *J Neurochem* **62**, 1039-47 (1994).
65. Woodruff, G. *et al.* Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer’s Disease Mutations. *Cell Reports* **17**, 759-773 (2016).
66. Maxfield, F.R. Role of endosomes and lysosomes in human disease. *Cold Spring Harb Perspect Biol* **6**, a016931 (2014).
67. Yang, X., Li, J., Liu, B., Li, Y. & Jiang, T. Impact of PICALM and CLU on hippocampal degeneration. *Hum Brain Mapp* **37**, 2419-30 (2016).
68. Tan, L. *et al.* Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts. *Sci Rep* **6**, 26027 (2016).
69. Harel, A., Wu, F., Mattson, M.P., Morris, C.M. & Yao, P.J. Evidence for CALM in directing VAMP2 trafficking. *Traffic* **9**, 417-29 (2008).
70. Yao, P.J. Synaptic frailty and clathrin-mediated synaptic vesicle trafficking in Alzheimer’s disease. *Trends in neurosciences* **27**, 24-29 (2004).
71. Baig, S. *et al.* Distribution and expression of picalm in Alzheimer disease. *J Neuropathol Exp Neurol* **69**, 1071-7 (2010).
72. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. *Nat Rev Neurosci* **12**, 723-38 (2011).
73. Thambisetty, M. *et al.* Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. *Arch Gen Psychiatry* **67**, 739-48 (2010).
74. Weinstein, G. *et al.* Plasma clusterin levels and risk of dementia, Alzheimer’s disease, and stroke. *Alzheimers Dement (Amst)* **3**, 103-9 (2016).
75. Braskie, M.N. *et al.* Common Alzheimer’s disease risk variant within the CLU gene affects white matter microstructure in young adults. *J Neurosci* **31**, 6764-70 (2011).

76. Sachdev, P.S., Zhuang, L., Braidy, N. & Wen, W. Is Alzheimer's a disease of the white matter? *Curr Opin Psychiatry* **26**, 244-51 (2013).
77. Sun, X. & Jia, Z. A brief review of biomarkers for preventing and treating cardiovascular diseases. *J Cardiovasc Dis Res* **3**, 251-4 (2012).
78. Upadhyay, R.K. Emerging risk biomarkers in cardiovascular diseases and disorders. *J Lipids* **2015**, 971453 (2015).

Chapter 3.2

Genetic predisposition, modifiable risk factor profile and long-term dementia risk in the general population

Silvan Licher, Shahzad Ahmad, Hata Karamujić-Čomić, Trudy Voortman, Maarten J.G. Leening, M. Arfan Ikram and M. Kamran Ikram

This chapter is published in *Nature Medicine*. 2019 August; 25:1364–1369

Supplementary information for this chapter is available at:
<https://doi.org/10.1038/s41591-019-0547-7>

Abstract

The exact etiology of dementia is still unclear, but both genetic and lifestyle factors are thought to be key drivers of this complex disease. The recognition of familial patterns of dementia has led to the discovery of genetic factors that have a role in the pathogenesis of dementia, including the apolipoprotein E (*APOE*) genotype and a large and still growing number of genetic variants^{1,2}. Beyond genetic architecture, several modifiable risk factors have been implicated in the development of dementia³. Prevention trials of measures to halt or delay cognitive decline are increasingly recruiting older individuals who are genetically predisposed to dementia. However, it remains unclear whether targeted health and lifestyle interventions can attenuate or even offset increased genetic risk. Here, we leverage long-term data on both genetic and modifiable risk factors from 6,352 individuals aged 55 years and older within the population-based Rotterdam Study. In this study, we demonstrate that in individuals at low- and intermediate genetic risk, favorable modifiable risk profiles are related to a lower risk of dementia compared to unfavorable profile. In contrast, these protective associations were not found in those at high genetic risk.

Main

Recent analyses have shown that if currently known modifiable risk factors were to be eliminated at a population level, over one-third of all dementia cases could be prevented³. In view of these findings, several dementia prevention trials have been conducted to investigate the efficacy of lifestyle interventions, but have yielded inconsistent results so far⁴⁻⁶. Such interventions have been proposed to be more effective when targeted at individuals who have an increased risk of dementia, as identified through their genetic or clinical profile, or a combination thereof⁷.

The genetic risk of developing dementia or Alzheimer's disease (AD) might be detrimental for some individuals⁸, yet this risk may be mitigated for most when adhering to a healthy lifestyle. A recent subgroup analysis from a 2-year multi-domain intervention trial found that healthy lifestyle changes had beneficial effects on cognitive performance, even in *APOE* $\epsilon 4$ carriers, which is the variant of the gene associated with the highest risk of dementia⁹. Evidence from randomized controlled trials is necessary to determine whether positive effects, including those beyond cognitive performance, also occur in dementia. However, since treatment effects from lifestyle interventions at an individual level are generally small, large trials with a long follow-up are needed. Such trials are expensive and prone to high attrition rates. Instead, data from long-term prospective cohort studies can be leveraged to gain insights into the interplay between genetic and lifestyle factors, with the potential to inform the design of future clinical trials.

Prior studies have mostly focused on the risk of dementia associated with an individual protective factor^{10,11}, yet the combination of multiple factors may yield more beneficial effects than the individual parts¹². Combining data about a number of factors is also important because it takes into account the multi-factorial nature of late life-dementia¹³. We used data from the Rotterdam Study to determine to what extent a favorable profile based on modifiable risk factors is associated with a lower risk of dementia among individuals at low, intermediate or high genetic risk.

In 6,352 participants, we determined genetic risk using two approaches: (1) *APOE* genotype and (2) a weighted polygenic risk score based on 27 genetic variants (excluding *APOE*) that showed genome-wide significant evidence for associations with AD (Supplementary Table 1). For the first approach, we grouped participants into high *APOE*-risk ($\epsilon 2\epsilon 4$, $\epsilon 3\epsilon 4$ or $\epsilon 4\epsilon 4$ genotypes), intermediate-risk ($\epsilon 3\epsilon 3$) or low risk ($\epsilon 2\epsilon 2$ or $\epsilon 2\epsilon 3$); for the second, the distribution of the polygenic risk scores was divided into tertiles, and individuals were grouped into these tertiles. In these participants, we also measured several health and/or lifestyle factors that have been implicated in lower the risk of dementia^{11,14}. These include: (1) abstaining from smoking, (2) absence of depression, (3) absence of diabetes, (4) regular physical activity, (5) avoiding social isolation, and (6) adherence to a healthy diet, which included limited alcohol consumption (see Methods for additional information). Using these six factors, we computed an overall score based on modifiable risk factors, ranging from zero to six. A higher score reflects a more favorable

profile. Subsequently, we categorized participants into three groups: an unfavorable profile (a score of ≤ 2 protective factors); an intermediate profile (a score of 3 or 4 factors); and a favorable profile (a score of ≥ 5 factors). Alternatively, we determined modifiable risk on the basis of the Ideal Cardiovascular Health score defined using a seven-item tool from the American Heart Association comprising four lifestyle measures (abstaining from smoking and ideal body weight, regular physical activity and diet at optimal levels) and three health measures (optimal plasma cholesterol and glucose levels, and blood pressure at optimal levels—and the 10-year predicted risk of fatal cardiovascular diseases¹⁵. We subsequently stratified participants by both their genetic and modifiable risk. We calculated the risk of developing dementia for each stratum separately, on both a relative and absolute scale using Cox and competing risk models, respectively.

This study included more women (56.2%) than men. Baseline characteristics were roughly similar across categories of *APOE*-risk (Table 1). As expected, *APOE* $\epsilon 4$ carriers were generally diagnosed with dementia at a younger age ($P = 1.38 \times 10^{-12}$), more often had a parental history of dementia ($P = 4.55 \times 10^{-4}$), and had higher total cholesterol levels ($P = 1.24 \times 10^{-19}$), compared with non-carriers. The median follow-up was 14.1 years among the 6,352 participants; in this timeframe, 915 individuals were diagnosed with dementia, of whom 739 were diagnosed with AD, and 2,644 participants died free from dementia.

Dementia risk was significantly higher among participants at a high or intermediate *APOE* risk compared with those at low *APOE* risk (Figure 1 and Table 2). The risk of dementia also increased in participants who had fewer protective factors (P for trend= 0.0044), such that those with an unfavorable profile (≤ 2 out of 6 factors) had a 32% higher risk of dementia than participants with a favorable one (≥ 5 out of 6 factors) (Figure 1 and Table 2). The strength of this association




Figure 1: Cumulative incidence of dementia during follow-up. a, according to genetic risk based on *APOE* genotyping, and b, according to modifiable risk factor profiles. For a and b, shaded areas represent 95% confidence intervals.

Table 1: Baseline characteristics per genetic risk category based on *APOE* carrier status

	Low risk (ε2ε2 or ε2ε3) N = 887	Intermediate risk (ε3ε3) N = 3,718	High risk (ε2ε4, ε3ε4 or ε4ε4) N = 1,747	P for difference
Age, years	69.4 (8.5)	69.2 (8.3)	68.7 (7.9)	0.042
Women	529 (59.6)	2072 (55.8)	971 (55.5)	0.102
Educational years, median (IQR)	10 (7-13)	10 (7-13)	10 (7-13)	0.325
Parental history of dementia	53 (8.1)	219 (7.8)	155 (11.6)	4.55×10 ⁻⁴
History of stroke	33 (3.7)	138 (3.7)	61 (3.5)	0.929
Body mass index, kg/m ²	27.4 (4.0)	27.0 (4.0)	26.9 (3.9)	0.014
Systolic blood pressure, mmHg	145 (22)	143 (21)	143 (21)	0.045
Diastolic blood pressure, mmHg	77 (11)	77 (12)	77 (11)	0.239
Total cholesterol, mmol/L	5.6 (1.0)	5.8 (1.0)	5.9 (1.0)	1.24×10 ⁻¹⁹
High-density lipoprotein cholesterol, mmol/L	1.43 (0.4)	1.39 (0.4)	1.35 (0.4)	1.00×10 ⁻⁵
Fasting glucose, mmol/L	5.6 (1.5)	6.0 (1.6)	6.0 (1.6)	0.902
Baseline MMSE score, median (IQR)	28 (27-29)	28 (27-29)	28 (27-29)	0.049
Age of dementia diagnosis	85.5 (5.9)	84.1 (6.3)	81.3 (6.5)	1.38×10 ⁻¹²
Modifiable health and lifestyle factors				
No current smoking	714 (81.0)	2961 (80.1)	1389 (79.9)	0.801
Absence of depression	799 (90.1)	3351 (90.1)	1567 (89.7)	0.881
Absence of diabetes	744 (88.3)	3096 (88.3)	1461 (89.0)	0.750
Regular physical activity	484 (56.0)	2109 (58.5)	1005 (59.4)	0.501
Absence of social isolation	588 (66.7)	2664 (72.4)	1256 (72.1)	0.005
Adherence to a healthy diet	141 (15.9)	559 (15.0)	252 (14.4)	0.649
Modifiable risk profile category				
Favorable: 5-6 health and lifestyle factors	568 (64.0)	2453 (66.0)	1132 (64.8)	
Intermediate: 3-4 health and lifestyle factors	224 (25.2)	884 (23.8)	443 (25.4)	0.648
Unfavorable: 0-2 health and lifestyle factors	95 (10.7)	381 (10.2)	172 (9.8)	

Abbreviations: N, number of individuals at risk; IQR, interquartile range; MMSE, Mini-Mental State Examination.

Data are presented as the frequency in the stratum (percentage) for categorical values and as mean±the standard deviation for continuous variables unless indicated otherwise. We compared baseline characteristics across *APOE* strata using analysis of variance (ANOVA) tests. In the case of frequency distributions or when data were non-normally distributed, we compared variables between groups using non-parametric tests (chi-squared, Mann–Whitney or Kruskal–Wallis). Two-sided *P* values were uncorrected for multiple testing.

Table 2: Risk of incident dementia according to *APOE*-related risk and lifestyle categories

<i>APOE</i> -related risk	N/n	Model 1	Model 2
		HR (95% CI)	HR (95% CI)
Low risk (ε2ε2/ ε2ε3)	887/85	Reference	Reference
Intermediate risk (ε3ε3)	3718/456	1.45 (1.15;1.83)	1.45 (1.15;1.83)
High risk (ε2ε4/ε3ε4/ ε4ε4)	1747/374	3.02 (2.38;3.82)	3.02 (2.38;3.83)
<i>P</i> for trend		2.10×10 ⁻³⁰	1.87×10 ⁻³⁰
Lifestyle risk category			
Favorable	4153/538	Reference	Reference
Intermediate	1551/259	1.15 (0.98;1.34)	1.14 (0.98;1.33)
Unfavorable	648/118	1.32 (1.08;1.63)	1.29 (1.05;1.59)
<i>P</i> for trend		0.0044	0.0087

Abbreviations: N, number of individuals at risk; n, number of dementia cases during follow-up; HR, hazard ratio; CI, confidence interval

Model 1 - adjusted for: age, sex and education

Model 2 - additionally adjusted for: parental history of dementia, history of stroke, systolic blood pressure, total and high-density lipoprotein cholesterol

remained nearly identical after adjusting for parental history of dementia and cardiovascular risk factors (hazard ratio (HR) = 1.29 (95% confidence interval (CI) = 1.05–1.59), *P* for trend = 0.0087).

APOE genotype significantly modified the association between protective factors and dementia (*P* for interaction = 0.023). In those at low or intermediate *APOE* risk, the risk of dementia in participants with an unfavorable profile was higher than that for those with a favorable one (HR = 2.51, 95% CI = 1.40–4.48 and HR = 1.39, CI = 1.04–1.85, respectively; Table 3). In those at high *APOE* risk, we did not find differences in dementia risk between individuals with unfavorable or intermediate profiles compared with those who had a favorable profile (HR = 1.00, 95% CI = 0.79–1.28 and HR = 1.05, 95% CI = 0.73–1.50, respectively).

Among those at low *APOE*-risk, the mean anticipated absolute risk of developing dementia within 15-year ranged from 32.1% (95% CI = 0.0-59.9) for those with an unfavorable profile to 12.6% (95% CI = 4.5-26.8) for those with a favorable one (Supplementary Table 2). Individuals at intermediate *APOE*-risk with an unfavorable profile had a 22.0% (95% CI = 8.3-39.2) anticipated risk, which was 13.5% (95% CI = 8.9-15.6) for those with a favorable profile. Among participants at high *APOE* risk, the anticipated 15-year risk of dementia remained largely unchanged across the different profiles (ranging from 18.2% for a favorable to 19.5% for an unfavorable profile).

Table 3: Risk of incident dementia while stratifying participants on both their *APOE*-related risk and modifiable risk factor profile

<i>APOE</i> -related risk	Risk factor profile	N/n	HR (95% CI)
Low ($\epsilon 2\epsilon 2/\epsilon 2\epsilon 3$)	Favorable	568/44	Reference
	Intermediate	224/23	1.14 (0.66;1.96)
	Unfavorable	95/18	2.51 (1.40;4.48)
	<i>P</i> for trend		0.0059
Intermediate ($\epsilon 3\epsilon 3$)	Favorable	2453/253	Reference
	Intermediate	884/139	1.27 (1.02;1.57)
	Unfavorable	381/64	1.39 (1.04;1.85)
	<i>P</i> for trend		0.0087
High ($\epsilon 2\epsilon 4/\epsilon 3\epsilon 4/\epsilon 4\epsilon 4$)	Favorable	1132/241	Reference
	Intermediate	443/97	1.00 (0.79;1.28)
	Unfavorable	172/36	1.05 (0.73;1.50)
	<i>P</i> for trend		0.8300

Abbreviations: n, number of cases; N, number of people at risk; HR, hazard ratio; CI, confidence interval
Adjusted for: age, sex and education

Stratified analyses showed that protective associations of favorable risk profiles against dementia tended to be stronger in younger individuals than in older individuals, and were most pronounced for younger individuals at low *APOE*-risk (Supplementary Tables 3 and 4). In all of these analyses, no significant protective associations were found in *APOE* $\epsilon 4$ carriers. There was no effect modification of the association between risk profiles and dementia risk by sex (Supplementary Table 5).

In sensitivity analyses, using a different approach, namely a polygenic risk score for AD (without *APOE*), we also found that associations between protective factors were modified (*P* for interaction = 0.0003); patterns across polygenic risk strata were attenuated yet largely comparable to those of the *APOE* (Supplementary Tables 6 and 7).

These patterns also remained unchanged when we varied the composition of modifiable risk factors. For instance, similar results were found when we stratified participants on their Ideal Cardiovascular Health score (*P* for interaction = 0.026, Supplementary Table 8), and when we stratified participants on the basis of their predicted absolute 10-year risk of fatal cardiovascular diseases using the SCORE equation (European Coronary Risk Equation, including age, sex, current smoking, level of total cholesterol and systolic blood pressure) (*P* for interaction = 7.82×10^{-5} , Supplementary Table 9). All of the individual health and lifestyle factor-specific associations with dementia risk that were included in the different profiles are presented in Supplementary Tables 10-12, respectively.

Most evidence on the interaction between specific genetic and modifiable factors with dementia comes from observational studies. These studies primarily examined the associations and interactions of single health or lifestyle factors, such as diabetes, physical activity, alcohol use, smoking or diet, with different *APOE* alleles. Most of these studies reported a lower risk of dementia among individuals¹⁶⁻¹⁹, who had optimal levels of one of these single risk factors¹⁶⁻¹⁹ compared with those who had more adverse ones. These effects were generally more pronounced in *APOE* $\epsilon 4$ carriers during midlife¹⁶⁻¹⁹. In contrast, studies conducted in older individuals (aged ≥ 60 years), primarily found beneficial effects of these factors on risk of dementia among non-carriers²⁰⁻²⁶, or reported no interaction^{27,28}.

More evidence comes from the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) Study of middle-aged individuals that took multiple protective factors into consideration²⁹. *APOE* genotype modified the association between several lifestyle factors and the risk of dementia. The results from CAIDE indicate that *APOE* $\epsilon 4$ carriers are particularly prone to developing dementia if they have hazardous health and lifestyle factors during midlife. The participants in CAIDE were younger (mean age 50.6 years) than the individuals in this study (mean age 69.1 years). This may have led to survival bias in the current study because dementia risk in older *APOE* $\epsilon 4$ carriers is potentially less affected by modifiable risk factors later in life.

To our knowledge, only the Prevention of Dementia by Intensive Vascular Care (preDIVA) trial has assessed the effects of health and lifestyle interventions on dementia¹⁶. This trial showed that intensive vascular care management in a primary-care setting had no overall benefit on dementia incidence. In a subgroup analysis in this trial, no significant differences were observed between *APOE* $\epsilon 4$ carriers and non-carriers. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) trial assessed the effects of multiple lifestyle interventions on cognitive performance in older individuals⁴. A pre-specified subgroup analysis in this trial uncovered similar beneficial effects on cognitive performance in both *APOE* $\epsilon 4$ carriers and non-carriers after two years of follow-up⁹.

In the current study, we aimed to complement evidence from these clinical trials with long-term observational data. Such an approach has been previously undertaken to study potential interaction between genetic and modifiable factors and other chronic diseases, such as heart disease and stroke^{30,31}. Our results confirm that individuals with a favorable profile have a lower risk of dementia than those with intermediate or unfavorable profiles based on modifiable risk factors. In contrast with the FINGER subgroup analysis, this study found that a favorable profile could not offset high *APOE*-risk. The FINGER trial intervened in multiple lifestyle factors simultaneously, whereas, in our observational study, data on health and lifestyle factors were used to establish risk factor profiles. Non-differential misclassification may, in part, have led to an underestimation of the benefits of a favorable risk factor profile in our study. This may, for instance, apply to physical activity and diet quality because we have chosen cut-off

points to depict 'favorable', 'intermediate' or 'unfavorable' for these variables on the basis of guideline recommendations^{32,33}. Moreover, we lacked validated questionnaires to measure social engagement, so we may not have fully captured its beneficial effect on dementia. Misclassification may have occurred in genetic risk stratifications because we did not have enough participants to divide them into strata based on specific genotype. We therefore had to collate some categories of genetic risk to estimate meaningful effect sizes. As an example, we grouped individuals who are either heterozygous or homozygous for *APOE* $\epsilon 4$. This may have led to an underestimation of the benefits of a favorable profile for individuals who are heterozygous for *APOE* $\epsilon 4$, as this group resembles an intermediate risk group between those who are homozygous for *APOE* $\epsilon 3$ and for *APOE* $\epsilon 4$ ¹.

Furthermore, we studied the interplay between genetic and lifestyle factors in the long-term risk of developing dementia, whereas the FINGER subgroup analysis assessed effects on cognitive performance after a 2-year follow-up. Although cognitive performance was improved in the group that received the multi-domain lifestyle intervention compared with that of the control group, which received standard health advice, in the short-term, it remains questionable whether such effects also occur in the longterm. For instance, participants in the FINGER trial may already have developed essential *APOE*-related brain changes earlier in life³⁴, making them vulnerable to development of dementia later in life, irrespective of their modifiable risk factor profile.

In this study, a high risk of developing dementia based on *APOE* carrier status was not offset by a favorable profile. These findings contrast with those from other large, observational population-based studies that examined the interaction between genetic and modifiable factors for other chronic diseases, including for instance heart disease and stroke^{30,31}. These studies found protective associations of favorable modifiable profiles across levels of genetic risk, even for those at the highest genetic risk. Several reasons may underlie this discrepancy.

First, the harmful effects of *APOE* $\epsilon 4$ on cholesterol metabolism are apparent throughout life, and there are cumulative effects on dementia risk as age advances¹. Second, *APOE* $\epsilon 4$ alters neuronal functioning which may lead to irreversible neuronal cell loss³⁵. With advancing age, these effects build up and may, in the absence of disease-modifying drugs and proven preventive strategies, ultimately have a more detrimental effect on the risk of dementia in older individuals. Third, the risk for competing diseases at older ages, such as coronary heart disease and stroke, may be mitigated or even reversed, by having a favorable risk profile through the reduction of atherosclerotic disease^{36,37}. Fourth, potential epigenetic changes, such as methylation effects of *APOE* or additional variants, may be age-dependent and exert their effects in midlife or even earlier but this notion deserves further study. Finally, the *APOE* $\epsilon 4$ allele triggers cascades that may be more independent of the profiles that we studied, for example pathways in inflammatory response. Such a response may lead to blood-barrier breakdown, which in turn causes

neurovascular dysfunction³⁸. In summary, the interaction between genetic and environmental factors plays an important role in the pathophysiology of dementia.

Our findings provide a less optimistic outlook for individuals at high genetic risk of dementia, yet they may have important implications for the design of future clinical trials. Considering the earlier age at onset of dementia among *APOE* $\epsilon 4$ carriers compared with non-carriers, our results imply that these individuals need to be targeted earlier in the disease process (for example midlife or even earlier) to influence their risk¹. Additionally, other interventions beyond lifestyle improvements warrant further study. For instance, drugs that lower lipid levels might be considered to lower dementia risk in these individuals, yet evidence for such interventions is still inconclusive³⁹. On the positive side, results from this study show that avoiding an unhealthy lifestyle could potentially prevent or postpone the onset of dementia in most individuals in the population (73%), namely those at low and intermediate genetic risk. Among those, the majority were categorized as having a favorable profile (66%), yet room for improvement is still substantial because potential relative risk reductions of up to 30% can be achieved when individuals adhere to the lifestyle factors that confer a favorable risk profile.

Several limitations of this study need to be addressed. First, we lacked data waves on hearing impairment, a potentially important modifiable risk factor for dementia, because assessments to measure hearing were implemented in the study protocol from 2011 onwards. Second, the components used to compute the modifiable risk factor profile were measured at baseline, which does not capture the possibility of shifting from a more adverse risk profile to a more optimal one during follow-up, or vice versa. Third, by stratifying participants using both genetic and environmental information, results are based on small samples in each stratum, resulting in wide confidence intervals around point estimates. Results of this single-cohort study therefore warrant replication in other population-based studies. Nevertheless, we were able to show the robustness of our findings in several sensitivity analyses; thus, it was less likely that our findings were a result of chance. Finally, members of this older population are predominantly of European descent (97%), limiting the generalizability of these findings to younger populations and to other ethnicities. Strengths of this study include the availability of genetic data in combination with the meticulous assessment of several health and lifestyle factors, along with long-term and consistent dementia follow-up.

In conclusion, this large population-based study demonstrates that among those at low- and intermediate genetic risk, a favorable modifiable risk profile is related to a risk of dementia lower than that in individuals with an unfavorable one. In contrast, these protective associations were not found among those at high genetic risk. These results may inform clinical trial design, because dementia prevention trials increasingly recruit individuals genetically predisposed to dementia.

Acknowledgments

We acknowledge the dedication, commitment, and contribution of inhabitants, general practitioners, and pharmacists of the Ommoord district who took part in the Rotterdam Study. We acknowledge Frank van Rooij as data manager, and Brenda C.T. Leening-Kieboom as study coordinator. We thank Jolande Verkroost-van Heemst, for her invaluable contribution to the collection of the data. The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. Further support was obtained from the Netherlands Consortium for Healthy Ageing and the Dutch Heart Foundation (2012T008) and the Dutch Cancer Society (NKI-20157737). This project has received funding from the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (project: ORACLE, grant agreement No: 678543).

References

1. van der Lee, S.J. *et al.* The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *Lancet Neurol* **17**, 434-444 (2018).
2. Kunkle, B.W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430 (2019).
3. de Bruijn, R.F. *et al.* The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. *BMC Med* **13**, 132 (2015).
4. Ngandu, T. *et al.* A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. *Lancet* **385**, 2255-63 (2015).
5. Andrieu, S. *et al.* Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. *Lancet Neurol* **16**, 377-389 (2017).
6. Moll van Charante, E.P. *et al.* Effectiveness of a 6-year multidomain vascular care intervention to prevent dementia (preDIVA): a cluster-randomised controlled trial. *Lancet* **388**, 797-805 (2016).
7. Licher, S. *et al.* Development and Validation of a Dementia Risk Prediction Model in the General Population: An Analysis of Three Longitudinal Studies. *Am J Psychiatry*, appiajp201818050566 (2018).
8. Guerreiro, R., Bras, J. & Hardy, J. SnapShot: genetics of Alzheimer's disease. *Cell* **155**, 968-968 e1 (2013).
9. Solomon, A. *et al.* Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention: A Subgroup Analysis of a Randomized Clinical Trial. *JAMA Neurol* (2018).
10. Baumgart, M. *et al.* Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. *Alzheimers Dement* **11**, 718-26 (2015).
11. Livingston, G. *et al.* Dementia prevention, intervention, and care. *Lancet* **390**, 2673-2734 (2017).
12. Peters, R. *et al.* Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis. *BMJ Open* **9**, e022846 (2019).
13. Boyle, P.A. *et al.* Attributable risk of Alzheimer's dementia attributed to age-related neuropathologies. *Ann Neurol* **85**, 114-124 (2019).
14. Organization, W.H. Risk reduction of cognitive decline and dementia: WHO guidelines. Vol. CC BY-NC-SA 3.0 IGO (WHO, Geneva, 2019).
15. Conroy, R.M. *et al.* Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. *Eur Heart J* **24**, 987-1003 (2003).
16. Rovio, S. *et al.* Leisure-time physical activity at midlife and the risk of dementia and Alzheimer's disease. *Lancet Neurol* **4**, 705-11 (2005).
17. Anttila, T. *et al.* Alcohol drinking in middle age and subsequent risk of mild cognitive impairment and dementia in old age: a prospective population based study. *BMJ* **329**, 539 (2004).

18. Laitinen, M.H. *et al.* Fat intake at midlife and risk of dementia and Alzheimer's disease: a population-based study. *Dement Geriatr Cogn Disord* **22**, 99-107 (2006).
19. Karlsson, I.K. *et al.* Apolipoprotein E epsilon4 genotype and the temporal relationship between depression and dementia. *Neurobiol Aging* **36**, 1751-1756 (2015).
20. Podewils, L.J. *et al.* Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. *Am J Epidemiol* **161**, 639-51 (2005).
21. Huang, T.L. *et al.* Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. *Neurology* **65**, 1409-14 (2005).
22. Barberger-Gateau, P. *et al.* Dietary patterns and risk of dementia: the Three-City cohort study. *Neurology* **69**, 1921-30 (2007).
23. Luchsinger, J.A., Tang, M.X., Siddiqui, M., Shea, S. & Mayeux, R. Alcohol intake and risk of dementia. *J Am Geriatr Soc* **52**, 540-6 (2004).
24. Merchant, C. *et al.* The influence of smoking on the risk of Alzheimer's disease. *Neurology* **52**, 1408-12 (1999).
25. Ott, A. *et al.* Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam Study. *Lancet* **351**, 1840-3 (1998).
26. Lindsay, J. *et al.* Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. *Am J Epidemiol* **156**, 445-53 (2002).
27. Ritchie, K. *et al.* Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. *BMJ* **341**, c3885 (2010).
28. Samieri, C. *et al.* Association of Cardiovascular Health Level in Older Age With Cognitive Decline and Incident Dementia. *JAMA* **320**, 657-664 (2018).
29. Kivipelto, M. *et al.* Apolipoprotein E epsilon4 magnifies lifestyle risks for dementia: a population-based study. *J Cell Mol Med* **12**, 2762-71 (2008).
30. Khera, A.V. *et al.* Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. *N Engl J Med* **375**, 2349-2358 (2016).
31. Rutten-Jacobs, L.C. *et al.* Genetic risk, incident stroke, and the benefits of adhering to a healthy lifestyle: cohort study of 306 473 UK Biobank participants. *BMJ* **363**, k4168 (2018).
32. Voortman, T. *et al.* Adherence to the 2015 Dutch dietary guidelines and risk of non-communicable diseases and mortality in the Rotterdam Study. *Eur J Epidemiol* **32**, 993-1005 (2017).
33. Craig, C.L. *et al.* International physical activity questionnaire: 12-country reliability and validity. *Med Sci Sports Exerc* **35**, 1381-95 (2003).
34. Chang, L. *et al.* Gray matter maturation and cognition in children with different APOE epsilon genotypes. *Neurology* **87**, 585-94 (2016).
35. Kim, J., Basak, J.M. & Holtzman, D.M. The role of apolipoprotein E in Alzheimer's disease. *Neuron* **63**, 287-303 (2009).
36. Ornish, D. *et al.* Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. *Lancet* **336**, 129-33 (1990).

Chapter 3

37. Licher, S. *et al.* Lifetime risk and multimorbidity of non-communicable diseases and disease-free life expectancy in the general population: A population-based cohort study. *PLoS Med* **16**, e1002741 (2019).
38. Bell, R.D. *et al.* Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* **485**, 512-6 (2012).
39. McGuinness, B., Craig, D., Bullock, R. & Passmore, P. Statins for the prevention of dementia. *Cochrane Database Syst Rev*, CD003160 (2016).
40. Ikram, M.A. *et al.* The Rotterdam Study: 2018 update on objectives, design and main results. *Eur J Epidemiol* **32**, 807-850 (2017).

Methods

Study population

We used data from participants of the Rotterdam Study, a prospective population-based cohort study. In 1990, all residents aged 55 and older living in Ommoord, a district of Rotterdam, the Netherlands, were invited. Of 10215 invited inhabitants, 7983 (78%) agreed to participate in the baseline examination. In 2000, the cohort was extended: all residents who turned 55 or moved into the research area. Of the 4472 invitees, 3011 (67%) agreed to participate. Follow-up examinations take place every 3 to 4 years⁴⁰.

Analyses of this study are based on data obtained from the third examination of the original cohort in 1997-1999 (N=4797) and the first examination of the extended cohort in 2000-2001 (N=3011). These two cohorts were similar in design and examinations were identical. After excluding participants who did not complete the interview and research center visit in these rounds (N=873), had dementia or insufficient screening for dementia at baseline (N=170), did not undergo genotyping (N=365), did not provide informed consent to access medical records and hospital discharge letters (N=33), or if there was no follow-up due to logistic reasons (N=15), 6352 participants were included for analysis in this study (study flowchart displayed in Supplementary Figure 1. A comparison of baseline characteristics for in- and excluded participants is presented in Supplementary Table 13).

Ethics statement

The Rotterdam Study has medical ethics committee approval per the Population Study Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sport of the Netherlands. Written informed consent was obtained from all participants.

APOE genotyping

DNA was extracted from blood samples drawn at baseline. *APOE* genotype was determined using a polymerase chain reaction in the original cohort and was determined with a bi-allelic TaqMan assay (rs7412 and rs429358) in the extended cohort on coded DNA samples. *APOE* $\epsilon 4$ carrier status was defined as carrier of one or two $\epsilon 4$ alleles.

Calculation of a polygenic risk score

The majority of samples (81.1%) were further genotyped with the Illumina 610K and 660K chips and imputed to the Haplotype Reference Consortium reference panel (version 1.0) with Minimac 3. We included 27 genetic variants that showed genome-wide significant evidence for associations with AD to calculate a weighted polygenic risk score. Supplementary Table 1 provides an overview of the included variants. The polygenic risk score was calculated as the sum of the products of single nucleotide polymorphism dosages of the 27 genetic variants (excluding

APOE) and their respective reported effect estimates. All 27 variants selected for the calculation of the polygenic risk score were well imputed (imputation score $R^2 > 0.6$, median 0.99).

Modifiable risk factor profile

We adapted six health and/or lifestyle factors shown to be important during later life to lower dementia risk, as set out by a recent meta-analysis and endorsed by the World Health Organization (WHO)^{11,14}. Among these are: (1) abstaining from smoking, (2) absence of depression, (3) absence of diabetes, (4) regular physical activity, (5) avoiding social isolation, and (6) adherence to a healthy dietary pattern, which included limited alcohol consumption. Based on these six factors, we computed an overall profile of modifiable risk factors ranging from zero to six, and we subsequently grouped participants into three categories of modifiable risk (unfavorable-: ≤ 2 , intermediate-: 3-4, and favorable profiles: ≥ 5 protective factors)

Assessment of individual health and lifestyle factors

During a structured home interview, participants were enquired about their smoking habits. Participants were classified as never, former or, current smokers. In addition, the participants were screened with the Center for Epidemiologic Studies Depression Scale during the interview. Presence of depressive symptoms was defined as a score of >16 points on scale of 0 to 60. Diabetes was defined as fasting serum glucose levels ≥ 7.0 mmol/L, non-fasting serum glucose levels ≥ 11.0 mmol/L (if fasting samples were unavailable), and/or the use of blood glucose-lowering medication. Physical activity levels were assessed using a validated adapted version of Zutphen Physical Activity Questionnaire and expressed in Metabolic Equivalent of Task hours (METhours) per week. The METhours/week are the product of MET-values of specific activities (walking, cycling, domestic work, sports, and gardening) with time in hours per week spent in that activity. Categories were calculated based on International Physical Activity Questionnaire and also expressed in METhours/week. We defined being physically active based on a minimum of ≥ 40 minutes of exercise per week with a MET intensity of ≥ 4 ³³. Social engagement was constructed using three domains based on various questionnaires. We included marital status, living arrangements (living alone, with spouse or with others) and asked if the participant felt lonely during the past week. If a participant lived alone and felt lonely during the past week – we considered them as being less socially engaged. A validated food frequency questionnaire was used to measure the dietary pattern of participants³². A healthy dietary pattern was ascertained on the basis of adherence to at least half of the following dietary guidelines: consumption of a sufficient amount of fruits, nuts, vegetables, whole grains, fish, and dairy products and a limited amount of refined grains, processed meats, unprocessed red meats, sugar-sweetened beverages, trans fats, sodium and alcohol, for which further details and cut-off values are described elsewhere³².

Other covariates

Participants were questioned about parental history of dementia during the interview. During the center visit, blood pressure was assessed at the right upper arm with the participant in sitting

position. The mean of two measurements was used in the analyses. Serum total cholesterol, and high-density lipoprotein cholesterol were acquired by an automated enzymatic procedure (Boehringer Mannheim System). Glucose levels were measured after overnight fasting (8–14 h). The history of clinical stroke was assessed by both self-report and continuous monitoring of medical records through digitized linkage of files from general practitioners with the study database. All strokes were adjudicated by a panel of study physicians.

Ascertainment of dementia

Participants were screened for dementia at baseline and subsequent center visits with the Mini-Mental State Examination and the Geriatric Mental Schedule organic level³. Those with a Mini-Mental State Examination score <26 or Geriatric Mental Schedule score >0 underwent further investigation and informant interview, including the Cambridge Examination for Mental Disorders of the Elderly. All participants also underwent routine cognitive assessment. In addition, the entire cohort was continuously under surveillance for dementia through electronic linkage of the study database with medical records from general practitioners and the regional institute for outpatient mental health care. Available information on cognitive testing and clinical neuroimaging was used when required for diagnosis of dementia subtype. An event adjudication panel led by a consultant neurologist established the final diagnosis according to standard criteria for dementia (DSM-III-R) and AD (NINCDS–ADRDA). Follow-up until 1st of January 2016 was virtually complete (95.5% of potential person-years). Within this period, participants were followed until the date of dementia diagnosis, death, loss to follow-up, or 1st of January 2016, whichever came first.

Statistical analysis

We used Cox proportional hazard models to assess the association of *APOE*-risk and the health and lifestyle factors with incident dementia. We verified the proportionality assumption with use of Schoenfeld residuals. We tested for interaction between *APOE* carrier status and the level of the modifiable risk factor profiles on a multiplicative scale. We subsequently evaluated the hazard ratios (HRs) for participants with a high *APOE* risk status ($\epsilon 2\epsilon 4$, $\epsilon 3\epsilon 4$ or $\epsilon 4\epsilon 4$ genotypes), and compared those with hazard ratios from those with an intermediate risk ($\epsilon 3\epsilon 3$ genotype) or low risk status ($\epsilon 2\epsilon 2$ or $\epsilon 2\epsilon 3$ genotypes). Similarly, we calculated hazard ratios for participants with a favorable profile (which was defined as the presence of at least five of the six health and/or lifestyle factors) with an intermediate profile (three or four factors) or an unfavorable profile (two or less factors). Models were adjusted for age, sex and level of attained education. In extended models, we additionally adjusted for parental history of dementia and cardiovascular risk factors. Finally, we used a competing risk framework based on the Fine & Gray model to calculate the 15-year absolute dementia risk for participants within each category of genetic risk and modifiable risk profile separately. Confidence intervals were computed based on 1000 bootstrap samples.

Chapter 3


In stratified analyses, we explored whether associations differed among younger and older participants by stratifying on the median age of this study (68.2 years) and additionally on the age of 70 years as this age range is often used as an eligibility criterion to recruit individuals for preventative trials that assess multi-domain lifestyle interventions⁴⁻⁶. Finally, we stratified on sex.

In sensitivity analyses, we studied the robustness of our findings by varying the definitions and compositions of both modifiable risk factors and genetic risk factors that were used in the main analyses. This is in particular important since some of the included modifiable risk factors, such as depression and social isolation, may have been altered by pre-clinical dementia. Similar to the main analyses, we first explored statistical interaction on a multiplicative scale between the studied genetic component (*APOE* or the polygenic score), and the risk factor profile under study. We subsequently repeated the main analyses while categorizing participants on the Ideal Cardiovascular Health metric (favorable, intermediate and unfavorable), instead of the currently employed modifiable risk factors. Similarly, we replaced the current modifiable risk factors by the 10-year predicted absolute risk of fatal cardiovascular disease and subsequently categorized participants into low-to-moderate <5%, high risk 5-10%, and very high risk > 10%, based on the European Coronary Risk Equation (SCORE), that includes age, sex, and several adverse risk factors namely current smoking, level of cholesterol and systolic blood pressure¹⁵.

Regarding genetic risk factors, we repeated the main analyses stratified for an AD polygenic risk score that included 27 genome-wide significant variants (excluding *APOE*), comparing participants at high genetic risk (i.e. highest tertile of the polygenic score) with those at intermediate risk (middle tertile), or low risk (lowest tertile).


We compared baseline characteristics across *APOE* strata using analysis of variance (anova) tests. In the case of frequency distributions or when data were non-normally distributed, we compared variables between groups using non-parametric tests (chi-square, Mann-Whitney or Kruskal Wallis).

Data were handled and analyzed with SPSS Statistics version 24.0.0.1 (IBM Corp., Armonk, NY) and R, CRAN version 3.5.1, with packages *survival*, *rms* and *cmprsk*. All analyses were performed at the significance level of 0.05 (2-tailed). P values were uncorrected for multiple testing.



Chapter 4

Proteomics and metabolomics of Alzheimer's disease



Chapter 4.1

CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in *APOE* ϵ 4 carriers

Shahzad Ahmad, Marta del Campo Milan, Oskar Hansson, Ayse Demirkan, Ruiz Agustin, Maria E Sáez, Nikolaos Giagtzoglou, Alfredo Cabrera-Socorro, Margot H.M. Bakker, Alfredo Ramirez, Thomas Hankemeier, Erik Stomrud, Niklas Mattsson-Carlsson, Philip Scheltens, Wiesje M. van der Flier, M. Arfan Ikram, Anders Malarstig, Charlotte E Teunissen, Najaf Amin, Cornelia M. van Duijn

This chapter is published in Scientific Reports. 2020 May; 10:8233

The Supplementary information for this chapter is available at:
<https://doi.org/10.1038/s41598-020-65038-5>

Abstract

Many Alzheimer's disease (AD) genes including Apolipoprotein E (*APOE*) are found to be expressed in blood-derived macrophages and thus may alter blood protein levels. We measured 91 neuro-proteins in plasma from 316 participants of the Rotterdam Study (incident AD = 161) using Proximity Extension Ligation assay. We studied the association of plasma proteins with AD in the overall sample and stratified by *APOE*. Findings from the Rotterdam study were replicated in 186 AD patients of the BioFINDER study. We further evaluated the correlation of these protein biomarkers with total tau (t-tau), phosphorylated tau (p-tau) and amyloid-beta ($A\beta$) 42 levels in cerebrospinal fluid (CSF) in the Amsterdam Dementia Cohort (N = 441). Finally, we conducted a genome-wide association study (GWAS) to identify the genetic variants determining the blood levels of AD-associated proteins. Plasma levels of the proteins, CDH6 ($\beta = 0.638$, $P = 3.33 \times 10^{-4}$) and HAGH ($\beta = 0.481$, $P = 7.20 \times 10^{-4}$), were significantly elevated in *APOE* $\epsilon 4$ carrier AD patients. The findings in the Rotterdam Study were replicated in the BioFINDER study for both CDH6 ($\beta = 1.365$, $P = 3.97 \times 10^{-3}$) and HAGH proteins ($\beta = 0.506$, $P = 9.31 \times 10^{-7}$) when comparing cases and controls in *APOE* $\epsilon 4$ carriers. In the CSF, CDH6 levels were positively correlated with t-tau and p-tau in the total sample as well as in *APOE* $\epsilon 4$ stratum ($P < 1 \times 10^{-3}$). The HAGH protein was not detected in CSF. GWAS of plasma CDH6 protein levels showed significant association with a cis-regulatory locus (rs111283466, $P = 1.92 \times 10^{-9}$). CDH6 protein is implicated in cell adhesion and synaptogenesis while HAGH protein is related to the oxidative stress pathway. Our findings suggest that these pathways may be altered during presymptomatic AD and that CDH6 and HAGH may new blood-based biomarkers.

Introduction

Apolipoprotein E (*APOE*) is the most common genetic risk factor for Alzheimer's disease (AD)^{1,2} and an important driver of the lifetime risk for AD^{3,4}. *APOE* interacts with other common genetic determinants of AD^{2,5}, suggesting an interaction with specific protein pathways. Despite two decades of research, the role of *APOE* in determining the risk of AD is far from being understood⁶. The IMI ADAPTED (The Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development) is an Innovative Medicine Initiative (IMI) that aims to improve the understanding about the role of *APOE* gene in AD.

AD pathology is characterized by the extracellular deposition of amyloid-beta (A β)-42 and intracellular accumulation of phosphorylated tau in the brain. Cerebrospinal fluid (CSF) levels of A β -42, phosphorylated (p-tau) and total tau (t-tau) are well-established biomarkers of the central nervous system and brain AD pathology⁷. However, there is a growing evidence for a relation between other pathologies and AD, such as vascular pathology⁸. For example, studies integrating epidemiological and vascular research showed that vascular pathology may affect brain function and increase the risk of AD⁹. *APOE* and many of the novel genes implicated in AD are expressed in monocytes/macrophages¹⁰⁻¹² in the blood, and thus these genes may alter the protein signatures in blood. There is also a growing body of evidence indicating that A β may disrupt the cerebral microcirculation regulation¹³⁻¹⁵, endothelial function^{16,17}, and brain perivascular macrophages function¹⁸. Thus, protein and metabolite homeostasis in blood may also be altered as a consequence of (early) amyloid pathology. Indeed, there is an increasing interest in the relation between protein levels in plasma and AD during presymptomatic stages of AD¹⁹. Multiple studies have investigated the association of a range of proteins with AD in plasma, but few have addressed the effect of *APOE*¹⁹⁻²⁵. Furthermore, there is lack of investigations connecting molecular signatures of AD in blood to neuropathological AD markers in CSF.

Advances in high-throughput omics technologies have allowed the detection and quantification of several classes of plasma-based biomolecular compounds including circulating metabolites and proteins²⁶. In the present study, we aimed to identify altered levels of proteins in the circulation of presymptomatic AD patients in the overall population and among various genetic risk groups based on the *APOE* gene, with a view to obtaining insights into molecular signatures in the circulation. To this end, we have examined the association of neurology relevant proteins in a prospective population-based, the Rotterdam Study. Proteins associated with AD were further tested for replication in the BioFINDER study. Next, we conducted a genome-wide association study to find the genetic variants determining the blood levels of AD-associated proteins. Finally, we studied the association of the protein consistently associated with AD to amyloid and tau levels in CSF in the Amsterdam Dementia Cohort (ADC).

Results

Association of plasma proteins with AD

Detailed results of overall and *APOE* stratified association analysis of proteins with AD are provided in Table 1 and Figure 1. No significantly associated protein to AD was identified in the overall analyses at an $FDR < 0.05$. Overall, there is a tendency that protein levels are more likely increased (positive effect size, β) than decreased (negative effect size, β) in AD patients that carry the *APOE* ϵ_4 allele (Figure 1a) and those homozygous for *APOE* ϵ_3 allele (Figure 1c) but not for *APOE* ϵ_2 patients (Figure 1d). In *APOE* stratified discovery analysis, we observed that levels of CDH6 ($\beta = 0.638$, $P = 3.33 \times 10^{-4}$, $FDR = 0.030$) and HAGH ($\beta = 0.481$, $P = 7.20 \times 10^{-4}$, $FDR = 0.033$) were significantly increased in AD patients who carry the *APOE* ϵ_4 allele (see Table 1).




Figure 1: Volcano plots representing the association of plasma protein levels with Alzheimer's disease (AD) in (a) overall analysis; (b) *APOE4* stratum; (c) *APOE33* stratum and (d) *APOE2* stratum. Each dot represents a protein with regression coefficient (β) of association plotted on x-axis and $-\log_{10}$ of P -values on y-axis. Proteins showing nominal association (P -value < 0.05) are annotated in overall and stratified analysis. Light blue color of dot indicates decreased protein levels with β -0.0 to -0.184 and dark blue to indicate with $\beta < -0.184$ while pink color indicates increased protein levels with β ranging from 0.0 to 0.184 and red color shows $\beta > 0.184$. Black dots are used for proteins which pass the multiple testing (false discovery rate < 0.05).

Table 1: Results of plasma-based proteome association with Alzheimer's disease

Uniprot id	Annotation	Effect size (β)	OR	SE	<i>P</i> -value	<i>FDR</i> -value
Overall population						
P55285	CDH6	0.334	1.397	0.106	1.78×10^{-3}	0.162
Q2VWP7	PRTG	0.286	1.331	0.100	4.62×10^{-3}	0.210
O94779	CNTN5	0.155	1.168	0.061	1.24×10^{-2}	0.377
P12544	GZMA	0.129	1.138	0.059	2.88×10^{-2}	0.598
O14594	NCAN	0.183	1.201	0.088	3.93×10^{-2}	0.598
O14793	GDF-8	0.095	1.100	0.047	4.42×10^{-2}	0.598
Q16775	HAGH	0.147	1.158	0.074	4.60×10^{-2}	0.598
<i>APOE4</i> stratum						
P55285	CDH6	0.638	1.893	0.171	3.33×10^{-4}	0.030
Q16775	HAGH	0.481	1.618	0.138	7.20×10^{-4}	0.033
Q92752	TN-R	0.280	1.323	0.094	3.72×10^{-3}	0.113
P01138	Beta-NGF	0.431	1.539	0.182	2.00×10^{-2}	0.340
Q8NFP4	MDGA1	0.164	1.178	0.070	2.22×10^{-2}	0.340
P57087	JAM-B	0.318	1.374	0.137	2.24×10^{-2}	0.340
P41217	CD200	0.335	1.398	0.155	3.31×10^{-2}	0.394
Q9BS40	LXN	0.619	1.857	0.292	3.67×10^{-2}	0.394
P16234	PDGF-R-alpha	0.324	1.383	0.159	4.42×10^{-2}	0.394
Q6ISS4	LAIR-2	0.107	1.113	0.053	4.84×10^{-2}	0.394
<i>APOE33</i> stratum						
Q2VWP7	PRTG	0.309	1.362	0.122	1.22×10^{-2}	0.778
O94779	CNTN5	0.193	1.213	0.081	1.85×10^{-2}	0.778
O14594	NCAN	0.248	1.281	0.110	2.57×10^{-2}	0.778
P55285	CDH6	0.202	1.224	0.150	1.79×10^{-1}	0.842
Q16775	HAGH	-0.018	0.982	0.092	8.42×10^{-1}	0.957
<i>APOE2</i> stratum						
P17405	SMPD1	-0.447	0.640	0.203	3.51×10^{-2}	0.966
Q2TAL6	VWC2	-0.362	0.696	0.166	3.69×10^{-2}	0.966
Q16775	HAGH	0.482	1.619	0.227	4.25×10^{-2}	0.966
P55285	CDH6	0.498	1.645	0.324	1.35×10^{-1}	0.966

Abbreviations: β , regression coefficient; OR, odds ratio; SE, standard error; *APOE*, apolipoprotein E; FDR, False discovery rate

Note: Multiple testing correction by false discovery rate (FDR) < 0.05 was considered significant

Both CDH6 ($\beta = 0.624$, $P = 5.52 \times 10^{-4}$, $FDR = 0.030$) and HAGH ($\beta = 0.491$, $P = 6.62 \times 10^{-4}$, $FDR = 0.030$) proteins remained significantly associated with AD even after adjusting for other covariates in model 2 (Supplementary Table 1).

In the replication analysis in the BioFINDER study (Table 2), plasma levels of CDH6 and HAGH were significantly associated with AD in the overall sample (CDH6: $\beta = 1.212$, $P = 5.18 \times 10^{-4}$; HAGH: $\beta = 0.631$, $P = 7.56 \times 10^{-15}$) as well as in *APOE* $\epsilon 4$ carriers (CDH6: $\beta = 1.365$, $P = 3.97 \times 10^{-3}$; HAGH: $\beta = 0.506$, $P = 9.31 \times 10^{-7}$) but not in *APOE* $\epsilon 2$ carriers. Plasma levels of HAGH protein were also associated with AD in *APOE* $\epsilon 33$ carriers ($\beta = 0.739$, $P = 3.76 \times 10^{-7}$) but in this subgroup no association with CDH6 was seen.

Figure 2 shows that the *APOE* genotype modifies the association between proteins and AD based on nominal statistical significance. In discovery analysis, eight additional proteins (TN-R, Beta-NGF, MDGA1, JAM-B, CD200, LXN, PDGF-R-alpha, and LAIR-2) were also positively associated with AD *APOE* $\epsilon 4$ carriers ($\beta > 0.107$, $P < 0.05$), but they did not survive multiple testing. In the *APOE2* stratum, the levels of two proteins including SMPD1 and VWC2 were reduced in AD cases compared to the *APOE* genotype matched controls (Supplementary Figure 1). In *APOE33* stratum, PRTG, CNTN5 and NCAN proteins, that do not emerge in the *APOE4* or *APOE2* stratum (see Figure 2), showed suggestive associations but did not survive multiple testing ($\beta > 0.193$, $P < 2.57 \times 10^{-2}$). Both CDH6 ($\beta = 0.202$, $P = 1.79 \times 10^{-1}$) and HAGH ($\beta = -0.018$, $P = 8.42 \times 10^{-1}$) did not show association with AD in *APOE33* carriers while HAGH showed nominal association in *APOE* $\epsilon 2$ carriers ($\beta = 0.482$, $P = 4.25 \times 10^{-2}$) (See Table 1).

Sensitivity analyses

Sensitivity analyses were performed in the Rotterdam Study to test the robustness of our findings. In the first sensitivity analysis (Supplementary Table 2), we adjusted for follow-up time, taking into account that some cases or controls may die of other diseases. This analysis showed that levels of both HAGH ($\beta = 0.477$, $P = 6.47 \times 10^{-4}$) and CDH6 ($\beta = 0.661$, $P = 1.48 \times 10^{-4}$) proteins were significantly increased in AD patients compared to controls in *APOE* $\epsilon 4$ carriers. In the second sensitivity analysis, we only analyzed protein that were assessed directly (non-imputed data). Similarly, the association of HAGH and CDH6 proteins with AD remained significant in *APOE* $\epsilon 4$ carriers when analyzing non-imputed proteomics data (Supplementary Table 3). Last but not least, we performed a formal interaction test to evaluate the interaction of *APOE* with each of the 91 proteins (Supplementary Table 4). Only three of 91 proteins showed interaction with *APOE* (P -value < 0.05) including HAGH ($\beta_{\text{interaction}} = 0.414$, $P_{\text{interaction}} = 1.70 \times 10^{-2}$), G-CSF ($\beta_{\text{interaction}} = 0.276$, $P_{\text{interaction}} = 2.78 \times 10^{-2}$) and CRTAM ($\beta_{\text{interaction}} = -0.221$, $P_{\text{interaction}} = 3.77 \times 10^{-2}$). Except, HAGH other two proteins (G-CSF, CRTAM) did not show association with AD in any of the analyzed *APOE* stratum (P -value > 0.05). For CDH6, the test for was not significant ($\beta_{\text{interaction}} = 0.078$, $P_{\text{interaction}} = 7.23 \times 10^{-1}$).




Figure 2: Venn diagram showing the overlap of proteins identified in the association analysis results of overall and *APOE* stratified analysis.

Association of CDH6 and HAGH protein levels with A β -42, p-tau, and t-tau in CSF

Among the two proteins that were associated to the future risk of AD, CDH6 and HAGH, the latter was not detected in the CSF in > 90% of the subjects in ADC cohort. CSF CDH6 protein levels were not associated with AD ($\beta = 0.329$, SE = 0.220, $P = 0.136$) in the overall as well as in *APOE* stratified analysis ($P > 0.114$; see Supplementary Table 5). However, multiple regression analysis adjusted for age and sex revealed a significant association of CDH6 CSF levels with both p-tau ($\beta = 23.2$, SE = 3.4, $P = 3.48 \times 10^{-11}$) and t-tau ($\beta = 207.4$, SE = 36.4, $P = 2.40 \times 10^{-8}$) when pooling AD patients and controls (Table 3 and Figure 3). In the *APOE* stratified analysis, levels of CDH6 were significantly associated with p-tau and t-tau levels but not with A β -42 levels in CSF in three *APOE* strata (see Table 3). When stratifying by case-control status (Supplementary Table 6), CDH6 levels were significantly associated with p-tau and t-tau levels in both cases and controls. In controls, also A β -42 was positively associated with CDH6 ($P < 1 \times 10^{-3}$; see Supplementary Table 6).

Association of proteins with *APOE*

Next, we associated the *APOE* genotype to the protein levels significantly associated with AD (CDH6 and HAGH). Results of the association of protein levels with *APOE* genotypes are provided in Supplementary Table 7 and Figure 2. In the overall sample, CDH6 protein levels were increased in the *APOE* $\epsilon 4$ carriers compared to *APOE* $\epsilon 2$ carriers ($\beta = 0.163$, $P = 3.79 \times 10^{-3}$). In controls, levels of CDH6 protein were decreased ($\beta = -0.131$, $P = 0.026$) in *APOE* $\epsilon 2$ carriers




Figure 3: Correlation plot between cerebrospinal fluid (CSF) levels of CDH6 with A β -42, p-tau and t-tau.

compared to *APOE* $\epsilon 3$ carriers. In the controls, levels of HAGH were decreased in the *APOE* $\epsilon 4$ ($\beta = -0.192$, $P = 0.028$) and *APOE* $\epsilon 2$ carriers ($\beta = -0.214$, $P = 0.042$) compared to *APOE* $\epsilon 3$ carriers.

Genome-Wide Association Study (GWAS)

The GWAS was conducted to determine the genetic drivers of the CDH6 and HAGH protein levels (Supplementary Figure 3:A and 4 respectively). We identified 13 genome-wide significant cis protein quantitative trait loci (pQTLs) located at 5p13.3 locus of chromosome 5 for CDH6 protein levels. All genome-wide significant pQTLs are located in the intergenic region at 5' UTR region of the *CDH6* gene. Among the 13 identified pQTLs, rs111283466 was the lead pQTL with the effect estimate (β) of 1.068 and P -value 1.92×10^{-9} (Supplementary Table 8). Q-Q plot (Supplementary Figure 5:A) indicates that the results are well adjusted for population stratification ($\lambda = 1.0056$). Further lookups in the GTEx database showed that the lead pQTL (rs111283466) also affects the expression of *CDH6* gene in various body tissues. GWAS analysis of HAGH protein levels did not identify any genome-wide significant pQTLs. Manhattan plot and Q-Q plot for GWAS results of HAGH protein levels are provided in the Supplementary materials (Supplementary Figure 4 and 5:B).

Discussion

In our study, plasma levels of CDH6 and HAGH proteins are significantly increased in presymptomatic AD patients compared to controls in the *APOE* $\epsilon 4$ stratum. In the replication analysis, both CDH6 and HAGH proteins showed significant association with AD in the BioFINDER study in *APOE* $\epsilon 4$ carriers. CDH6 protein levels were significantly correlated with

Table 2: Association of plasma levels of CDH6 and HAGH proteins with Alzheimer's disease in the BioFINDER Study

Biomarkers	APOE4 stratum			APOE33 stratum			APOE2 stratum			
	β	SE	P-value	β	SE	P-value	β	SE	P-value	
CDH6	1.212	0.349	5.18×10^{-4}	1.365	0.474	3.97×10^{-3}	0.961	0.585	1.01×10^{-1}	4.16 $\times 10^{-1}$
HAGH	0.631	0.081	7.56×10^{-15}	0.506	0.103	9.31×10^{-7}	0.739	0.145	3.76×10^{-7}	1.62 $\times 10^{-1}$

Abbreviations: AD, Alzheimer's disease; β , regression coefficient; SE, standard error
 *Logistic regression analysis adjusting for age and sex

Table 3: Association of CSF based CDH6 protein levels with AD biomarkers in Amsterdam Dementia Cohort

Biomarkers	APOE4 stratum			APOE33 stratum			APOE2 stratum			
	β	SE	P-value	β	SE	P-value	β	SE	P-value	
A β -42	16.574	26.827	5.37×10^{-1}	33.701	35.001	3.37×10^{-1}	14.499	44.966	7.48×10^{-1}	1.45 $\times 10^{-1}$
p-tau	23.189	3.404	3.48×10^{-11}	26.674	5.781	8.36×10^{-6}	21.981	5.564	1.17×10^{-4}	2.29 $\times 10^{-3}$
T-tau	207.396	36.437	2.40×10^{-8}	235.009	59.158	1.10×10^{-4}	193.859	64.068	2.90×10^{-3}	1.66 $\times 10^{-3}$

Abbreviations: AD, Alzheimer's disease; β , regression coefficient; SE, standard error
 *Linear regression analysis adjusting for age and sex

p-tau and t-tau measurements in CSF of the ADC. In GWAS analysis, we have also identified a genome-wide significant pQTL for CDH6 protein levels in the blood (rs111283466), which also affects the expression levels of *CDH6* transcripts in several tissues.

We observed a significant increase of CDH6 protein levels in the plasma of presymptomatic AD cases carrying the *APOE* $\epsilon 4$ allele which was also replicated in the BioFINDER study. When comparing our findings to the other studies¹⁹⁻²², we do not have an overlap in understudy proteins. However, like previous studies we do find an effect of the *APOE* gene on plasma level of proteins^{21,22}. In the *APOE* $\epsilon 4$ stratum, we see that the volcano plot (Figure 1) is clearly asymmetric suggesting increased levels of most neuronal proteins in AD patients carrying this allele before the clinical onset of disease. This might be explained by an increase in the blood-brain barrier permeability in *APOE* $\epsilon 4$ carriers²⁷, which may lead to increased levels of CDH6 in the blood as a result of higher levels of CDH6 in the brain. We found that CDH6 levels in the blood are driven by a genetic variant (rs111283466) in the cis-regulatory region. This may determine the CDH6 levels in both brain and blood cells, leaving the possibility open that elevated CDH6 has a blood-derived origin. Yet, such a mechanism does not explain why elevated levels in the blood are only seen in patients carrying the *APOE* $\epsilon 4$ allele. It is of note that the CDH6 coding gene is part of a larger cluster of cadherin (CDH) genes including *CDH9*, *CDH10*, *CDH12* and *CDH18*. As all of the CDH genes are paralogues and share homology, it is crucial to exclude cross-reactions of the antibodies²⁸ used by Olink across CDH proteins. Our GWAS benchmarks that the protein assessed in our plasma is indeed CDH6, as we found that the most important driver of the protein is in the promoter region of *CDH6*. None of the recently published GWAS of proteins reported significant pQTLs for CDH6 protein based on SomaLogic^{29,30}. The aptomere based measurement of the SomaLogic yields a different protein spectrum than that of the antibody-based method of Olink³¹. Our identified pQTLs did not show any association with AD (P -value < 0.05) in the largest AD GWAS¹¹. However, we find in our study that levels of CDH6 were increased in *APOE* $\epsilon 4$ carriers compared to *APOE* $\epsilon 2$ carriers. We do find that the region is associated to postcentral gyri in GWAS³² and a study has reported reduced volume of postcentral gyri in dementia patients³³.

Interestingly, we found significant positive associations of CSF levels of CDH6 protein with p-tau and t-tau levels in overall as well as in AD and controls only analyses, which are considered as biomarkers of neuronal injury and tau pathology^{34,35}. The upregulation of CDH6 protein in cerebral cortices of AD mice models (*APP/PS1*) compared to wild type has been reported by Lu *et al.*,³⁶ which is in line with our observation of positive correlation between CDH6 levels and AD pathological markers in CSF. Yet, we did not observe an association of the CDH6 protein with AD in CSF. We also observed positive association between CDH6 levels with amyloid-beta 42 in CSF of the controls, which might indicate disturbance in the amyloid-beta 42 metabolism which precedes decades before the buildup of A β in the brain³⁷. Alternatively, it may point towards a similar mechanism of production of the A β -42 and CDH6 proteins in a

healthy state³⁸. Increased levels of phosphorylated CDH6 protein levels were reported upon the addition of amyloid-beta in cortical neuronal cells³⁹, which adds evidence to the role of CDH6 in AD pathology. Taken together, these findings suggest that CSF levels of CDH6 protein may be associated with neuronal and axonal cell injury and neurofibrillary tangles in AD.

CDH6 is a cell surface glycoprotein that belongs to type II cadherin's⁴⁰. Cadherins are highly expressed in the brain and other tissues. They strongly interact with other molecules to perform molecular processes including synaptic functions⁴¹⁻⁴³, synaptogenesis⁴⁴, TGF-B signaling⁴⁵, neural crest differentiation⁴⁶, presenilin-mediated signaling and integrity of blood-brain barrier⁴⁷. Although it is not possible to infer whether the correlation of AD pathology with CDH6 in plasma and CSF, are cause or consequence of the disease, several pieces of evidence favor the role of CDH6 in the pathogenesis of AD^{39,48}. A recent study showed that the ADAM10 enzyme, whose coding gene is associated with AD¹¹, is involved in proteolytic cleavage of the *CDH6* protein, resulting in the formation of C-terminal fragment⁴⁹, in a similar manner as it cleaves the amyloid precursor protein (*APP*)^{50,51}. The transmembrane N-cadherin (*CDH2*), a paralogue of CDH6 and functionally related to CDH6⁴³, is also known to be cleaved by ADAM10 into N-cadherin C-terminal fragment 1 (NcadCTF1). Andreyeva *et al.*,⁵² have demonstrated that NcadCTF1 leads to accelerated amyloid- β -induced synaptic impairment, a process that characterizes an early stage event in AD^{53,54}. Increased levels of NcadCTF1 were also found in postmortem AD brain tissues compared with controls, suggesting that cadherins might induce synaptic dysfunction in a synergistic manner⁵².

In addition to CDH6, increased plasma levels of HAGH (Hydroxyacylglutathione hydrolase, mitochondrial) protein also showed significant association with AD in those who carry the *APOE* $\epsilon 4$ variant and suggestive association in overall and in *APOE* $\epsilon 2$ carriers. This finding is in line with the recently published findings of the BioFINDER study²⁵ and further supported by the *APOE* stratified analysis in the BioFINDER study that was conducted for the present study. In the replication analysis, plasma levels of HAGH showed significant association in both *APOE* $\epsilon 4$ and *APOE* $\epsilon 33$ carriers while in the discovery analysis in Rotterdam Study HAGH only showed significant association in *APOE* $\epsilon 4$ carriers which may be due to the lack of power. The HAGH protein is also known as glyoxalase-2, an enzyme, which is involved in the glyoxalase system along with glyoxalase-1 and its cofactor glutathione, a key player in oxidative stress control^{55,56}. Overall, the glyoxalase system is involved in the detoxification of glycolysis by-products particularly cytotoxic metabolite methylglyoxal⁵⁷. Levels of methylglyoxal in plasma are elevated during various disease conditions including hyperglycemia, which leads to the formation of reactive oxygen species (ROS) and causes oxidative stress. Moreover, methylglyoxal is also the precursor of glycation end products (AGEs) which are implicated in neurodegeneration and AD^{58,59}. The most compelling evidence for the role of the glyoxalase-2 protein in AD is that the AGEs and glyoxalase system is implicated in the regulation of amyloid precursor protein (*APP*) expression^{60,61}. Although glyoxalase system attributes protection against methylglyoxal mediated

oxidative stress, earlier studies have also observed increased levels of glyoxalase-1 enzyme (involved in the first step of methylglyoxal detoxification) in early AD stages^{62,63}. Increased levels of glyoxalase-2 (involved in the second step of methylglyoxal detoxification) in plasma might be a compensatory mechanism to increased levels of methylglyoxal during the early phase of disease or a general stress response⁵⁵. The growing number of studies have suggested the involvement of oxidative stress during the prodromal stage of AD⁶⁴⁻⁶⁶, which is in line with our finding of increased levels of glyoxalase-2 observed before the onset of AD.

The strength of the current study includes that it is conducted in the prospective population-based RS cohort, where samples were selected with mean 6.9 years of follow-up preceding the diagnosis of AD. It allowed us to study the plasma proteomics changes prior to the development of AD clinical symptoms. As AD is a disorder of the brain, we have validated that CSF levels of CDH6 are also associated with biomarkers of AD in CSF in an independent cohort. Further, we used the Olink neurology proteomic panel of 91 proteins for the quantification of proteins in the plasma, which estimates targeted proteins expressed in the brain from different pathways. One of the major limitations of our study is the limited sample size, including a small number of *APOE* $\epsilon 4$ carrier controls in the stratified analysis.

In conclusion, we observed elevated protein levels of CDH6 in plasma of AD patients carrying *APOE* $\epsilon 4$ allele in the discovery and replication analysis, a protein that plays a role in synaptogenesis. Positive correlation of CSF CDH6 levels with p-tau and t-tau may also indicate the association of CDH6 with neurodegeneration. We further found the association of the plasma levels of HAGH protein to AD in those carrying the *APOE* $\epsilon 4$ allele. Association of HAGH with AD further suggest the involvement of the glyoxalase and oxidative stress pathways in the pathogenesis of AD.

Methods

Study populations

Rotterdam Study

The Rotterdam Study (RS) is a prospective population-based study comprising of 14,926 middle and older aged (≥ 45 years) individuals from the Ommoord district of Rotterdam. The RS consists of three cohorts including RS-I (started in 1990, N=7983 participants), RS-II (started in 2000, N=3011) and RS-III (started in 2006, N=3932)⁶⁷. Study participants were extensively interviewed and physically examined at baseline and after every 3 to 4 years. For each participant fasting blood was collected at a dedicated center, centrifuged (Speed=3500g for 20 min at 4°C) within 4 hours of venipuncture to collect plasma and stored at -80°C. The study has been approved by the Medical Ethical Committee of Erasmus Medical Center and by the Ministry of Health, Welfare and Sport of the Netherlands. Written informed consent was obtained from

each study participant to participate and to collect information from their treating physicians. All methods were performed in accordance with the relevant guidelines and regulations. In current nested case-control proteomics analysis, we chose 161 incident AD cases and 155 controls match with respect to their age and sex, from the fifth visit of RS-I (RS-I-5) cohort. Table 4 shows the baseline characteristics of the selected sample. There were no significant differences in age, sex and body mass index (BMI). AD patients were more often carriers of the *APOE* ϵ 4 variant and less often of the *APOE* ϵ 2 variant. Blood for the proteome profiling was collected on average 6.9 years (standard deviation [SD] = 1.7) before the onset of clinical dementia in patients and mean 8.7 years (SD = 3.2) before the latest follow-up in controls.

Table 4: Population descriptive

	Total participants	Incident AD cases	Controls
N	316	161	155
Age (SD) blood collection, years	77.16(5.39)	77.43(5.21)	76.89(5.59)
Age at onset/last follow up	84.99(5.33)	84.37(5.01)	85.63(5.56)
Female (%)	201(63%)	104 (65%)	97 (63%)
Body Mass index	27.32(4.10)	27.29(3.75)	27.37(4.46)
Follow-up (SD) years	7.82(2.71)	6.94(1.71)	8.74(3.22)
<i>APOE</i> genotype			
<i>APOE</i> 44/34/24	98	68	30
<i>APOE</i> 33	171	76	95
<i>APOE</i> 22/23	34	13	21

Abbreviations: AD, Alzheimer's disease, SD, Standard deviation, *APOE*, apolipoprotein E gene

Dementia diagnosis

Over time, all participants were screened for dementia using the Mini-Mental State Examination (MMSE)⁶⁸ and Geriatric Mental Schedule (GMS)⁶⁹ organic level for all participants. Screen-positive subjects (MMSE<26 or GMS organic level > 0) underwent the Cambridge examination for mental disorders of the elderly (CAMDEX)⁷⁰ and participants suspected of having dementia were extensively examined with neuropsychological testing and neuroimaging biomarkers when available. Patients were further ascertained by linking them with their medical records from general practitioners, the regional institute for outpatient mental health care and municipality. Dementia of all patients was diagnosed based on the internationally accepted Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R) criteria and AD using the National Institute of Neurological Disorders and Stroke–Association Internationale pour la Recherche et l'Enseignement en Neurosciences (NINCDS-ADRDA)⁷¹ criteria for possible, probable and definite AD. NINCDS-ADRDA criteria were also used to diagnose vascular dementia. The final diagnosis was confirmed by a panel of neurologists, neurophysiologists, and research physicians⁷². AD diagnosis in RS is also provided in more detail in earlier publications⁷².

Proteome profiling

Proteomics profiling of the 316 plasma samples was performed using neurology panel of OLINK's Proximity Extension Assay (ProSeek, OLINK AB, Uppsala, Sweden), which includes 91 proteins involved in various pathways including axon development, axon guidance, cell adhesion, cell death, cell differentiation, cell growth, cellular metabolic process, immune response, MAPK cascade, neurogenesis, proteolysis, signal transduction and synapse assembly (<https://www.olink.com/products/neurology/>). This method uses affinity-based assay, in which a pair of oligonucleotide-labeled antibody probes bind to a target protein. Proximity-dependent DNA polymerization event forms a polymerase chain reaction (PCR) target sequence between two probes bound in close proximity. The generated PCR target sequence is detected and quantified using real-time PCR method. The resultant protein abundance is provided as NPX (Normalized Protein Expression), which is an arbitrary unit on log₂ scale. Lower limit of detection is estimated based on negative controls inserted in each run and measurements below this limited were treated as missing. None of the detected markers in our dataset reach missingness more than 10 percent. Protein markers with missing values less than 10% were imputed with the lowest detected limit for further analysis. More detailed information about detection limits, assay performance and validation methods are available from the service provider (www.olink.com)⁷³.

APOE genotyping

In the RS *APOE* genotyping was performed using Polymerase chain reaction (PCR) and amplified PCR product was digested with *HhaI* enzyme. Restriction fragments of enzyme products were visualized by silver staining after getting them separated with precast ExcelGel gels (Pharmacia Biotech, Uppsala, Sweden). Genotype results were examined by three independent persons. In the case of non-agreement *APOE* genotype was repeated^{74,75}.

Genotyping and imputations

In the RS participant's blood was collected during baseline and follow-up visit. DNA genotyping was performed for all the participants with proper DNA quality with the 550K, 550K duo, or 610K Illumina arrays. In genotyping quality control, genetic variants exclusion criteria include, call rate < 95%, Hardy-Weinberg equilibrium $P < 1.0 \times 10^{-6}$ and Minor Allele Frequency (MAF) < 1%. Sample exclusion criteria include excess autosomal heterozygosity (0.336), call rate < 97.5%, duplicate or family relationships and ethnic outliers identified by the identity-by-state clustering analysis (having identity-by-state probability < 97% or > 3 standard deviation from population mean)⁷⁶. Further, genetic variants were imputed with the Haplotype Reference Consortium (HRC) reference panel (version 1.0)⁷⁷, using the Michigan imputation server⁷⁸. The server uses SHAPEIT2 (v2.r790)⁷⁹ to phase the genotype data and performs imputation with Minimac 3 software⁸⁰. Genotyping information was available for 281 among 316 participants included in the current study.

BioFINDER Study

In the current study, replication analysis was performed in 671 participants (AD patients = 186, Controls = 485) of the BioFINDER (Biomarkers For Identifying Neurodegenerative Disorders Early and Reliably) study. Characteristics of the BioFINDER study participants included in the replication analysis are provided in Supplementary Table 9. The BioFINDER study includes participants from southern Sweden recruited between 2009 and 2014 (www.biofinder.se). The study participants were assessed by experienced physicians including the neurological, psychiatric and cognitive assessments⁸¹. The NINCDS-ADRDA criteria were used to classify Alzheimer's disease dementia patients for probable Alzheimer's disease patients. All dementia due to Alzheimer's disease patients had pathological CSF A β 42/A β 40 ratio of < 0.1. The inclusion criteria for the cognitively normal elderly participants included i) aged 60–80 years, ii) MMSE scores ranging between 28–30 at their baseline screening visit, iii) no cognitive impairment symptoms assessed by a physician, and iv) not fulfilling the criteria for mild cognitive impairment or dementia. Exclusion criteria included i) refused lumbar puncture, ii) significant neurological or psychiatric disease, iii) current alcohol or substance misuse, or iv) systematic illness preventing them from participating in the study^{25,81}. Written Informed consents were collected from each study participant and the study has been approved by the Regional Ethics Committee in Lund, Sweden.

Protein profiling

During the baseline visit of the BioFINDER study, plasma and lumbar CSF samples were collected from non-fasting participants. Standardized protocol was followed to analyze the plasma and CSF samples. All samples were centrifuged at 2000 g (+4 °C for 10 min), and aliquoted into 1 ml polypropylene tubes (Sarstedt AG & Co., Nümbrecht, Germany), and stored at -80°C. Before the proteomics profiling, plasma and CSF samples underwent one cycle of freeze-thaw, and further aliquoted into 200L Lobind tubes (Eppendorf Nordic A/S, Denmark). Protein concentrations were quantified using the ProSeek multiplex immunoassay, developed by Olink Proteomics (Uppsala, Sweden)²⁵.

Amsterdam Dementia Cohort (ADC)

In the validation analysis of most interesting proteins, we used 441 participants from the ADC cohort whose CSF samples were already profiled for neurology related proteins using the OLINK's Proximity Extension Assay (ProSeek, OLINK AB, Uppsala, Sweden). Information about characteristics of patients included in current analysis as a part of the validation dataset is listed in Supplementary Table 9.

The ADC is a prospective memory-clinic cohort that was established in September 2000 at the Alzheimer Center Amsterdam of Amsterdam UMC. The cohort has included 6000 individuals until September 2017^{82, 83,84}. All participants underwent standardized cognitive screening including neurological and cognitive examination, blood sampling, a lumbar puncture to collect

CSF and brain magnetic resonance imaging. All CSF samples were stored in agreement with the JPNB-BIOMARKAPD guidelines⁸⁵. All subjects provided written informed consent for use of biomaterial and clinical data for research and the study was approved by the local medical ethical review board. All methods were performed in accordance with the relevant guidelines and regulations. A sample of 441 participants selected for our validation analysis consists of 242 AD and 199 cognitively normal controls who were presented at the memory clinic with subjective cognitive decline (i.e., Criteria for mild cognitive impairment and dementia not fulfilled)). As additional inclusion criteria, controls were required to have normal AD CSF biomarkers profile: low CSF β -amyloid 1–42 ($A\beta_{42}$) and high p- or t-tau level (applying local laboratory cut-offs) and to remain cognitively stable for 2 years. All participants underwent standard neurological and cognitive assessments and the diagnosis was assigned according to consensus AD criteria⁸⁶. Global Mini-Mental State Examination (MMSE) was used to examine global cognition. The levels of CSF AD-related biomarkers ($A\beta_{42}$, total and phosphorylated tau [t-Tau and p-Tau₁₈₁]) were analyzed at Amsterdam UMC as part of the routine diagnostic procedure using commercially available kits (Innotest $A\beta(1-42)$, total Tau, phospho-Tau(181P); Fujirebio, Ghent, Belgium)^{10,24}.

Statistical analysis

Plasma protein association with AD

To identify AD-associated proteins, plasma levels of 91 proteins were compared between incident AD cases and non-demented controls using logistic regression, adjusted for age and sex in the first model. In the second model, we additionally adjusted for body mass index (BMI), smoking, educational status and medication use (lipid-lowering medications, antihypertensive and anti-inflammatory medication). To identify *APOE* specific associations of proteins with AD, we performed stratified association analysis based on *APOE* genotype carrier status. All participants were divided into *APOE4* stratum (*APOE* 44/34/24), *APOE3* stratum (*APOE* 33) and *APOE2* stratum (*APOE* 22/23). Participants with *APOE 24* genotypes were pooled within the *APOE4* stratum because an earlier study has demonstrated that the risk profiles of *APOE 24* genotype to AD and dementia is similar to those with *APOE 34* genotype carriers⁵. The association results were corrected for multiple testing using false discovery rate (*FDR*) by Benjamini and Hochberg method separately for the overall analysis, and in each *APOE* stratum⁸⁷ and association tests with *FDR* < 0.05 were considered significant. All analyses were performed using R software (<https://www.r-project.org>).

Sensitivity analyses

Moreover, we performed sensitivity analyses. In the first sensitivity analysis, we repeated the overall and *APOE* stratified regression analysis (Model 1: age and sex) additionally adjusting for the follow-up time (the time between blood collection and onset of AD or last follow-up for controls). In the second sensitivity analysis, to assess the differential bias due to missingness, we performed the overall and *APOE* stratified association analysis in the non-imputed proteomics

data adjusting for age and sex. We also tested the interaction of *APOE* genotype ($\epsilon 4$ carriers and non-carriers) and proteins levels using logistic regression model adjusting for age and sex.

Additional analysis of proteins showing association with AD

A detailed flowchart of the analysis is provided in Figure 4 about the discovery, replication and validation analysis. Proteins that appeared significantly altered in overall or *APOE* stratified analysis were further tested for association with *APOE* genotypes; second GWAS was performed to identify pQTLs, regulating the levels of protein in blood.

Replication analysis

Replication analysis of two proteins was performed in an independent BioFINDER study. We performed association of plasma levels of proteins with AD versus controls (AD cases = 186, controls = 485) in the overall sample and stratified by *APOE* genotype: *APOE4* stratum (*APOE* 44/34), *APOE3* stratum (*APOE* 33) and *APOE2* stratum (*APOE* 22/23). We used logistic regression analysis adjusted for age, sex and date of sample collection.

Validation analysis: Association of CSF protein levels with A β -42, p-tau, and t-tau

In the validation analysis of specific proteins in an independent ADC cohort (N = 441), we performed association of CSF protein levels with AD versus control group and with A β -42, p-tau and t-tau levels in CSF. All the validation analyses were performed in the overall sample and stratified by *APOE* genotype: *APOE4* stratum (*APOE* 44/34), *APOE3* stratum (*APOE* 33) and *APOE2* stratum (*APOE* 22/23). We used linear regression analysis adjusted for age and sex to evaluate the association of proteins measured in CSF with AD brain pathology biomarkers in the overall sample and stratified by clinical diagnosis (AD and controls).

Association of plasma protein levels with APOE genotype

To further evaluate the association of proteins with *APOE* genotypes, we compared protein levels, among *APOE* genotype groups (*APOE* 44/34/24=1 versus *APOE* 33=0, *APOE* 44/34=1 versus *APOE* 22/23=0 and *APOE* 22/23=1 versus *APOE* 33=0) in the overall study sample, in AD patients, and in control groups separately. Linear regression analysis was performed using protein levels as outcome and *APOE* status as predictor, adjusted for age and sex.

Genome-wide association study

Further, we performed the genome-wide association study (GWAS) to identify protein quantitative trait loci (pQTLs) for candidate proteins. We regressed out protein levels against age, sex and principal components to calculate residuals. To normalize the calculated residuals we applied Rank-inverse transformation on residuals. Principal components derived from genotypes were used in the association analysis to adjust for population stratification. GWAS of rank-inverse normalized residuals was performed using score test option in RVTEST software⁸⁸. Variants with

Discovery (Rotterdam Study)




Figure 4: Flowchart of the analyses. Rotterdam Study was used as discovery cohort in plasma-based proteomics analysis. Altered proteins in plasma analysis were replicated in the BioFINDER study and further validated in Amsterdam Dementia Cohort participants. Abbreviations; AD: Alzheimer's disease; *APOE*: apolipoprotein E; GWAS: genome-wide association study; CSF: cerebrospinal fluid.

low imputation quality $R^2 < 0.3$ and minor allele count less than five were excluded from the results. Manhattan and quantile-quantile (Q-Q) plots for GWAS results were generated with web-based utility Functional mapping and annotation of genetic associations (FUMA)⁸⁹ and regional association plots using LocusZoom (<http://locuszoom.org>). pQTLs with a P -value $< 2.5 \times 10^{-8}$ ($5 \times 10^{-8}/2$ tested proteins) were considered genome-wide significant. To check the overlap of identified pQTL with expression quantitative loci (eQTLs) we used GTEx data base⁹⁰.

Data access and availability

Current study used data from RS and ADC, where sharing of participants data is not allowed publicly due to legal and ethical permissions. Informed consents collected for both studies do not allow to share individual participants data in public repository. Data access can be made available for interested researchers upon request to corresponding author Cornelia M. van Duijn (Cornelia.vanDuijn@ndph.ox.ac.uk).

Acknowledgement

This study was funded by the ADAPTED: Alzheimer's Disease Apolipoprotein Pathology for Treatment Elucidation and Development consortium which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115975. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. This study was also funded by the PERADES Program (Defining Genetic, Polygenic and Environmental Risk for Alzheimer's disease, using multiple powerful cohorts, focused Epigenetics and Stem cell metabolomics), Project number 733051021 and Memorabel supported by ZonMW (Project number 733050814). The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam, Netherlands Organization for the Health Research and Development (ZonMw), the Research Institute for Diseases in the Elderly (RIDE), the Ministry of Education, Culture and Science, the Ministry for Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The authors are grateful to the study participants, the staff from the Rotterdam Study and the participating general practitioners and pharmacists. The generation and management of GWAS genotype data for the Rotterdam Study (RS-I, RS-II, RS-III) was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands. The GWAS datasets are supported by the Netherlands Organization of Scientific Research NWO Investments (Project number 175.010.2005.011, 911-03-012), the Genetic Laboratory of the Department of Internal Medicine, Erasmus MC, the Research Institute for Diseases in the Elderly (014-93-015; RIDE2), the Netherlands Genomics Initiative (NGI)/Netherlands Organization for Scientific Research (NWO) Netherlands Consortium for Healthy Aging (NCHA), project number 050-060-810. We thank Pascal Arp, Mila Jhamai, Marijn

Verkerk, Lizbeth Herrera and Marjolein Peters, MSc, and Carolina Medina-Gomez, MSc, for their help in creating the GWAS database, and Karol Estrada, PhD, Yurii Aulchenko, PhD, and Carolina Medina-Gomez, MSc, for the creation and analysis of imputed data.

Amsterdam Dementia Cohort

The Alzheimer Center Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc funds. The clinical database structure was developed with funding from Stichting Dioraphte. CSF analysis were supported by the Weston Brain Institute and Stichting Alzheimer Nederland.

Competing interests

S.A., M.C.M., A.D., R.A., M.E.S., A.R., T.H., E.S., N.M., P.S., M.A.I., N.A., C.M.D. declare no competing interests. O.H. has acquired research support (for the institution) from Roche, Pfizer, GE Healthcare, Biogen, AVID Radiopharmaceuticals and Euroimmun. In the past 2 years, O.H. has received consultancy/speaker fees (paid to the institution) from Biogen and Roche. Dr. Nikolaos Giagtzoglou was an employee at Biogen Idec, USA. Dr. Alfredo Cabrera-Socorro is an employee of Janssen Pharmaceutical NV, Turnhoutseweg 30, 2340 Beerse, Belgium. Dr. Margot H.M. Bakker is a full time employee of AbbVie GmbH & Co KG and owns AbbVie stock. AbbVie contributed to the study design, research, and interpretation of data, reviewing, and approving the publication. Prof. dr. Teunissen has functioned in advisory boards of Roche, received non-financial support in the form of research consumables from ADxNeurosciences and Euroimmun, performed contract research or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, EIP farma, PeopleBio, Roche. Research programs of Prof. dr. Wiesje van der Flier have been funded by ZonMW, NWO, EU-FP7, Alzheimer Nederland, CardioVascular Onderzoek Nederland, stichting Dioraphte, Gieskes-Strijbis fonds, Pasmaan stichting, Biogen MA Inc, Boehringer Ingelheim, Piramal Neuroimaging, Roche BV, Janssen Stellar, Combinostics. WF holds the Pasmaan chair. WF has performed contract research for Biogen MA Inc and Boehringer Ingelheim. WF has been an invited speaker at Boehringer Ingelheim and Biogen MA Inc. All funding is paid to her institution.

References

1. Au, R., Piers, R.J. & Lancashire, L. Back to the future: Alzheimer's disease heterogeneity revisited. *Alzheimers Dement (Amst)* **1**, 368-370 (2015).
2. Corder, E.H. *et al.* Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-3 (1993).
3. Corder, E.H. *et al.* Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. *Nat Genet* **7**, 180-4 (1994).
4. Seshadri, S., Drachman, D.A. & Lippa, C.F. Apolipoprotein E epsilon 4 allele and the lifetime risk of Alzheimer's disease. What physicians know, and what they should know. *Arch Neurol* **52**, 1074-9 (1995).
5. van der Lee, S.J. *et al.* The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *Lancet Neurol* **17**, 434-444 (2018).
6. Fernandez, C.G., Hamby, M.E., McReynolds, M.L. & Ray, W.J. The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer's Disease. *Frontiers in aging neuroscience* **11**, 14 (2019).
7. Sunderland, T. *et al.* Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. *Biol Psychiatry* **56**, 670-6 (2004).
8. de la Torre, J.C. Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. *Lancet Neurol* **3**, 184-90 (2004).
9. Larsson, S.C. *et al.* Modifiable pathways in Alzheimer's disease: Mendelian randomisation analysis. *BMJ* **359**, j5375 (2017).
10. Henstridge, C.M., Hyman, B.T. & Spires-Jones, T.L. Beyond the neuron—cellular interactions early in Alzheimer disease pathogenesis. *Nature Reviews Neuroscience*, 1 (2019).
11. Kunkle, B.W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430 (2019).
12. Colonna, M. TREMs in the immune system and beyond. *Nat Rev Immunol* **3**, 445-53 (2003).
13. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nature Reviews Neuroscience* **12**, 723 (2011).
14. Katusic, Z.S. & Austin, S.A. Endothelial nitric oxide: protector of a healthy mind. *European heart journal* **35**, 888-894 (2013).
15. Koizumi, K., Wang, G. & Park, L. Endothelial dysfunction and amyloid- β -induced neurovascular alterations. *Cellular and molecular neurobiology* **36**, 155-165 (2016).
16. Han, B.H. *et al.* Cerebrovascular dysfunction in amyloid precursor protein transgenic mice: contribution of soluble and insoluble amyloid- β peptide, partial restoration via α -secretase inhibition. *Journal of Neuroscience* **28**, 13542-13550 (2008).
17. Tong, X.-K., Lecrux, C. & Hamel, E. Age-dependent rescue by simvastatin of Alzheimer's disease cerebrovascular and memory deficits. *Journal of neuroscience* **32**, 4705-4715 (2012).


18. Park, L. *et al.* Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer Abeta Peptides. *Circ Res* **121**, 258-269 (2017).
19. Hye, A. *et al.* Proteome-based plasma biomarkers for Alzheimer's disease. *Brain* **129**, 3042-50 (2006).
20. Ray, S. *et al.* Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. *Nature medicine* **13**, 1359 (2007).
21. Soares, H.D. *et al.* Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. *Archives of neurology* **69**, 1310-1317 (2012).
22. Ringman, J.M. *et al.* Plasma signaling proteins in persons at genetic risk for Alzheimer disease: influence of APOE genotype. *Archives of neurology* **69**, 757-764 (2012).
23. Hu, W.T. *et al.* Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. *Neurology* **79**, 897-905 (2012).
24. Llano, D.A., Devanarayan, V., Simon, A.J. & Alzheimer's Disease Neuroimaging, I. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. *Alzheimer Disease & Associated Disorders* **27**, 233-243 (2013).
25. Whelan, C.D. *et al.* Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. *Acta neuropathologica communications* **7**, 1-14 (2019).
26. Blankenburg, M., Haberland, L., Elvers, H.D., Tannert, C. & Jandrig, B. High-Throughput Omics Technologies: Potential Tools for the Investigation of Influences of EMF on Biological Systems. *Curr Genomics* **10**, 86-92 (2009).
27. Bell, R.D. *et al.* Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. *Nature* **485**, 512-6 (2012).
28. Phizicky, E., Bastiaens, P.I., Zhu, H., Snyder, M. & Fields, S. Protein analysis on a proteomic scale. *Nature* **422**, 208-15 (2003).
29. Emilsson, V. *et al.* Co-regulatory networks of human serum proteins link genetics to disease. *Science* **361**, 769-773 (2018).
30. Sun, B.B. *et al.* Genomic atlas of the human plasma proteome. *Nature* **558**, 73-79 (2018).
31. Gold, L. *et al.* Aptamer-based multiplexed proteomic technology for biomarker discovery. *Nature Precedings*, 1-1 (2010).
32. Zhao, B. *et al.* Genome-wide association analysis of 19,629 individuals identifies variants influencing regional brain volumes and refines their genetic co-architecture with cognitive and mental health traits. *Nature genetics* **51**, 1637-1644 (2019).
33. Harper, L. *et al.* Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. *Journal of Neurology, Neurosurgery & Psychiatry* **88**, 908-916 (2017).
34. Sutphen, C.L. *et al.* Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. *Alzheimers Dement* **14**, 869-879 (2018).
35. Hesse, C. *et al.* Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. *Neuroscience letters* **297**, 187-190 (2001).

36. Lv, J. *et al.* Quantitative proteomics reveals that PEA15 regulates astroglial Abeta phagocytosis in an Alzheimer's disease mouse model. *J Proteomics* **110**, 45-58 (2014).
37. Ye, L. *et al.* Abeta seeding potency peaks in the early stages of cerebral beta-amyloidosis. *EMBO Rep* **18**, 1536-1544 (2017).
38. Asada-Utsugi, M. *et al.* N-cadherin enhances APP dimerization at the extracellular domain and modulates A β production. *Journal of neurochemistry* **119**, 354-363 (2011).
39. Henriques, A.G. *et al.* Altered protein phosphorylation as a resource for potential AD biomarkers. *Sci Rep* **6**, 30319 (2016).
40. Gul, I.S., Hulpiau, P., Saeys, Y. & van Roy, F. Evolution and diversity of cadherins and catenins. *Exp Cell Res* **358**, 3-9 (2017).
41. Fannon, A.M. & Colman, D.R. A model for central synaptic junctional complex formation based on the differential adhesive specificities of the cadherins. *Neuron* **17**, 423-34 (1996).
42. Obst-Pernberg, K. & Redies, C. Cadherins and synaptic specificity. *J Neurosci Res* **58**, 130-8 (1999).
43. Yamagata, M., Duan, X. & Sanes, J.R. Cadherins Interact With Synaptic Organizers to Promote Synaptic Differentiation. *Front Mol Neurosci* **11**, 142 (2018).
44. Arikath, J. & Reichardt, L.F. Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. *Trends Neurosci* **31**, 487-94 (2008).
45. Sancisi, V. *et al.* Cadherin 6 is a new RUNX2 target in TGF-beta signalling pathway. *PLoS One* **8**, e75489 (2013).
46. Clay, M.R. & Halloran, M.C. Cadherin 6 promotes neural crest cell detachment via F-actin regulation and influences active Rho distribution during epithelial-to-mesenchymal transition. *Development* **141**, 2506-15 (2014).
47. Montagne, A. *et al.* Blood-brain barrier breakdown in the aging human hippocampus. *Neuron* **85**, 296-302 (2015).
48. Inoue, T., Tanaka, T., Suzuki, S.C. & Takeichi, M. Cadherin-6 in the developing mouse brain: expression along restricted connection systems and synaptic localization suggest a potential role in neuronal circuitry. *Dev Dyn* **211**, 338-51 (1998).
49. Kuhn, P.H. *et al.* Systematic substrate identification indicates a central role for the metalloprotease ADAM10 in axon targeting and synapse function. *Elife* **5**(2016).
50. Malinverno, M. *et al.* Synaptic localization and activity of ADAM10 regulate excitatory synapses through N-cadherin cleavage. *Journal of Neuroscience* **30**, 16343-16355 (2010).
51. Marambaud, P. *et al.* A CBP binding transcriptional repressor produced by the PS1/ ϵ -cleavage of N-cadherin is inhibited by PS1 FAD mutations. *Cell* **114**, 635-645 (2003).
52. Andreyeva, A. *et al.* C-terminal fragment of N-cadherin accelerates synapse destabilization by amyloid-beta. *Brain* **135**, 2140-54 (2012).
53. Hu, N.W. *et al.* Extracellular Forms of Abeta and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity. *Cell Rep* **23**, 1932-1938 (2018).
54. Togashi, H. *et al.* Cadherin regulates dendritic spine morphogenesis. *Neuron* **35**, 77-89 (2002).
55. Chen, F. *et al.* Role for glyoxalase I in Alzheimer's disease. *Proc Natl Acad Sci U S A* **101**, 7687-92 (2004).

Chapter 4


56. Thornalley, P.J. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. *Biochem J* **269**, 1-11 (1990).
57. Xu, Y. & Chen, X. Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. *J Biol Chem* **281**, 26702-13 (2006).
58. Desai, K.M. *et al.* Oxidative stress and aging: is methylglyoxal the hidden enemy? *Can J Physiol Pharmacol* **88**, 273-84 (2010).
59. Takeuchi, M. *et al.* Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. *Curr Alzheimer Res* **1**, 39-46 (2004).
60. Ko, S.Y., Lin, Y.P., Lin, Y.S. & Chang, S.S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. *Free Radic Biol Med* **49**, 474-80 (2010).
61. Wang, J.Z., Wang, Z.H. & Tian, Q. Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer's disease. *Neurosci Bull* **30**, 359-66 (2014).
62. More, S.S., Vartak, A.P. & Vince, R. Restoration of glyoxalase enzyme activity precludes cognitive dysfunction in a mouse model of Alzheimer's disease. *ACS Chem Neurosci* **4**, 330-8 (2013).
63. Kuhla, B. *et al.* Age- and stage-dependent glyoxalase I expression and its activity in normal and Alzheimer's disease brains. *Neurobiol Aging* **28**, 29-41 (2007).
64. Shea, T.B., Rogers, E., Ashline, D., Ortiz, D. & Sheu, M.S. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. *Free Radic Biol Med* **33**, 1115-20 (2002).
65. Baldeiras, I. *et al.* Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. *J Alzheimers Dis* **15**, 117-28 (2008).
66. Guidi, I. *et al.* Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. *Neurobiol Aging* **27**, 262-9 (2006).
67. Hofman, A. *et al.* The Rotterdam Study: 2016 objectives and design update. *Eur J Epidemiol* **30**, 661-708 (2015).
68. Folstein, M.F., Folstein, S.E. & McHugh, P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J Psychiatr Res* **12**, 189-98 (1975).
69. Copeland, J.R. *et al.* A semi-structured clinical interview for the assessment of diagnosis and mental state in the elderly: the Geriatric Mental State Schedule. I. Development and reliability. *Psychol Med* **6**, 439-49 (1976).
70. Roth, M. *et al.* CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. *Br J Psychiatry* **149**, 698-709 (1986).
71. McKhann, G. *et al.* Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-44 (1984).
72. Ott, A., Breteler, M.M., van Harskamp, F., Stijnen, T. & Hofman, A. Incidence and risk of dementia. The Rotterdam Study. *Am J Epidemiol* **147**, 574-80 (1998).

73. Brann, E. *et al.* Inflammatory markers in late pregnancy in association with postpartum depression-A nested case-control study. *Psychoneuroendocrinology* **79**, 146-159 (2017).
74. Slooter, A.J. *et al.* Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. *J Neurol* **246**, 304-8 (1999).
75. Slooter, A.J. *et al.* Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. *Arch Neurol* **55**, 964-8 (1998).
76. Roshchupkin, G.V. *et al.* Fine-mapping the effects of Alzheimer's disease risk loci on brain morphology. *Neurobiol Aging* **48**, 204-211 (2016).
77. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279-83 (2016).
78. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-7 (2016).
79. Delaneau, O., Marchini, J., Genomes Project, C. & Genomes Project, C. Integrating sequence and array data to create an improved 1000 Genomes Project haplotype reference panel. *Nat Commun* **5**, 3934 (2014).
80. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G.R. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. *Nat Genet* **44**, 955-9 (2012).
81. Palmqvist, S. *et al.* Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid beta-amyloid 42: a cross-validation study against amyloid positron emission tomography. *JAMA Neurol* **71**, 1282-9 (2014).
82. van der Flier, W.M. & Scheltens, P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. *J Alzheimers Dis* **62**, 1091-1111 (2018).
83. van der Flier, W.M. *et al.* Optimizing patient care and research: the Amsterdam Dementia Cohort. *Journal of Alzheimer's disease* **41**, 313-327 (2014).
84. Van Der Flier, W.M. & Scheltens, P. Amsterdam dementia cohort: performing research to optimize care. *Journal of Alzheimer's Disease* **62**, 1091-1111 (2018).
85. Reijs, B.L.R. *et al.* The Central Biobank and Virtual Biobank of BIOMARKAPD: a resource for studies on neurodegenerative diseases. *Frontiers in neurology* **6**, 216 (2015).
86. van der Flier, W.M. *et al.* Optimizing patient care and research: the Amsterdam Dementia Cohort. *J Alzheimers Dis* **41**, 313-27 (2014).
87. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *Journal of the royal statistical society. Series B (Methodological)*, 289-300 (1995).
88. Zhan, X., Hu, Y., Li, B., Abecasis, G.R. & Liu, D.J. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics* **32**, 1423-6 (2016).
89. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
90. Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* **45**, 580-5 (2013).



Chapter 5

Gut-Liver-Brain axis



Chapter 5.1

Association of altered liver enzymes with Alzheimer's disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers

Kwangsik Nho*, Alexandra Kueider-Paisley*, Shahzad Ahmad*, Siamak MahmoudianDehkordi, Matthias Arnold, Shannon L. Risacher, Gregory Louie, Colette Blach, Rebecca Baillie, Xianlin Han, Gabi Kastenmüller, John Q. Trojanowski, Leslie M. Shaw, Michael W. Weiner, P. Murali Doraiswamy, Cornelia van Duijn, Andrew J. Saykin[#], Rima Kaddurah-Daouk[#], for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium

This chapter is published in JAMA Network Open. 2019 Jul 3;2(7): e197978

**First authors contributed equally to the work*

#Senior authors contributed equally to the work

Supplementary information for this chapter is available at:
[10.1001/jamanetworkopen.2019.7978](https://doi.org/10.1001/jamanetworkopen.2019.7978)

Abstract

Importance: Increasing evidence suggests an important role of liver function in the pathophysiology of Alzheimer's disease (AD). The liver is a major metabolic hub; therefore, investigating the association of liver function with AD, cognition, neuroimaging, and CSF biomarkers would improve the understanding of the role of metabolic dysfunction in AD.

Objective: To examine whether liver function markers are associated with cognitive dysfunction and the "A/T/N" (amyloid, tau, and neurodegeneration) biomarkers for AD.

Design, Setting, and Participants: In this cohort study, serum-based liver function markers were measured from September 1, 2005, to August 31, 2013, in 1581 AD Neuroimaging Initiative participants along with cognitive measures, cerebrospinal fluid (CSF) biomarkers, brain atrophy, brain glucose metabolism, and amyloid- β accumulation. Associations of liver function markers with AD-associated clinical and A/T/N biomarkers were assessed using generalized linear models adjusted for confounding variables and multiple comparisons. Statistical analysis was performed from November 1, 2017, to February 28, 2019.

Exposure: Five serum-based liver function markers (total bilirubin, albumin, alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase) from AD Neuroimaging Initiative participants were used as exposure variables.

Main Outcomes and Measures: Primary outcomes included diagnosis of AD, composite scores for executive functioning and memory, CSF biomarkers, atrophy measured by magnetic resonance imaging, brain glucose metabolism measured by fludeoxyglucose F 18 (18F) positron emission tomography, and amyloid- β accumulation measured by [18F] florbetapir positron emission tomography.

Results: Participants in the AD Neuroimaging Initiative ($n = 1581$; 697 women and 884 men; mean [SD] age, 73.4 [7.2] years) included 407 cognitively normal older adults, 20 with significant memory concern, 298 with early mild cognitive impairment, 544 with late mild cognitive impairment, and 312 with AD. An elevated aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratio and lower levels of ALT were associated with AD diagnosis (AST to ALT ratio: odds ratio, 7.932 [95% CI, 1.673-37.617]; $P = .03$; ALT: odds ratio, 0.133 [95% CI, 0.042-0.422]; $P = .004$) and poor cognitive performance (AST to ALT ratio: β [SE], -0.465 [0.180]; $P = .02$ for memory composite score; β [SE], -0.679 [0.215]; $P = .006$ for executive function composite score; ALT: β [SE], 0.397 [0.128]; $P = .006$ for memory composite score; β [SE], 0.637 [0.152]; $P < .001$ for executive function composite score). Increased AST to ALT ratio values were associated with lower CSF amyloid- β 1-42 levels (β [SE], -0.170 [0.061]; $P = .04$) and increased amyloid- β deposition (amyloid biomarkers), higher CSF phosphorylated

tau181 (β [SE], 0.175 [0.055]; $P = .02$) (tau biomarkers) and higher CSF total tau levels (β [SE], 0.160 [0.049]; $P = .02$) and reduced brain glucose metabolism (β [SE], -0.123 [0.042]; $P = .03$) (neurodegeneration biomarkers). Lower levels of ALT were associated with increased amyloid- β deposition (amyloid biomarkers), and reduced brain glucose metabolism (β [SE], 0.096 [0.030]; $P = .02$) and greater atrophy (neurodegeneration biomarkers).

Conclusion and Relevance: Consistent associations of serum-based liver function markers with cognitive performance and A/T/N biomarkers for AD highlight the involvement of metabolic disturbances in the pathophysiology of AD. Further studies are needed to determine if these associations represent a causative or secondary role. Liver enzyme involvement in AD opens avenues for novel diagnostics and therapeutics.

Introduction

Metabolic activities in the liver determine the state of the metabolic readout of peripheral circulation. Mounting evidence suggests that patients with Alzheimer's disease (AD) display metabolic dysfunction¹. Clinical studies suggest that impaired signaling, energy metabolism, inflammation, and insulin resistance play a role in AD^{2,3}. This observation is in line with the observation that many metabolic disorders (e.g., diabetes, hypertension, obesity, dyslipidemia) are risk factors for AD⁴. This evidence highlights the importance of the liver in the pathophysiological characteristics of AD. Focused investigation to assess the role of liver function in AD and its endophenotypes is required to bridge the gap between these observations.

Peripheral blood levels of biochemical markers including albumin, alkaline phosphatase, alanine aminotransaminase (ALT), aspartate aminotransferase (AST), and total bilirubin are used to assess liver function. ALT and AST are used in general clinical practice to measure liver injury^{5,6} and are factors associated with cardiovascular and metabolic diseases^{7,8}, known risk factors of AD and cognitive decline^{9,10}. Given this fact, it is conceivable that aminotransferases are surrogate biomarkers of liver metabolic functioning. A systematic search yielded few reports related to research in humans linking peripheral biomarkers of liver functioning to central biomarkers related to AD including amyloid- β and tau accumulation, brain glucose metabolism, and structural atrophy.

We investigated the association of peripheral liver function markers with AD diagnosis, cognition, and biomarkers of AD pathophysiological characteristics including neuroimaging (magnetic resonance imaging [MRI] and positron emission topography [PET]) and cerebrospinal fluid (CSF) from older adults in the AD Neuroimaging Initiative (ADNI) cohort. The AD biomarkers were selected and defined consistent with the National Institute on Aging-Alzheimer Association Research Framework (amyloid, tau and neurodegeneration[A/T/N]) for AD biomarkers that defines three general groups of biomarkers based on the nature of pathologic process that each measures¹¹.

Methods

Study population

Individuals in this study were participants of ADNI. The initial phase (ADNI-1) was launched in 2003 to test whether serial MRI markers, PET markers, other biological markers, and clinical and neuropsychological assessment could be combined to measure the progression of mild cognitive impairment (MCI) and early AD. The initial phase was extended to subsequent phases (ADNI-GO, ADNI-2, and ADNI-3) for follow-up of existing participants and additional new enrollments. Inclusion and exclusion criteria, clinical and neuroimaging protocols, and other

information are reported elsewhere^{12,13} (<http://adni.loni.usc.edu/>). Demographic and clinical information, raw data from neuroimaging scans, CSF biomarkers, information on *APOE* status, and cognitive scores were downloaded from the ADNI data repository. Baseline data were collected from September 1, 2005, to August 31, 2013. Written informed consent was obtained at enrollment which included permission for analysis and data sharing. This study was approved by each participating site's Institutional Review Board. This report followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines for cohort studies.

Liver function markers

Five laboratory tests were downloaded from the ADNI data repository and used in the study: total bilirubin, albumin, alkaline phosphatase, ALT, and AST. The liver function markers followed a normal distribution after log transformation. For each marker, participants with values greater or smaller than 4 SDs from its mean value were considered outliers and were removed. To determine if outliers had a significant effect on our findings, we performed a sensitivity analysis and observed few differences (or slightly more significant), if any, in results when including outliers (Supplementary Table 1).

Dementia diagnosis

Participants in ADNI were classified as cognitively normal controls (CN) or having significant memory concerns (SMC), MCI, or mild clinical AD. Criteria for classification were as follows: Mini-Mental State Examination score range (range, 0 [worst] to 30 [best]) for CN and MCI was 24 to 30, and for AD was 20 to 26; and overall Clinical Dementia Rating score (range for each, 0 [best] to 3 [worst]) for CN was 0, for MCI was 0.5 with a mandatory requirement of memory box score of 0.5 or greater, and for AD 0.5 or 1¹⁴. Cognitively normal controls did not have any significant impairment in cognition or activities of daily living. Participants with SMC had normal cognition and no significant impairment in activities of daily living, but had a score of 16 or more on the first 12-items of the self-report version of the Cognitive Change Index (range, 12 [no change] to 60 [severe change])¹⁵. Participants with MCI had cognitive impairments in memory and/or other domains but were able to perform activities of daily living and did not qualify for a diagnosis of dementia¹⁴. Participants with AD had to meet the National Institute of Neurological and Communicative Disorders and Stroke-AD and Related Disorders Association criteria for probable AD¹⁶. Participants from the ADNI-1 cohort with MCI were all classified as late MCI, with a memory impairment approximately 1.5 SD below education-adjusted norms. In the ADNI GO and ADNI-2 cohort, participants with MCI were classified as either early MCI, with a memory impairment approximately 1 SD below education-adjusted norms or late MCI (same criteria as in ADNI-1). All ADNI-1 and ADNI-GO and ADNI-2 met the criteria for amnesic MCI, but many in the ADNI GO and ADNI-2 cohort included the earlier stage MCI designation (i.e., early MCI)¹⁷.

Cognition

Composite scores were used to measure memory and executive functioning. A memory composite score was created from the following: memory tasks from the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS-Cog), the Rey Auditory Verbal Learning Test, memory components of the Mini-Mental State Examination, and the Logical Memory task¹⁸. An executive function composite score included the following: Wechsler Adult Intelligence Scale-Revised Digit Symbol Substitution task and Digit Span backward task, Trail Making Test Parts A and B, category fluency (animals and vegetables), and 5 clock drawing items. Composite scores have a mean of 0 and an SD of 1¹⁹.

Neuroimaging processing

MRI scans

Baseline T₁-weighted brain MRI scans were acquired using a sagittal 3-dimensional magnetization prepared rapid gradient echo scans following the ADNI MRI protocol^{20,21}. As previously detailed, FreeSurfer, version 5.1, a widely used automated MRI analysis approach, was used to process MRI scans and extract whole-brain and region-of-interest (ROI) based neuroimaging endophenotypes including volumes and cortical thickness determined by automated segmentation and parcellation²²⁻²⁴. The cortical surface was reconstructed to measure thickness at each vertex. The cortical thickness was calculated by taking the Euclidean distance between gray and white boundary and the gray and CSF boundary at each vertex on the surface²⁵⁻²⁷.

PET scans

Preprocessed fludeoxyglucose (FDG) F 18 (¹⁸F) and [¹⁸F] Flortetapir PET scans (coregistered, averaged, standardized image and voxel size, and uniform resolution) were downloaded from the ADNI Laboratory of Neuro Imaging (LONI) site (<http://adni.loni.usc.edu/>) as described in previously reported methods for acquisition and processing of PET scans^{22,28}. For [¹⁸F] FDG-PET, scans were intensity-normalized using a pons ROI to create [¹⁸F] FDG standardized uptake value ratio (SUVR) images. For [¹⁸F] Flortetapir PET, scans were intensity-normalized using a whole cerebellum reference region to create SUVR images.

CSF biomarkers

The ADNI generated CSF biomarkers (amyloid- β 1-42, total tau [t-tau], and phosphorylated tau₁₈₁ [p-tau181]) in pristine aliquots of 2401 ADNI CSF samples using the validated and highly automated Roche Elecsys electrochemiluminescence immunoassays^{29,30} and the same reagent lot for each of these 3 biomarkers. Cerebrospinal fluid biomarker data were downloaded from the ADNI LONI site (http://adni.loni.usc.edu).

Statistical analysis

Statistical analysis was conducted from November 1, 2017, to February 28, 2019. Logistic regression analysis was performed to explore the diagnostic group differences between AD

diagnosis and each liver function marker separately. Age, sex, body mass index (BMI), and *APOE* $\epsilon 4$ status were used as covariates. We performed a linear regression analysis to assess the association of liver function markers with composite scores for memory and executive functioning using age, sex, years of education, BMI, and *APOE* $\epsilon 4$ status as covariates. We also performed a linear regression analysis using age, sex, BMI, and *APOE* $\epsilon 4$ status as covariates.

ROI-based analysis of structural MRI and PET scans

Mean hippocampal volume was used as an MRI-related phenotype. For FDG-PET, a mean SUVR value was extracted from a global cortical ROI representing regions where patients with AD show decreased glucose metabolism relative to CN participants from the full ADNI-1 cohort, normalized to pons²⁸. For [¹⁸F] Florbetapir PET, a mean SUVR value was extracted using MarsBaR from a global cortical region generated from an independent comparison of ADNI-1 [¹¹C] Pittsburgh Compound B SUVR scans (regions where AD > CN). We performed a linear regression analysis using age, sex, BMI, and *APOE* $\epsilon 4$ status as covariates to evaluate the association of liver function markers with AD-related endophenotypes from MRI and PET scans. For hippocampal volume, years of education, intracranial volume (ICV), and magnetic field strength were added as additional covariates³¹.

Whole-brain imaging analysis

The SurfStat software package (www.math.mcgill.ca/keith/surfstat/) was used to perform a multivariable analysis of cortical thickness to examine the association of liver function markers with brain structural changes on a vertex-by-vertex basis using a general linear model approach²⁷. General linear models were developed using age, sex, years of education, intracranial volume, BMI, *APOE* $\epsilon 4$ status, and magnetic field strength as covariates. The processed FDG-PET and [¹⁸F] Florbetapir PET images were used to perform a voxelwise statistical analysis of the association of liver function markers with brain glucose metabolism and amyloid- β accumulation across the whole brain using SPM8 (www.fil.ion.ucl.ac.uk/spm/). We performed a multivariable regression analysis using age, sex, BMI, and *APOE* $\epsilon 4$ status as covariates. In the whole-brain surface-based analysis, the adjustment for multiple comparisons was performed using the random field theory correction method with $P < 0.05$ adjusted as the level for significance³²⁻³⁴. In the voxelwise whole-brain analysis, the significant statistical parameters were selected to correspond to a threshold of $P < 0.05$ (false discovery rate [FDR]-corrected)³⁵.

Multiple testing correction

Results of the analysis of liver function markers with AD diagnosis groups, cognitive composite measures, and A/T/N biomarkers for AD separately were corrected for multiple testing using the FDR with the Benjamini-Hochberg procedure (p.adjust command in R [R Project for Statistical Computing]).

Results

Study sample

Our analyses included 1581 ADNI participants (407 CN, 20 with SMC, 298 with early MCI, 544 with late MCI, and 312 with AD). Demographic information as well as mean and SD of liver function markers stratified by clinical diagnosis are presented in Supplementary Table 2 in the Supplement.

Diagnostic group difference of liver function markers with AD diagnosis

Levels of ALT were significantly decreased in AD compared with CN (odds ratio, 0.133; 95% CI, 0.042-0.422; $P = .004$) (Table 1), while AST to ALT ratio values were significantly increased in AD (odds ratio, 7.932; 95% CI, 1.673-37.617; $P = .03$). There was a trend to suggest that ALT levels were increased and AST to ALT ratio values were decreased in MCI compared with CN, but these became nonsignificant after adjustment for multiple comparisons (Supplementary Table 3).

Table 1: Results of association of liver function biomarkers with Alzheimer's disease diagnosis*

Liver function marker	Odds Ratio (95% CI)	Corrected P -value
Albumin (g/dL)	5.789 (0.040-843.993)	4.90×10^{-1}
Alkaline Phosphatase (U/L)	3.620 (0.844-15.529)	1.25×10^{-1}
ALT (U/L)	0.133 (0.042-0.422)	3.63×10^{-3}
AST (U/L)	0.229 (0.045-1.175)	1.25×10^{-1}
AST to ALT ratio	7.932 (1.673-37.617)	2.73×10^{-2}
Total Bilirubin (mg/dL)	1.405 (0.585-3.377)	4.90×10^{-1}

Abbreviations: AST, Aspartate aminotransferase; ALT, alanine aminotransferase; CI, confidence interval.

*Cognitively normal vs Alzheimer's disease. Analyses were adjusted for age, sex, body mass index, and *APOE* $\epsilon 4$ status.

Cognition

After adjusting for multiple comparison correction using FDR, we identified significant associations of liver function markers with cognition (Table 2). Higher levels of alkaline phosphatase and AST to ALT ratio were associated with lower memory scores (alkaline phosphatase: β [SE], -0.416 [0.162]; $P = .02$; AST to ALT ratio: β [SE], -0.465 [0.180]; $P = .02$) and executive functioning scores (alkaline phosphatase: β [SE], -0.595 [0.193]; $P = .006$; AST to ALT ratio: β [SE], -0.679 [0.215]; $P = .006$). Higher ALT levels were associated with higher memory scores (β [SE], 0.397 [0.128]; $P = .006$) and executive functioning scores (β [SE], 0.637 [0.152]; $P < .001$), whereas higher AST levels were associated with higher executive functioning scores (β [SE], 0.607 [0.215]; $P = .01$).

Table 2: Results of association of liver function biomarkers with composite cognitive performance measures*

Liver function marker	Memory composite score		Executive function composite score	
	β (SE)	Corrected <i>P</i> -value	β (SE)	Corrected <i>P</i> -value
Albumin (g/dL)	-0.872 (0.576)	1.73×10^{-1}	-0.203 (0.689)	7.68×10^{-1}
Alkaline Phosphatase (U/L)	-0.416 (0.162)	1.74×10^{-2}	-0.595 (0.193)	6.33×10^{-3}
ALT (U/L)	0.397 (0.128)	6.33×10^{-3}	0.637 (0.152)	3.71×10^{-4}
AST (U/L)	0.339 (0.180)	9.00×10^{-2}	0.607 (0.215)	1.16×10^{-2}
AST to ALT ratio	-0.465 (0.180)	1.74×10^{-2}	-0.679 (0.215)	6.33×10^{-3}
Total Bilirubin (mg/dL)	-0.068 (0.103)	6.07×10^{-1}	-0.066 (0.123)	6.5×10^{-1}

Abbreviations: AST, Aspartate aminotransferase; ALT, alanine aminotransferase; SE, standard error

*Analyses were adjusted for age, sex, education, body mass index, and *APOE* $\epsilon 4$ status.

Biomarkers of amyloid- β

We used CSF amyloid- β 1-42 levels and a global cortical amyloid deposition measured from amyloid PET scans as biomarkers of amyloid- β . The regression coefficient of the AST to ALT ratio showed a negative association with CSF amyloid- β 1-42 levels (β [SE], -0.170 [0.061]; $P = .04$), indicating that higher AST to ALT ratio values were associated with CSF amyloid- β 1-42 positivity (Figure 1). However, there was no significant correlation between liver function markers and global cortical amyloid deposition.

In the whole-brain analysis using multivariable regression models to determine the association of liver function markers with amyloid- β load measured from amyloid PET scans on a voxelwise level. We identified significant associations for two liver function markers. Higher ALT levels were significantly associated with reduced amyloid- β deposition in the bilateral parietal lobes (Figure 2A). Increased AST to ALT ratio values were significantly associated with increased amyloid- β deposition in the bilateral parietal lobes and right temporal lobe (Figure 2C).

Biomarkers of fibrillary tau

We used CSF p-tau levels as a biomarker of fibrillary tau. We investigated the association of liver function markers with CSF p-tau, adjusting for *APOE* $\epsilon 4$ status as a covariate. Higher AST to ALT ratio values were associated with higher CSF p-tau values (β [SE], 0.175 [0.055]; $P = .02$) (Figure 1).




Figure 1: Results of association of liver function biomarkers with A/T/N biomarkers for Alzheimer’s disease. Heat map of q-values of association between liver function markers and the A/T/N biomarkers for AD. P-values estimated from linear regression analyses were corrected for multiple testing using FDR (q-value). Color code: white indicates q-value>0.05, red indicates significant positive association, and green indicates significant negative association. Aβ indicates amyloid-β; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CSF, cerebrospinal fluid; FDG, fludeoxyglucose positron emission tomography; MRI, magnetic resonance imaging; and p-tau, phosphorylated tau.

Biomarkers of neurodegeneration or neuronal injury

We used structural atrophy measured from MRI scans, brain glucose metabolism from FDG-PET scans, and CSF total tau (t-tau) levels as biomarkers of neurodegeneration or neuronal injury.

Brain glucose metabolism

We performed an ROI-based association analysis of liver function markers with a global cortical glucose metabolism value measured from FDG-PET scans across 1167 ADNI participants with both FDG-PET scans and measurement of liver function markers. The association analysis




Figure 2: Detailed whole-brain voxel-based imaging analysis for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to ALT ratio levels using positron emission topography (PET) scans. Whole-brain multivariable analysis was performed to visualize the topography of the association of ALT levels and AST to ALT ratio values with amyloid- β load and glucose metabolism on a voxelwise level (false discovery rate-corrected $P < 0.05$). A: Higher ALT levels were significantly associated with reduced amyloid- β deposition in the bilateral parietal lobes. B: Increased ALT levels were significantly associated with increased glucose metabolism in a widespread manner, especially in the bilateral frontal, parietal, and temporal lobes. C: Increased AST to ALT ratio values were significantly associated with increased amyloid- β deposition in the bilateral parietal lobes and the right temporal lobe. D: Increased AST to ALT ratio values were significantly associated with reduced brain glucose metabolism in the bilateral frontal, parietal, and temporal lobes.

including *APOE* $\epsilon 4$ status as a covariate identified 2 markers as significantly associated with brain glucose metabolism after controlling for multiple testing using FDR (Figure 1). For ALT, higher levels were associated with increased glucose metabolism (β [SE], 0.096 [0.030]; $P = .02$), while for the AST to ALT ratio, higher ratio values were associated with reduced glucose metabolism (β [SE], -0.123 [0.042]; $P = .03$).

In the detailed whole-brain analysis to determine the association of liver function markers with brain glucose metabolism on a voxelwise level. Increased ALT levels were associated with increased glucose metabolism in a widespread pattern, especially in the bilateral frontal, parietal, and temporal lobes (Figure 2B). However, higher AST to ALT ratio values were significantly associated with reduced glucose metabolism in the bilateral frontal, parietal, and temporal lobes (Figure 2D).

Structural MRI (atrophy)

In the investigation of the association of liver function markers with mean hippocampal volume with *APOE* $\epsilon 4$ status as a covariate. We did not identify any significant association with hippocampal volume after controlling for multiple testing using FDR (Figure 1). Following the detailed whole-brain surface-based analysis of liver function markers using multivariable regression models to assess associations with cortical thickness. Higher ALT levels were significantly associated with larger cortical thickness in the bilateral temporal lobes (Figure 3), which showed consistent patterns in the associations of brain glucose metabolism.

CSF t-tau

Higher AST to ALT ratio values were associated with higher CSF t-tau levels (β [SE], 0.160 [0.049]; $P = .02$) (Figure 1), which showed consistent patterns in the associations of CSF amyloid- β 1-42 or p-tau levels and brain glucose metabolism.

Discussion

We investigated the association between serum-based liver function markers and AD diagnosis, cognition, and AD pathophysiological characteristics based on the A/T/N framework for AD biomarkers in the ADNI cohort³⁶. Our findings suggest that the decreased levels of ALT and elevated AST to ALT ratio that were observed in patients with AD were associated with poor cognition and reduced brain glucose metabolism. We also found that an increased AST to ALT ratio was associated with lower CSF amyloid- β 1-42 levels, greater amyloid- β deposition, and higher CSF p-tau and t-tau levels. Furthermore, we observed that decreased levels of ALT were associated with greater amyloid- β deposition and structural atrophy.




Figure 3: Detailed whole-brain surface-based imaging analysis for alanine aminotransferase (ALT) levels using magnetic resonance imaging (MRI) scans. A whole-brain multivariable analysis of cortical thickness across the brain surface was performed to visualize the topography of the association of ALT levels with brain structure. Statistical maps were threshold using a random field theory for a multiple testing adjustment to a corrected significance level of 0.05. The *P*-value for clusters indicates significant corrected *P* values with the lightest blue color. Higher ALT levels were significantly associated with greater cortical thickness, especially in bilateral temporal lobes.

Decreased levels of ALT and increased AST to ALT ratio values were observed in patients with AD and were associated with lower scores on measures of memory and executive function. Our findings are comparable with those of an earlier study that reported increased AST to ALT ratio values and lower levels of ALT in patients with AD compared with controls, although in that study, the association between AD and ALT levels did not reach statistical significance³⁷. Altered liver enzymes lead to disturbances in liver associated metabolites including branched-chain amino acids, ether phosphatidylcholines, and lipids³⁸, which we and others show are altered in AD^{1,39-41} and may play a role in disease pathophysiological characteristics⁴². Disturbed energy metabolism is one of the processes that may explain the observed lower levels of ALT and increased enzyme ratio in individuals with AD and impaired cognition^{3,5}. This finding is concordant with our observation that increased AST to ALT ratio values and lower levels of ALT showed a consistent significant association with reduced brain glucose metabolism particularly in the orbitofrontal cortex and temporal lobes, areas of the brain implicated in memory and executive function.

Brain glucose hypometabolism is an early feature of AD and cognitive impairment during the prodromal stage^{43,44}. Moreover, ALT and AST are key enzymes in gluconeogenesis in the liver and production of neurotransmitters required in maintaining synapses⁴⁵. Alanine aminotransferase catalyzes a reversible transamination reaction between alanine and α -ketoglutarate to form pyruvate and glutamate, while AST catalyzes a reversible reaction between aspartate and α -ketoglutarate to form oxaloacetate and glutamate⁴⁶. Although exact mechanisms remain unclear, 2 possible mechanisms may explain altered levels of enzymes in AD. First, reduced ALT levels lead to reduced pyruvate, which is required for glucose production via gluconeogenesis in the liver and glucose is distributed in various body tissues as an energy source⁴⁷, thus disturbing energy homeostasis. Second, altered levels of ALT and AST may affect levels of glutamate, an excitatory neurotransmitter of the central nervous system involved in synaptic transmission, which also plays an important role in memory⁴⁸.

In the case of low glucose metabolism in the brain, as observed in our current study, less α -ketoglutarate is available via the tricarboxylic acid cycle that favors glutamate catabolism vs glutamate synthesis in reversible reaction (catalyzed by AST and ALT)⁴⁹. Glutamate acts as a neurotransmitter in approximately two-thirds of the synapses in neocortical and hippocampal pyramidal neurons and thus is involved in memory and cognition via long-term potentiation⁵⁰. In a sample of healthy adults, plasma ALT and AST levels were significantly positively correlated with plasma glutamate levels^{5,51}, which indicates that lower levels of ALT will decrease glutamate levels in plasma. Based on evidence from earlier studies that peripheral blood levels of glutamate are positively correlated with levels of glutamate in the CSF⁵² and studies that reported lower levels of glutamate in patients with AD compared with controls in both blood⁵³ and brain tissues^{33,54-56}, we can infer that lower levels of ALT or AST may affect glutamate levels in AD. In older adults, lower serum ALT levels are associated with mortality^{57,58} and are thought to be a biomarker for increased frailty, sarcopenia and/or reduced levels of pyridoxine levels (Vitamin B6)⁵⁹. Pyridoxine phosphate is a coenzyme for the synthesis of amino acids, neurotransmitters (e.g., serotonin and norepinephrine) and sphingolipids. Alanine aminotransferase decreases with age⁶⁰ and may be a sign of hepatic aging. Glutamate levels also decrease with increasing age⁶¹. Together with the fact that age is the strongest risk factor for AD⁶², decreasing levels of ALT with age may also indicate a possible biological link between aging and AD. Nevertheless, further research is needed to determine the exact cause of reducing ALT levels with age and the pathway through which it can influence neurologic disorders including AD.

Increased AST to ALT ratio values are observed in individuals with nonalcoholic fatty liver disease which is the hepatic manifestation of metabolic syndrome⁶³. In the Framingham Heart Study, nonalcoholic fatty liver disease was associated with smaller total cerebral brain volume even after adjustment for multiple cardiovascular risk factors⁶⁴. Liver dysfunction is also associated with the development of disease including cardiovascular disease and insulin-resistance through disruptions in glucose and lipid metabolism, key physiological functions of

the liver^{65,66}. Thus, using the AST to ALT ratio as a marker for overall metabolic disturbance⁵, our study provides evidence of an association between altered metabolic status and AD, cognition, and AD endophenotypes.

In addition to ALT levels and the AST to ALT ratio, elevated levels of alkaline phosphatase were significantly associated with poor cognition. This is in line with results from the Oxford Project to Investigate Memory and Aging, which reported increased alkaline phosphatase levels in individuals with AD and an inverse association with cognition⁶⁷. Alkaline phosphatase is an enzyme primarily expressed in the liver and kidneys as well as in endothelial cells in the brain^{68,69}. The neuronal form of the alkaline phosphatase plays a role in developmental plasticity and activity-dependent cortical functions via contributing in γ -aminobutyric acid metabolism⁷⁰⁻⁷³. Changes in plasma levels of alkaline phosphatase may occur as a result of central nervous system injury⁷⁴.

Limitations

This study has several limitations. The observational design of this ADNI cohort study limits our ability to make assumptions about causality. There is need to evaluate the association of liver enzymes with AD in prospective manner. Another limitation of our study is that we did not adjust for alcohol consumption which was not available in ADNI. Alcohol consumption is associated with altered liver enzymes. Instead, we used a well-established surrogate marker of alcohol consumption, γ -glutamyltransferase. Elevations in γ -glutamyltransferase generally indicate long-term heavy drinking rather than episodic heavy drinking⁷⁵. Our key findings remained significant after adjustment for γ -glutamyltransferase and statin use (Supplementary Table 4, Table 5, and Figure in the Supplement). However, given the strong associations with liver function measures and A/T/N biomarkers for AD, it appears that liver function may play a role in the pathogenesis of AD, but limitations should be taken into account before further extrapolating our findings.

Conclusions

This study's results suggest that altered liver function markers are associated with AD diagnosis and impaired memory and executive function as well as amyloid- β , tau and neurodegenerative biomarkers of AD pathophysiological characteristics. These results are, to our knowledge, the first to show an association of peripheral markers of liver functioning with central biomarkers associated with AD. Although our results suggest an important role of liver functioning in AD pathophysiological characteristics, the causal pathways remain unknown. The liver-brain biochemical axis of communication should be further evaluated in model systems and longitudinal studies to gain deeper knowledge of causal pathways.

Acknowledgements

The Alzheimer's Disease Neuroimaging Initiative (ADNI): Data used in the preparation of this article were obtained from the ADNI database (<http://adni.loni.usc.edu>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Funding/Support: Funding for ADMC (Alzheimer's Disease Metabolomics Consortium, led by R.K.-D. at Duke University) was provided by the National Institute on Aging grant R01AG046171, a component of the Accelerated Medicines Partnership for AD (AMP-AD) Target Discovery and Preclinical Validation Project (<https://www.nia.nih.gov/research/dn/amp-ad-target-discovery-and-preclinical-validation-project>) and the National Institute on Aging grant RF1 AG0151550, a component of the M²OVE-AD Consortium (Molecular Mechanisms of the Vascular Etiology of AD – Consortium <https://www.nia.nih.gov/news/decoding-molecular-ties-between-vascular-disease-and-alzheimers>).

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD A.D.N.I. (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support A.D.N.I. clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

The work of various Consortium Investigators are also supported by various NIA grants [U01AG024904-09S4, P50NS053488, R01AG19771, P30AG10133, P30AG10124,

K01AG049050, R03 AG054936], the National Library of Medicine [R01LM011360, R01LM012535], and the National Institute of Biomedical Imaging and Bioengineering [R01EB022574]. Additional support came from Helmholtz Zentrum, the Alzheimer's Association, the Indiana Clinical and Translational Science Institute, and the Indiana University-IU Health Strategic Neuroscience Research Initiative.

Role of the Funder/Sponsor: [Funders listed above] had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: The authors are grateful to Lisa Howerton for administrative support and the numerous ADNI study volunteers and their families.

Disclosures

J.Q.T. may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is a co-inventor and he received revenue from the sale of Avid to Eli Lilly as a co-inventor on imaging-related patents submitted by the University of Pennsylvania. L.M.S. receives research funding from MJFox Foundation for PD Research and is a consultant for Eli Lilly, Novartis, and Roche; he provides QC over-sight for the Roche Elecsys immunoassay as part of responsibilities for the ADNI study. A.J.S. reports investigator-initiated research support from Eli Lilly unrelated to the work reported here. He has received consulting fees and travel expenses from Eli Lilly and Siemens Healthcare and is a consultant to Arkley BioTek. He also receives support from Springer-Nature publishing as Editor-In-Chief of *Brain Imaging and Behavior*. M.W.W. reports stock/stock options from Elan, Synarc, travel expenses from Novartis, Tohoku University, Fundacio Ace, Travel eDreams, MCI Group, NSAS, Danone Trading, ANT Congress, NeuroVigil, CHRU-Hopital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Lilly, University of California, San Diego–ADNI, Paris University, Institut Catala de Neurociencies Aplicades, University of New Mexico School of Medicine, Ipsen, Clinical Trials on Alzheimer's Disease, Pfizer, AD PD meeting. P.M.D. has received research grants and advisory/speaking fees from several health and technology companies. He serves as a director and/or owns stock in companies/organizations whose products are not discussed here. P.M.D is also a co-inventor, through Duke, on patent applications on metabolomics for Alzheimer disease which may accrue revenue in the future. R.K.D. is inventor on key patents in the field of metabolomics including applications for Alzheimer disease. All other authors report no disclosures.

References

1. Toledo, J.B. *et al.* Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimers Dement* **13**, 965-984 (2017).
2. Clarke, J.R., Ribeiro, F.C., Frozza, R.L., De Felice, F.G. & Lourenco, M.V. Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. *J Alzheimers Dis* **64**, S405-S426 (2018).
3. Kapogiannis, D. & Mattson, M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. *Lancet Neurol* **10**, 187-98 (2011).
4. Craft, S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. *Arch Neurol* **66**, 300-5 (2009).
5. Sookoian, S. *et al.* Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level, 2. *The American journal of clinical nutrition* **103**, 422-434 (2016).
6. Sookoian, S. & Pirola, C.J. Alanine and aspartate aminotransferase and glutamine-cycling pathway: Their roles in pathogenesis of metabolic syndrome. *World J Gastroenterol* **18**, 3775-81 (2012).
7. Goessling, W. *et al.* Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. *Gastroenterology* **135**, 1935-44, 1944.e1 (2008).
8. Sattar, N. *et al.* Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. *Diabetes* **53**, 2855-60 (2004).
9. Santos, C.Y. *et al.* Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. *Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring* **7**, 69-87 (2017).
10. Fillit, H., Nash, D.T., Rundek, T. & Zuckerman, A. Cardiovascular risk factors and dementia. *Am J Geriatr Pharmacother* **6**, 100-18 (2008).
11. Jack, C.R., Jr. *et al.* NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement* **14**, 535-562 (2018).
12. Saykin, A.J. *et al.* Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. *Alzheimers Dement* **11**, 792-814 (2015).
13. Weiner, M.W. *et al.* Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. *Alzheimers Dement* **13**, e1-e85 (2017).
14. Petersen, R.C. *et al.* Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. *Neurology* **74**, 201-9 (2010).
15. Rattanabannakit, C. *et al.* The Cognitive Change Index as a Measure of Self and Informant Perception of Cognitive Decline: Relation to Neuropsychological Tests. *J Alzheimers Dis* **51**, 1145-55 (2016).
16. McKhann, G. *et al.* Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. *Neurology* **34**, 939-44 (1984).

17. Aisen, P.S. *et al.* Clinical Core of the Alzheimer's Disease Neuroimaging Initiative: progress and plans. *Alzheimers Dement* **6**, 239-46 (2010).
18. Crane, P.K. *et al.* Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain imaging and behavior* **6**, 502-516 (2012).
19. Gibbons, L.E. *et al.* A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. *Brain imaging and behavior* **6**, 517-527 (2012).
20. Jack, C.R., Jr. *et al.* Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. *Alzheimers Dement* **6**, 212-20 (2010).
21. Jack, C.R., Jr. *et al.* The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. *J Magn Reson Imaging* **27**, 685-91 (2008).
22. Kim, S. *et al.* Influence of genetic variation on plasma protein levels in older adults using a multi-analyte panel. *PLoS One* **8**, e70269 (2013).
23. Nho, K. *et al.* Whole-exome sequencing and imaging genetics identify functional variants for rate of change in hippocampal volume in mild cognitive impairment. *Mol Psychiatry* **18**, 781-7 (2013).
24. Nho, K. *et al.* Protective variant for hippocampal atrophy identified by whole exome sequencing. *Ann Neurol* **77**, 547-52 (2015).
25. Fischl, B., Sereno, M.I. & Dale, A.M. Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system. *Neuroimage* **9**, 195-207 (1999).
26. Dale, A.M., Fischl, B. & Sereno, M.I. Cortical surface-based analysis. I. Segmentation and surface reconstruction. *Neuroimage* **9**, 179-94 (1999).
27. Chung, M.K., Worsley, K.J., Nacewicz, B.M., Dalton, K.M. & Davidson, R.J. General multivariate linear modeling of surface shapes using SurfStat. *Neuroimage* **53**, 491-505 (2010).
28. Risacher, S.L. *et al.* APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern. *Alzheimers Dement* **11**, 1417-29 (2015).
29. Bittner, T. *et al.* Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of beta-amyloid (1-42) in human cerebrospinal fluid. *Alzheimers Dement* **12**, 517-26 (2016).
30. Hansson, O. *et al.* CSF biomarkers of Alzheimer's disease concord with amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimers Dement* (2018).
31. Noble, K.G. *et al.* Hippocampal volume varies with educational attainment across the life-span. *Frontiers in Human Neuroscience* **6**, 307 (2012).
32. Hagler, D.J., Jr., Saygin, A.P. & Sereno, M.I. Smoothing and cluster thresholding for cortical surface-based group analysis of fMRI data. *Neuroimage* **33**, 1093-103 (2006).
33. Hayasaka, S., Phan, K.L., Liberzon, I., Worsley, K.J. & Nichols, T.E. Nonstationary cluster-size inference with random field and permutation methods. *Neuroimage* **22**, 676-87 (2004).
34. Worsley, K.J., Taylor, J.E., Tomaiuolo, F. & Lerch, J. Unified univariate and multivariate random field theory. *Neuroimage* **23 Suppl 1**, S189-95 (2004).

35. Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B-Methodological* **57**, 289-300 (1995).
36. Jack, C.R., Jr. *et al.* NIA-AA research framework: Towards a biological definition of Alzheimer's disease. in *Alzheimer's Association International Conference 1-57* (Alzheimer's Association, London, England, 2017).
37. Giambattistelli, F. *et al.* Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. *Neurobiol Aging* **33**, 1633-41 (2012).
38. Pietzner, M. *et al.* Hepatic steatosis associates with adverse molecular signatures in subjects without diabetes. *J Clin Endocrinol Metab* (2018).
39. Varma, V.R. *et al.* Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. *PLoS Med* **15**, e1002482 (2018).
40. Kaddurah-Daouk, R. *et al.* Alterations in metabolic pathways and networks in mild cognitive impairment and early Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* **9**, P571 (2013).
41. Kaddurah-Daouk, R. *et al.* Metabolomic changes in autopsy-confirmed Alzheimer's disease. *Alzheimers Dement* **7**, 309-17 (2011).
42. Botros, M. & Sikaris, K.A. The de Ritis ratio: the test of time. *Clin Biochem Rev* **34**, 117-30 (2013).
43. Mosconi, L. *et al.* Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. *J Nucl Med* **47**, 1778-86 (2006).
44. Drzezga, A. *et al.* Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. *Eur J Nucl Med Mol Imaging* **30**, 1104-13 (2003).
45. Rui, L. Energy metabolism in the liver. *Compr Physiol* **4**, 177-97 (2014).
46. Ellinger, J.J., Lewis, I.A. & Markley, J.L. Role of aminotransferases in glutamate metabolism of human erythrocytes. *J Biomol NMR* **49**, 221-9 (2011).
47. Qian, K. *et al.* Hepatic ALT isoenzymes are elevated in gluconeogenic conditions including diabetes and suppressed by insulin at the protein level. *Diabetes/metabolism research and reviews* **31**, 562-571 (2015).
48. Reis, H.J. *et al.* Neuro-transmitters in the central nervous system & their implication in learning and memory processes. *Curr Med Chem* **16**, 796-840 (2009).
49. Fleck, M.W., Henze, D.A., Barrionuevo, G. & Palmer, A.M. Aspartate and glutamate mediate excitatory synaptic transmission in area CA1 of the hippocampus. *J Neurosci* **13**, 3944-55 (1993).
50. Francis, P.T. Glutamatergic systems in Alzheimer's disease. *Int J Geriatr Psychiatry* **18**, S15-21 (2003).
51. Kamada, Y. *et al.* Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects. *BBA Clin* **5**, 101-7 (2016).

52. Alfredsson, G., Wiesel, F.A. & Tylec, A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. *Biol Psychiatry* **23**, 689-97 (1988).
53. Wang, G. *et al.* Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. *J Proteome Res* **13**, 2649-58 (2014).
54. Lowe, S.L., Bowen, D.M., Francis, P.T. & Neary, D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. *Neuroscience* **38**, 571-7 (1990).
55. Fayed, N., Modrego, P.J., Rojas-Salinas, G. & Aguilar, K. Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. *Am J Alzheimers Dis Other Demen* **26**, 450-6 (2011).
56. Procter, A.W. *et al.* Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. *J Neurochem* **50**, 790-802 (1988).
57. Liu, Z. *et al.* Complex Association between Alanine Aminotransferase Activity and Mortality in General Population: A Systematic Review and Meta-Analysis of Prospective Studies. *PLOS ONE* **9**, e91410 (2014).
58. Peltz-Sinvani, N. *et al.* Low ALT Levels Independently Associated with 22-Year All-Cause Mortality Among Coronary Heart Disease Patients. *Journal of General Internal Medicine* **31**, 209-214 (2016).
59. Vespasiani-Gentilucci, U. *et al.* Low Alanine Aminotransferase Levels in the Elderly Population: Frailty, Disability, Sarcopenia, and Reduced Survival. *The Journals of Gerontology: Series A* **73**, 925-930 (2018).
60. Elinav, E. *et al.* Correlation between serum alanine aminotransferase activity and age: an inverted U curve pattern. *Am J Gastroenterol* **100**, 2201-4 (2005).
61. Kaiser, L.G., Schuff, N., Cashdollar, N. & Weiner, M.W. Age-related glutamate and glutamine concentration changes in normal human brain: 1H MR spectroscopy study at 4 T. *Neurobiol Aging* **26**, 665-72 (2005).
62. Guerreiro, R. & Bras, J. The age factor in Alzheimer's disease. *Genome Med* **7**, 106 (2015).
63. Katsiki, N., Perez-Martinez, P., Anagnostis, P., Mikhailidis, D.P. & Karagiannis, A. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome? *Curr Vasc Pharmacol* **16**, 219-227 (2018).
64. Weinstein, G. *et al.* Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-aged Adults in the Framingham Study. *JAMA Neurol* **75**, 97-104 (2018).
65. Bedogni, G. *et al.* Relationship between glucose metabolism and non-alcoholic fatty liver disease severity in morbidly obese women. *J Endocrinol Invest* **37**, 739-744 (2014).
66. Perla, F.M., Prelati, M., Lavorato, M., Visicchio, D. & Anania, C. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease. *Children (Basel)* **4**(2017).
67. Kelleth, K.A.B., Williams, J., Vardy, E., Smith, A.D. & Hooper, N.M. Plasma alkaline phosphatase is elevated in Alzheimer's disease and inversely correlates with cognitive function. *Int J Mol Epidemiol Genet* **2**, 114-21 (2011).

68. Moss, D.W. Physicochemical and pathophysiological factors in the release of membrane-bound alkaline phosphatase from cells. *Clin Chim Acta* **257**, 133-40 (1997).
69. Goldstein, D.J., Rogers, C.E. & Harris, H. Expression of alkaline phosphatase loci in mammalian tissues. *Proc Natl Acad Sci U S A* **77**, 2857-60 (1980).
70. Fonta, C., Negyessy, L., Renaud, L. & Barone, P. Areal and subcellular localization of the ubiquitous alkaline phosphatase in the primate cerebral cortex: evidence for a role in neurotransmission. *Cereb Cortex* **14**, 595-609 (2004).
71. Waymire, K.G. *et al.* Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. *Nat Genet* **11**, 45-51 (1995).
72. Narisawa, S., Wennberg, C. & Millan, J.L. Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization. *J Pathol* **193**, 125-33 (2001).
73. Langer, D., Ikehara, Y., Takebayashi, H., Hawkes, R. & Zimmermann, H. The ectonucleotidases alkaline phosphatase and nucleoside triphosphate diphosphohydrolase 2 are associated with subsets of progenitor cell populations in the mouse embryonic, postnatal and adult neurogenic zones. *Neuroscience* **150**, 863-79 (2007).
74. Yamashita, M. *et al.* Measurement of serum alkaline phosphatase isozyme I in brain-damaged patients. *Neurol Med Chir (Tokyo)* **29**, 995-8 (1989).
75. Gjerde, H., Amundsen, A., Skog, O.-J., Mørland, J. & Aasland, O.G. Serum gamma-glutamyltransferase: An epidemiological indicator of alcohol consumption? *British Journal of Addiction* **82**, 1027-1031 (1987).

Chapter 5.2

Altered bile acid profile associates with cognitive impairment in Alzheimer's disease – An emerging role for gut microbiome

Siamak MahmoudianDehkordi*, Matthias Arnold*, Kwangsik Nho*, Shahzad Ahmad, Wei Jia, Guoxiang Xie, Gregory Louie, Alexandra Kueider-Paisley, M. Arthur Moseley, J. Will Thompson, Lisa St John Williams, Jessica D. Tenenbaum, Colette Blach, Rebecca Baillie, Xianlin Han, Sudeepa Bhattacharyya, Jon B. Toledo, Simon Schafferer, Sebastian Klein, Therese Koal, Shannon L. Risacher, Mitchel Allan Kling, Alison Motsinger-Reif, Daniel M. Rotroff, John Jack, Thomas Hankemeier, David A. Bennett, Philip L. De Jager, John Q. Trojanowski, Leslie M. Shaw, Michael W. Weiner, P. Murali Doraiswamy, Cornelia M. van Duijn, Andrew J. Saykin#, Gabi Kastenmüller#, Rima Kaddurah-Daouk#, for the Alzheimer's Disease Neuroimaging Initiative and the Alzheimer Disease Metabolomics Consortium

**First authors contributed equally to the work*

#Senior authors contributed equally to the work

This chapter is published in the Alzheimer's and dementia: The Journal of the Alzheimer's Association. 2019 January;15(1): 76–92

Supplementary information for this chapter is available at: <https://doi.org/10.1016/j.jalz.2018.07.217>

Abstract

Introduction: Increasing evidence suggests a role for the gut microbiome in central nervous system disorders and a specific role for the gut-brain axis in neurodegeneration. Bile acids (BAs), products of cholesterol metabolism and clearance, are produced in the liver and are further metabolized by gut bacteria. They have major regulatory and signaling functions and seem dysregulated in Alzheimer's disease (AD).

Methods: Serum levels of 15 primary and secondary BAs and their conjugated forms were measured in 1464 subjects including 370 cognitively normal older adults (CN), 284 with early mild cognitive impairment (MCI), 505 with late MCI, and 305 AD cases enrolled in the AD Neuroimaging Initiative. We assessed associations of BA profiles including selected ratios with diagnosis, cognition, and AD-related genetic variants, adjusting for confounders and multiple testing.

Results: In AD compared to CN, we observed significantly lower serum concentrations of a primary BA (cholic acid [CA]) and increased levels of the bacterially produced, secondary BA, deoxycholic acid (DCA), and its glycine and taurine conjugated forms. An increased ratio of DCA:CA, which reflects 7 α -dehydroxylation of CA by gut bacteria, strongly associated with cognitive decline, a finding replicated in serum and brain samples in the Rush Religious Orders and Memory and Aging Project. Several genetic variants in immune response-related genes implicated in AD showed associations with BA profiles.

Discussion: We report for the first time an association between altered BA profile, genetic variants implicated in AD and cognitive changes in disease using a large multicenter study. These findings warrant further investigation of gut dysbiosis and possible role of gut-liver-brain axis in the pathogenesis of AD.

Introduction

Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia in old age affecting over 40 million people worldwide¹. There are currently no therapies to prevent or slow down AD progression, highlighting our incomplete knowledge of disease mechanisms and the need for new drug targets. A large number of biochemical processes are affected in AD and genes implicated in AD highlight the possible roles for lipid processing, immune function, phagocytosis, (innate) immunity and neurotransmitter function, and biological pathways that may affect metabolism^{2,3}. Recent AD hypotheses implicate viral and bacterial contributions to disease pathogenesis⁴⁻⁶.

Bidirectional biochemical communication between the brain and the gut contribute to a variety of neurodegenerative and psychiatric diseases⁷⁻¹⁰. The gut microbiome and the host collaboratively produce a large array of small molecules that impacts human health^{11,12}. Recently, a role for the gut microbiome in motor dysfunction in Parkinson's disease has been highlighted¹³ and several animal models of AD showed a possible role of gut bacteria in amyloid- β pathology^{14,15}. The *APP* transgenic mouse model of AD had a drastically altered gut microbiome composition compared to wild-type mice¹⁵. Other studies linked proinflammatory bacteria, such as gram-negative producers of neurotoxic lipopolysaccharides, to brain amyloidosis and systemic inflammation, a central feature of AD^{16,17}. These studies suggest microbial dysbiosis or imbalance could potentially contribute to AD pathogenesis.

Cholesterol metabolism in the liver is thought to play a key role in AD¹⁸. In fact, many cholesterol metabolism-related genes (e.g., *BIN1*, *CLU*, *PICALM*, *ABCA7*, *ABCG1*, and *SORL1*) are among the top AD susceptibility loci identified by genome-wide association studies^{2,19}. Cholesterol is cleared through production of bile acids (BAs). Primary BAs, chenodeoxycholic acid (CDCA) and cholic acid (CA), are synthesized from cholesterol in the liver, conjugated with glycine or taurine, secreted into the gallbladder via the bile salt export pump, and transported to the intestine to be metabolized by gut bacteria (Figure 1). Intestinal anaerobic bacteria deconjugate the liver-derived BAs through the action of bile salt hydrolases to their respective free BAs. Subsequently, anaerobe bacteria convert primary BAs to the secondary BAs. That is, CA is converted to deoxycholic acid (DCA). CDCA is converted to lithocholic acid (LCA) and ursodeoxycholic acid through 7α or 7β -dehydroxylation, respectively^{20,21}. In the terminal ileum and colon, BAs are reabsorbed by the enterocytes and released into the portal vein for return to the liver where they are conjugated to produce their glycine and taurine forms.

Beyond BA's role in cholesterol clearance, BAs are major regulators for maintaining energy homeostasis through binding to nuclear receptors, including FXR and LXR, among others and seem to be indicators of gut dysbiosis. BAs also modulate the gut microbiome^{22,23}. Both primary and secondary BAs are present in the brains of mice and possibly humans with evidence that they




Figure 1: Bile acid synthesis and cholesterol clearance pathway. Regulation of bile acid synthesis by feedback mechanism and bile acid transport through enterohepatic circulation. In the liver, the bile acids (CDCA, DCA, LCA, CA) activate FXR that inhibits (via a repressor SHP, not shown here) the rate-limiting enzyme CYP7A1. The bile acids via FXR/SHP also inhibit the influx transporter NTCP; induce BSEP and canalicular bile acid secretion. In the intestine, bile acids, via FXR, inhibit the uptake transporter ASBT, decreasing absorption and increasing basolateral secretion into portal circulation by inducing OST α & β . Bile acid activated FXR in the intestine also exerts inhibition on CYP7A1 in the liver via FGF19 pathway. At the basolateral membrane of hepatocytes, transporters OST α & β , and also MRP3 and MRP4, secrete bile acids into the systemic circulation.

Abbreviations: ASBT: Apical sodium-dependent Bile acid Transporters; BSEP: Bile Salt Export Pump; FXR: Farnesoid X Receptor; NTCP: Sodium/Taurocholate Co-transporting Polypeptide; SHP: Small heterodimer partner.

cross the blood-brain barrier²⁴⁻²⁹. Some BAs such ursodeoxycholic acid exert beneficial effects while others are known to be cytotoxic³⁰⁻³⁴. In particular, DCA's toxicity has been associated with modulating apoptosis involving mitochondrial pathways in a variety of tissues and cell types³⁵⁻³⁸.

In recent pilot human studies, BA profiles were shown to be affected in AD^{26,38-41}. Here, we used a targeted metabolomics approach to evaluate BA profiles in a large cohort of 1464 individuals enrolled in the AD Neuroimaging Initiative (ADNI) where rich clinical, imaging, and genetic data exist. A schematic representation of study design is shown in Figure 2. We used these data to address the following:

1. Investigate if BA profiles are altered in mild cognitive impairment (MCI) and AD patients and if these differences are related to cognitive decline.
2. Use ratios of BAs to pinpoint possible enzymatic alterations in the liver and in the gut microbiome that directly contribute to altered BA profile.
3. Investigate whether immune-related AD genome-wide significant genes affect levels of BAs in circulation as markers for altered gut microbiome function.

In a subsequent study, we evaluated correlations between BAs and ATN (amyloid, tau and neurodegenerative) biomarkers of AD including cerebrospinal (CSF) biomarkers, brain atrophy, and brain glucose metabolism.




Figure 2: Schematic representation of study design.

Methods

Study cohorts and samples

ADNI baseline samples

Data used in the preparation of this article were downloaded from the ADNI database (<http://adni.loni.usc.edu/>). The ADNI studies have recruited over 1500 adults, ages 55 to 90, consisting of cognitively normal older individuals (CN), individuals with subjective memory concerns (SMC), subjects with early (EMCI) or late mild cognitive impairment (LMCI), and patients with early probable AD dementia. Subjects categorized as SMC were excluded in this study. For key clinical and demographic variables of ADNI participants included in this study, see Tables 1 and 2.

The Religious Orders Study and the Rush Memory and Aging Project (ROS/MAP) for replication of key finding

The ROS/MAP studies are both longitudinal cohort studies of aging and AD at Rush University and are designed to be used in joint analyses to maximize sample size. ROS enrolled individuals from religious orders (nuns, priests, brothers) across the United States⁴². MAP was designed to complement the ROS study by using a similar structure and design as ROS, but enrolling participants with a wider range of life experiences and socioeconomic status from the Chicago, IL metropolitan area⁴³. The entire ROS/MAP cohort consists of approximately 3300 participants, more than 1500 of whom have come to autopsy (www.radc.rush.edu). We measured a subset of serum BAs in 566 subjects (446 CN, 109 MCI, and 11 AD), as well as a subset of BAs in postmortem brain samples from the dorsolateral prefrontal cortex of 111 subjects with brain pathology measured (51 CN, 31 MCI, and 27 AD at time of death), of whom 93 had serum measurements. Key demographic characteristics of the ROS/MAP cohort are in Supplementary Table 1.

Rotterdam Study (RS)

RS was used to examine the association of BAs with AD genetic variants. RS is a prospective population-based study⁴⁴. At the baseline examination in 1990-1993, 7983 subjects ≥ 55 years of age were recruited from the Ommoord district of Rotterdam (RS-I). All the study participants were extensively interviewed and physically examined at baseline and after every 3 to 4 years. During 2000 to 2001, the baseline cohort (RS-I) was expanded with 3011 subjects ≥ 55 years of age, who were not yet part of RS-I (RS-II). In this analysis, fasting serum BAs were measured for 488 dementia-free subjects with mean(SD) age of 73.1(6.3) from RS-I using Metabolon platform (Durham, North Carolina, USA) as described previously⁴⁵ (see Supplementary Table 2 for demographics).

Table 1: Demographics of ADNI participants stratified by baseline diagnosis*

Variable	N	CN (N=370)	EMCI (N=284)	LMCI (N=505)	AD (N=305)	<i>P-value</i> [†]
Age	1464	74.58(5.71)	71.12(7.51)	73.95(7.59)	74.70(7.79)	0.001
Sex: Female, No. (%)	1464	190(51%)	130(46%)	197(39%)	139(46%)	0.004
Education, years	1464	16.28(2.92)	15.95(2.66)	15.87(2.90)	15.16(3.00)	0.001
BMI (Kg/M²)	1461	27.05(4.46)	28.06(5.41)	26.54(4.25)	25.83(4.69)	0.001
≥1 APOE ε4 allele, No. (%)	1464	104(28%)	121(43%)	273(54%)	202(66%)	0.001
ADAS-Cog13[‡]	1455	9.19(4.17)	12.64(5.40)	18.67(6.62)	29.67(8.20)	0.001

Abbreviations: AD: Alzheimer's disease; BMI: Body mass index; CN: Cognitively normal; EMCI: Early mild cognitive impairment; LMCI: Late mild cognitive impairment; ADAS-Cog13, Alzheimer Disease Assessment Scale 13-item cognitive subscale.

*Data are reported as mean (SD) unless otherwise indicated. Bolded values indicate statistical significance. SD: Standard deviation.

[†]Based on 2-sample *t* tests, or Pearson χ^2 tests.

[‡]Score explanations: ADAS-Cog13 range, 0 (best) to 85 (worst).

Table 2: Demographics of ADNI participants stratified by MCI progression to AD*

Variable	N	MCI-nonconverter (N=538)	MCI-converter (N=251)	<i>P-value</i> [†]
Age	789	72.47(7.90)	73.91(7.08)	0.01
Sex: Female, No. (%)	789	41% (223)	41% (104)	1
Education, years	789	15.95 (2.85)	15.79 (2.76)	0.43
BMI (Kg/M²)	788	27.37 (4.80)	26.47(4.61)	0.005
≥1 APOE ε4 allele, No. (%)	789	41% (223)	68% (171)	0.001
ADAS-Cog13	786	14.26 (6.04)	21.31 (5.94)	0.29

Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; ADAS-Cog13, Alzheimer Disease Assessment Scale 13-item cognitive subscale; MCI, mild cognitive impairment.

*MCI subjects that converted to AD dementia in 4 years after baseline were labeled as MCI converter.

[†]Based on 2-sample *t* tests, or Pearson χ^2 tests.

Sample collection and quantification of BAs

Targeted metabolomics profiling was performed to measure concentrations of 20 BA metabolites in serum samples of the ADNI cohorts. Morning fasting serum samples from the baseline visit were collected and aliquoted as described in the ADNI standard operating procedures. BA quantification was performed by liquid chromatography tandem mass spectrometry using the Biocrates® Life Sciences Bile Acids Kit (BIOCRATES Life Science AG, Innsbruck, Austria) according to manufacturer's instructions (see Table 3 for list of BAs, abbreviations and their levels across diagnosis groups).

Table 3: Levels of primary and secondary bile acids measured in the ADNI cohort stratified by clinical diagnosis*

Bile Acid	Category	N [†]	CN (N=370)	EMCI (N=284)	LMCI (N=505)	AD (N=305)
CA	Primary	1446	0.221(0.024)	0.155(0.021)	0.192(0.021)	0.135(0.025)
CDCA	Primary	1357	0.285(0.042)	0.241(0.034)	0.288(0.033)	0.216(0.033)
GCA	Primary Conjugated	1463	0.236(0.019)	0.234(0.021)	0.239(0.014)	0.297(0.037)
GCDCA	Primary Conjugated	1464	0.658(0.035)	0.724(0.059)	0.710(0.037)	0.806(0.049)
TCA	Primary Conjugated	1020	0.068(0.008)	0.057(0.006)	0.068(0.006)	0.066(0.009)
TCDC	Primary Conjugated	1426	0.090(0.006)	0.088(0.007)	0.091(0.006)	0.097(0.008)
TMCA	Primary Conjugated	1146	0.012(0.001)	0.011(0.001)	0.014(0.002)	0.014(0.002)
DCA	Secondary	1445	0.526(0.041)	0.574(0.043)	0.529(0.026)	0.627(0.045)
UDCA	Secondary	1111	0.065(0.007)	0.072(0.011)	0.091(0.010)	0.087(0.012)
GDCA	Secondary Conjugated	1439	0.440(0.034)	0.488(0.038)	0.502(0.031)	0.672(0.054)
TDCA	Secondary Conjugated	1430	0.058(0.006)	0.059(0.005)	0.065(0.005)	0.077(0.006)
GLCA	Secondary Conjugated	1037	0.027(0.002)	0.034(0.003)	0.030(0.002)	0.039(0.003)
TLCA	Secondary Conjugated	1008	0.005(0.0002)	0.005(0.0003)	0.005(0.0003)	0.006(0.0005)
GUDCA	Secondary Conjugated	1401	0.115(0.010)	0.114(0.012)	0.129(0.012)	0.136(0.015)
TUDCA	Secondary Conjugated	1369	0.008(0.001)	0.008(0.001)	0.008(0.001)	0.008(0.001)

Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; CA, cholic acid; CDCA, chenodeoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; TCA, taurocholic acid; TCDC, taurochenodeoxycholic acid; TMCA, tauromuricholic acid; DCA, deoxycholic acid; UDCA, ursodeoxycholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid; GLCA, glycolithocholic acid; TLCA, tauroolithocholic acid; GUDCA, glyoursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid.

*Values represent mM in mean (standard error of the mean).

[†]Number of nonmissing measurements.

In the ROS/MAP, quantification of BA concentrations in 566 serum samples and 111 postmortem brain samples was performed at the University of Hawaii cancer center using ultra-performance liquid chromatography coupled to a tandem mass spectrometry (UPLC-MS/MS) system (ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, MA)⁴⁶.

In the RS study, serum BAs were measured in 488 serum samples using the non-targeted Metabolon platform (Durham, North Carolina, USA).

Quality control of BA profiles

Metabolomics laboratory staff were blinded to diagnosis and pathological data in all the studies. In ADNI, after unblinding and data release, metabolite profiles went through quality-control (QC) checks and data preprocessing including batch-effect adjustment, missing value imputation, and log-transformation (Supplementary Methods and Supplementary Table 3). After QC correction, the data set included 15 BAs (Five BAs did not pass QC criteria) for a total of 1,464 subjects (after excluding 99 SMC). The preprocessed BA values after QC were used for subsequent association analyses directly or were adjusted to take into account the effect of medications on BA levels⁴⁷. The list of medications selected for adjustment for each BA is shown in Supplementary Table 7. We performed all analyses using both medication adjusted and unadjusted BA levels, results derived from medication-adjusted data and the adjustment process are described in Supplementary Methods and its accompanying tables.

In both RS and ROS/MAP, missing metabolite levels were imputed using half of the limit of detection. Log-transformed values were used in subsequent analyses.

Clinical Outcomes

For ADNI data, continuous response variables included the modified Alzheimer Disease Assessment Scale 13-item cognitive subscale (ADAS-Cog13; range, 0 [best] to 85 [worst] points), an index of general cognitive functioning. Categorical response variables included clinical diagnosis at baseline and MCI conversion (MCI-nonconverter, MCI-converter). For the ROS/MAP cohort, cognition was measured using a battery of tests (details are published⁴⁸⁻⁵¹). A composite measure of global cognition was created by averaging the z-scores of all tests as previously described⁵¹. Mean and standard deviation at baseline were used to compute z-scores. A negative z-score means that an individual has an overall score that is lower than the average of the entire sample at baseline. Cognitive tests were used from the same cycle as serum, and proximate to death for brain.

Genotype and whole-genome sequencing data

Whole-genome sequencing: For 817 ADNI participants, whole-genome sequencing (WGS) was performed on blood-derived genomic DNA. Samples were sequenced on the Illumina HiSeq2000 using paired-end read chemistry and read-length of 100 bp at 30–40X coverage. For data processing and QC, an established analysis pipeline based on GATK was used. The QC steps included participant sex check, participant identity check, and variant quality check of the Illumina-generated VCF files (see Saykin *et al.*, for details⁵²).

DNA genotyping in the participants of the RS cohort was performed using 550K, 550K duo, or 610K Illumina arrays at the internal genotyping facility of the Erasmus Medical Center, Rotterdam. Study samples with excess autosomal heterozygosity, call rate < 97.5%, ethnic outliers, and duplicate or family relationships were excluded during quality control analysis. Genotype exclusion criteria further included call rate < 95%, Hardy-Weinberg equilibrium $p < 1.0 \times 10^{-6}$ and Minor Allele Frequency (MAF) < 1%. Genetic variants were imputed to the Haplotype Reference Consortium (HRC) reference panel (version 1.0)⁵³ using the Michigan imputation server⁵⁴.

Reference genetic associations with BA profiles in healthy individuals were obtained from supplementary data of the atlas of genetic influences on blood metabolites⁴⁵. To obtain genome-wide genetic associations with DCA, we considered all suggestive significant results with $P < 1.0 \times 10^{-5}$. Gene and complex trait annotations of the 13 resulting genetic loci were performed using the SNIIPA tool v3.2⁵⁵ and the NHGRI-EBI Catalog of published genome-wide association studies (www.ebi.ac.uk/gwas; accessed 02/01/2018, version 1.0)⁵⁶. Lookup of AD genetic associations for DCA candidate variants was performed using the IGAP repository².

Statistical analysis

Differences of demographic, clinical, and cognitive measurements among the clinical diagnostic groups were evaluated using two-sample t -test (for continuous variables) and Pearson Chi-squared test (for categorical variables). All analyses were performed in a metabolite-wise manner and Bonferroni-adjusted critical values were used to assess statistical significance. All models included age at baseline, sex, *APOE* $\epsilon 4$, and \log_{10} -transformed body mass index (BMI). For cognition, number of years of education was added as an additional covariate.

Separate binary logistic regression models were conducted to examine cross-sectional association of each metabolite with baseline diagnosis (six models per metabolite). We performed logistic regression models to compare BA levels between the MCI-nonconverter and MCI-converter groups. Cox proportional hazard models were used to evaluate the association of metabolite levels with progression from MCI (combined EMCI and LMCI subjects) to AD. The cross-sectional association of ADAS-Cog13 with BAs was assessed using linear regression models with square root of ADAS-Cog13 as the dependent variable.

In ROS/MAP, one sample per individual was used. Linear regression models with global cognition score as dependent variable and metabolites as independent variables were used to assess the association of serum BAs with cognition, while adjusting for sex, age, *APOE* $\epsilon 4$, and years of education. Similar analyses were conducted for brain BAs separately.

We restricted our genetic variant analysis to single nucleotide polymorphisms in genes involved in the immune response pathway that were significantly associated with AD genome-wide^{2,57-59}.

Selected genetic variant included rs616338-T(*ABI3*), rs143332484-T(*TREM2*), rs72824905-C(*PLCG2*), rs9331896-T(*CLU*), rs6656401-A(*CRI*), rs35349669-T(*INPP5D*), rs11771145-G(*EPHA1*), rs983392-A(*MS4A6A*), and rs190982 -A(*MEF2C*). Associations of AD risk variants in immune-related genes with selected metabolic traits in ADNI and RS were computed using sex, age, and BMI as covariates.

Results

Characteristics of ADNI participants are depicted in Tables 1 and 2. Baseline cognitive measurements were significantly different among diagnostic groups, as expected. AD patients were more often carriers of at least one *APOE* $\epsilon 4$ allele. In addition, ADAS-Cog13 scores were not significantly different between the MCI-converter and nonconverter groups. However, the proportion of *APOE* $\epsilon 4$ carriers was higher in the MCI-converter group.

Serum BA profiles are significantly altered in AD

The Bonferroni-corrected threshold for statistical significance was determined as $P < 4.76 \times 10^{-4}$ (0.05 divided by 15 metabolites times seven phenotypes including cognition). When we compared BA profile in AD to CN, we detected a significant decrease in levels of the primary BA, CA ($P = 1.56 \times 10^{-4}$). In contrast, a significant increase of bacterially produced secondary BA, DCA was noted ($P = 1.61 \times 10^{-4}$) along with several secondary conjugated BAs, GDCA, TDCA, and GLCA (Table 4). GDCA and GLCA were significantly associated with ADAS-Cog13 where higher levels indicated worse cognition. Comparing BA levels between AD and both MCI groups yielded similar results, while the comparison of BA levels between the CN and MCI groups did not reach statistical significance (Supplementary Table 4).

Ratios reflective of conversion of BAs by gut microbiome are significantly associated with AD and cognitive performance

To determine which enzymatic processes in BA metabolism may underlie the differences noted in AD, we investigated eight selected ratios reflective of enzymatic activities in the liver and the gut microbiome. These ratios included the following:

1. The CA:CDCA ratio was selected to test if a possible shift in BA synthesis from the primary to the alternative BA pathway occurs in the liver.
2. Ratios of secondary to primary BAs (DCA:CA, GLCA:CDCA, and TLCA:CDCA) to investigate differences in gut microbiome enzymatic activity leading to altered production of secondary BAs. Because LCA was excluded in QC steps, the GLCA:CDCA and TLCA:CDCA ratios were used as proxies for the LCA:CDCA ratio.

Table 4: Cross-sectional association of bile acids with clinical diagnosis and cognition in the ADNI study*

Bile Acid	CN vs. AD ($n=673$) OR (95% CI); P -value [†]	ADAS-Cog13 ($n=1453$) β (95% CI); P -value [‡]
CA	0.85(0.78,0.92);1.56E-04	-0.04(-0.07,-0.01);2.81E-03
CDCA	0.94(0.87,1.01);7.19E-02	-0.02(-0.04,0.00);1.07E-01
GCA	1.07(0.96,1.18);2.03E-01	0.01(-0.02,0.05);4.36E-01
GCDCA	1.15(1.02,1.29);2.07E-02	0.06(0.02,0.09);4.60E-03
TCA	1.03(0.94,1.12);5.32E-01	-0.01(-0.03,0.03);7.92E-01
TCDCA	1.04(0.94,1.15);4.29E-01	0.02(-0.02,0.05);3.39E-01
TMCA	1.09(1.00,1.18);4.46E-02	0.029(0.00,0.06);4.21E-02
DCA	1.24(1.11,1.39);1.61E-04	0.05(0.01,0.08);9.26E-03
UDCA	0.96(0.90,1.03);2.41E-01	-0.01(-0.03,0.01);2.44E-01
GDCA	1.30(1.17,1.43);4.20E-07	0.07(0.04,0.10);1.05E-05
TDCA	1.19(1.08,1.30);3.26E-04	0.05(0.02,0.08);2.39E-03
GLCA	1.33(1.20,1.48);9.21E-08	0.07(0.04,0.11);1.97E-05
TLCA	1.19(1.07,1.31);9.53E-04	0.06(0.03,0.1);3.18E-04
GUDCA	1.09(1.00,1.19);5.39E-02	0.03(-0.00,0.06);6.04E-02
TUDCA	1.08(0.96,1.20);1.86E-01	0.01(-0.02,0.05);4.85E-01

Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; CA, cholic acid; CDCA, chenodeoxycholic acid; GCA, glycocholic acid; GCDCA, glycochenodeoxycholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TMCA, tauromuricholic acid; DCA, deoxycholic acid; UDCA, ursodeoxycholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid; GLCA, glycolithocholic acid; TLCA, tauroolithocholic acid; GUDCA, glyoursodeoxycholic acid; TUDCA, tauroursodeoxycholic acid.

*Statistically significant associations that passed Bonferroni correction are bolded.

[†]Odds ratios and p -values were obtained from logistic regressions. Models were corrected for age, sex, body mass index, and *APOE* $\epsilon 4$ status; Bonferroni-adjusted critical value was set to 5.76×10^{-4} (0.05 divided by 15 metabolites times 7 phenotypes including cognition)

[‡]Outcome: Square root of ADASCog-13 (0 [best] to 85 [worst]); Models were corrected for age, sex, years of education, body mass index and *APOE* $\epsilon 4$ status; Bonferroni-adjusted critical value was set to 2.17×10^{-3} .

- GDCA:DCA and TDCA:DCA ratios were used to test if the observed secondary BA dysregulation is related to enzymatic differences related to their taurine and glycine conjugation.

Here, we considered associations as significant at a Bonferroni-corrected $P < 3.11 \times 10^{-4}$ (0.05 divided by all 23 metabolic traits times seven phenotypes, which include cognition). The ratio of the primary BAs (CA:CDCA) showed no significant association with AD. Yet, for the ratio of DCA:CA (i.e., the conversion of unconjugated primary to unconjugated secondary BA), we

observed a highly significant association with AD diagnosis ($P=1.53 \times 10^{-8}$). Ratios between primary and secondary conjugated BAs showed the same effect and direction, including GDCA:CA ($P=8.53 \times 10^{-10}$), TDCA:CA ($P=9.83 \times 10^{-7}$), and GLCA:CDCA ($P=3.61 \times 10^{-6}$).

Ratios modeling the glycine and taurine conjugation step of DCA, i.e. GDCA:DCA, TDCA:DCA, were not significantly associated with diagnosis (Figure 3 and Table 5).




Figure 3: Ratios of bile acids reflective of liver and gut microbiome enzymatic activities in CN, Early MCI, Late MCI, and AD patients. Three types of ratios were calculated to inform about possible enzymatic activity changes in Alzheimer's patients. These ratios reflect one of the following: (1) Shift in bile acid metabolism from primary to alternative pathway. (2) Changes in gut microbiome correlated with production of secondary bile acids. (3) Changes in glycine and taurine conjugation of secondary bile acids. Color code: Green: cognitively normal; Yellow: EMCI; Blue: LMCI; Red: AD. Composition of selected ratios stratified by clinical diagnosis. Error bars indicate standard error of the means; Asterisks indicate statistical significance ($*P < 10^{-03}$, $**P < 10^{-04}$, and $***P < 10^{-05}$). P -values were estimated from logistic regression models and adjusted for age, sex, body mass index, and $APOE \epsilon 4$ status. The significance level was adjusted for multiple testing according to the Bonferroni method to $0.05/138 = 3.62 \times 10^{-4}$; LCA was excluded in the quality control steps.

Table 5: Ratios of bile acids reflective of gut microbiome and liver enzymatic activities and their correlation with disease status and cognitive function*

Ratios informative about metabolic processes	Ratios calculated	CN vs. AD ($n=673$) OR (95% CI); P -value [†]	ADAS-Cog13 ($n=1453$) β (95% CI); P -value [‡]
Bile acid synthesis: primary vs. alternative pathway	CA:CDCA	0.87(0.77,0.97);1.67E-02	-0.03(-0.07,0.01);1.27E-01
	DCA:CA	1.25(1.16,1.35);1.53E-08	0.05(0.03,0.08);1.05E-05
Conversion from primary to secondary BA by the gut microbiome	GDCA:CA	1.24(1.16,1.33);8.53E-10	0.06(0.04,0.08);1.20E-07
	TDCA:CA	1.16(1.10,1.24);9.83E-07	0.04(0.02,0.06);5.40E-05
	GLCA:CDCA	1.16(1.09,1.23);3.61E-06	0.04(0.02,0.06);9.15E-05
Glycine or Taurine conjugation of secondary bile acids by liver enzymes	TLCA:CDCA	1.09(1.03,1.16);1.60E-03	0.03(0.01,0.05);1.50E-03
	GDCA:DCA	1.16(1.02,1.31);2.41E-02	0.05(0.02,0.10);5.49E-03
	TDCA:DCA	1.02(0.93,1.11);7.40E-01	0.01(-0.02,0.04);4.15E-01

Abbreviations: AD, Alzheimer's disease; ADNI, Alzheimer's Disease Neuroimaging Initiative; CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GDCA, glycodeoxycholic acid; TDCA, taurodeoxycholic acid; GLCA, glycolithocholic acid; TLCA, tauroolithocholic acid.

*Several ratios were calculated to inform about possible enzymatic activity changes in Alzheimer's patients. These ratios reflect: (1) Shift in bile acid metabolism from primary to alternative pathway. (2) Changes in gut microbiome correlated with production of secondary bile acids. (3) Changes in glycine and taurine conjugation of secondary bile acids.

[†]Outcome: Baseline diagnosis; Odds ratios and p-values were obtained from logistics regressions. Models were corrected for age, sex, body mass index, and APOE $\epsilon 4$ status; Bonferroni-adjusted critical value was set to 1.04E-03 based on 6 possible pairwise comparison of diagnosis groups (CN, EMCI, LMCI, and AD) for 8 ratios.

[‡]Outcome: Square root of ADASCog-13 (0 [best] to 85 [worst]); Models were corrected for age, sex, years of education, body mass index, and APOE $\epsilon 4$ status; Bonferroni-adjusted critical value was set to $.11 \times 10^{-4}$ (0.05 divided by all 23 metabolic traits times 7 phenotypes, which include cognitive function).

Four ratios (including DCA:CA and GLCA:CDCA) were significantly associated with ADAS-Cog13. For the ratios we observed the same pattern as AD diagnosis, with higher ratios of secondary to primary BAs being highly significantly associated with worse cognitive performance, while neither conjugation, nor a shift between primary and alternative BA pathways in the liver was significantly linked to cognition (Table 5).

Serum BA levels were associated with progression from MCI to AD in ADNI

The nine metabolites and ratios associated with diagnosis were further investigated to assess their relationship with progression from MCI to AD. Out of 789 MCI (EMCI and LMCI) patients with mean (SD) follow-up 3.94 (2.35), 32.2% progressed to AD dementia in 4 years (labeled as MCI-converter ($n=251$) vs. those who did not progress MCI-nonconverter [$n=528$]). BA profiles were compared between the two groups using logistic regression models with conversion status as the dependent variable and metabolite as an independent variable. Models were adjusted for age,

sex, BMI, baseline ADAS-Cog13 score, and *APOE* $\epsilon 4$. The Bonferroni-corrected threshold for statistical significance was determined as $P < 5.56 \times 10^{-3}$ (0.05 divided by nine metabolites and ratios). We noted a decrease in CA levels ($P=9.12 \times 10^{-4}$) and an increase in ratios of GDCA:CA ($P=1.63 \times 10^{-3}$) and TDCA:CA ($P=1.72 \times 10^{-3}$) in MCI-converters (Figure 4 and Supplementary Table 5). Further survival analysis also revealed that levels of CA (hazard ratio [HR], 0.92;




Figure 4: Comparison of bile levels in MCI subjects who convert and those who did not convert to AD dementia. (A and B) Lower levels of CA and higher levels of two secondary to primary ratios were significantly associated with higher odds of converting from MCI to AD. EMCI and LMCI patients that converted to AD dementia in 4 years after baseline were labeled as MCI-converter; 9 bile acids and ratios that were significantly dysregulated between CN to AD were assessed; P -values were estimated from logistic regression models and adjusted for age, sex, body mass index, and *APOE* $\epsilon 4$ status; the significance level was adjusted for multiple testing according to Bonferroni $0.05/9 = 5.56 \times 10^{-3}$. (C and D) Cox hazards model of the association of conversion from MCI to AD. Red line: 1st quantile, blue line: 3rd quantile. Analysis was conducted using quantitative values and stratification by quantiles was used only for graphical representation.

$P = 3.79 \times 10^{-3}$), GDCA:CA (HR, 1.07; $P = 2.81 \times 10^{-3}$), and TDCA:CA (HR, 1.06; $P = 3.19 \times 10^{-3}$) ratios predicted MCI progression (Figure 4).

Replication of association between cognition and DCA:CA ratio in serum and brain from ROS/MAP

To confirm the associations observed in ADNI, we used an independent cohort of older adults (ROS/MAP) with measures of BAs in serum and brain to replicate our findings. Because the sample sizes in ROS/MAP were smaller than ADNI and AD cases were strongly underrepresented (566 serum samples 11 of which were AD and 111 brains 27 of which were AD), we focused on replicating our key findings related to the association between cognition and the DCA:CA ratio (as proxy for BA processing by the gut microbiome). Here, we had to use global cognition scores where higher values indicate better cognition. Separate linear regression models were used for brain and serum samples. Pearson's correlation coefficient between serum DCA:CA and DCA:CA in 93 matching brain samples was 0.303 ($P = 0.003$). In both serum and brain samples, higher levels of DCA:CA were associated with worse cognition (serum: $\beta = -0.06$; $P = 0.011$; brain: $\beta = -0.21$; $P = 0.032$), confirming our ADNI finding.

Genetic risk variants for AD in genes related to immune function are associated with bile acid levels

To further evaluate that altered BA profiles in AD are related to processes in the gut microbiome, we investigated if BA profiles were associated with immune-related AD risk genes which may contribute to differences in gut microbiome composition. Using the ADNI ($n = 817$ with WGS data) and RS ($n = 488$) cohorts, association of selected BAs in the primary BA pathway (CA, DCA, GDCA, and TDCA) as well as the DCA:CA ratio with the selected genetic risk variants in 9 candidate genes with immune-related functions were assessed. In addition, we included associations from a published large cohort-based study⁴⁵ to increase sample size. With the exception of rs983392 in *MS4A6A*, we found nominally significant associations for the candidate variants in all of these genes (Supplementary Table 10). Three associations were significant after Bonferroni-correction ($P < 1.1 \times 10^{-3}$) in at least one of the studies: rs616338 (*ABI3*) and rs190982 (*MEF2C*) were significantly associated with the DCA:CA ratio, and rs11771145 (*EPHA1*) was significantly linked to both DCA and TDCA.

Genetic loci associated with DCA may influence susceptibility for AD

To follow up on the hypothesis that elevated DCA levels in AD that are linked to gut dysbiosis are relevant in the pathogenesis of AD, we collected (suggestive) significant genetic associations with DCA levels ($P < 1.0 \times 10^{-5}$) from a previous study of genetic influences on blood metabolite levels in large population-based cohorts ($n = 7,800$)⁴⁵. We then annotated the resulting 13 loci with genetic trait associations, including AD associations from the IGAP study², and tried to replicate associations with DCA in ADNI (Supplementary Table 11). Two of the 13 genes, *CYP7A1* and *IMPA2*, also showed association with DCA levels in ADNI subjects. Notably, six of the 13 genes

have been previously linked via genetic studies to AD (*ABCA7*) or AD phenotypes, including cognitive decline and CSF protein levels (*LRRC7*, *CYCS*, *GPC6*, *FOXN3*, and *CNTNAP4*).

Discussion

In this study, we interrogated a possible role for BA end products of cholesterol metabolism and clearance in cognitive changes in AD. Using stored blood samples from ADNI studies we established that BA profile is significantly altered in AD patients. We noted a significant decrease in serum levels of a liver-derived primary BA (CA) and an increase in levels of a bacterially produced secondary BAs and their conjugated forms (DCA, GDCA and TDCA, GLCA) in AD patients compared to CN subjects (Table 4, Figure 1). Higher levels of secondary conjugated BAs (GDCA, GLCA, and TLCA) were significantly associated with worse cognitive function (ADAS-Cog13; Table 4). In a follow-up study, we illustrate that these changes are also correlated with changes in CSF markers of disease and brain imaging changes.

To inform about enzymatic activity changes in the liver and the gut, three types of metabolite ratios were evaluated to inform about mechanisms leading to the noted altered BA profile in AD. We found no shift in metabolism between primary and alternative pathways (Figure 3; no change in CA:CDCA); a significant change in production of secondary BAs via enzymatic activities in the gut microbiome (increased DCA:CA as well as GLCA:CDCA and TLCA:CDCA as proxies for LCA:CDCA) and no change in processes involved in glycine and taurine conjugation of secondary BAs in the liver (no change in GDCA:DCA or TDCA:DCA). The significant increase in ratios of secondary to primary BAs (e.g., DCA:CA; Figure 3), suggest altered activity of bacterial 7α -dehydroxylases leading to excess production of secondary BAs many of which are cytotoxic^{34,60-62}. This indicates potential gut dysbiosis in AD patients possibly caused by enhanced colonization of the large and possibly the small intestine with anaerobic bacteria capable of CA and CDCA 7α -dehydroxylation. Increases in these ratios also significantly correlated with poorer cognition (Table 5). Together, these findings suggest that enzymatic steps in conversion of primary to secondary BAs in the gut might contribute to disease.

We also evaluated effects of BA levels on risk of progression to AD among 789 MCI patients. Lower levels of CA and higher ratio of secondary to primary BAs, GDCA:CA, and TDCA:CA were significantly associated with risk of developing AD dementia (Figure 4, Supplementary Table 6).

The increased production of bacterially produced DCA from CA modeled by ratio DCA:CA and its link to cognition was replicated in the independent ROS/MAP cohort. Association of the DCA:CA ratio with disease severity was evaluated separately in 566 serum and 111 brain samples. Because of the small number of AD patients ($n=11$, serum $n = 27$, brains), we used

global cognitive scores as an index of disease severity. Most of the BAs primary and bacterially produced secondary were found in the brain. Similar to ADNI findings, an increase in the DCA:CA ratio in both serum and brain were significantly associated with worse cognition. This finding suggests that downstream effects of the gut-directed dysregulation of primary versus secondary BAs are not limited to the periphery but also might affect metabolic homeostasis and/or signaling functions in the human brain.

Earlier smaller studies suggested differences in BA levels in AD^{26,38-41}. For example, in a study of 495 plasma metabolites comparing MCI ($n=58$) and AD ($n = 100$) with those of cognitively normal controls ($n=93$), levels of DCA, LCA, and GLCA were significantly elevated in the disease state⁴¹. Mapstone and colleagues³⁹ identified increased levels of glyoursodeoxycholic acid (GUDCA) in subjects likely to develop amnesic MCI or AD within 2 to 3 years compared to control. In a small pilot study, Marksteiner and colleagues³⁸ reported increased levels of LCA, GDCA, and GLCA in AD ($n=30$) relative to MCI ($n=20$). We replicated these findings with the exception of LCA (Excluded during QC) and glyoursodeoxycholic acid, which showed only a nonsignificant trend of upregulation in the AD group ($P = 0.054$). Marksteiner³⁸ did not report a significant increase in DCA or decrease in CA which we observed in the ADNI cohort. However, there is a trend in their data to suggest that DCA levels are increased in AD relative to CN. Our analyses build upon these pilot studies to include a large well-characterized cohort with rich clinical, neuroimaging, and genetics data. Our analyses include links to innate immunity-related genes which was not possible in smaller studies. In addition, we controlled for medication use which is known to significantly affect the gut microbiome and BAs. In our follow-up study, we explore the association of serum BAs with CSF and neuroimaging biomarkers of AD.

Composition and functional changes of the gut microbiome have been implicated in several diseases. Microbiome GWAS revealed that variants in many human genes involved in immunity and gut architecture are associated with an altered gut microbiome composition⁶³. Although many factors such as diet can affect the microbial organisms residing in the gut, emerging data support the hypothesis that certain host genetic variants predispose an individual toward microbiome dysbiosis and this can be linked to disorders of metabolism and immunity such as type 2 diabetes mellitus, obesity, and autism⁶³.

Accumulating evidence links dysregulation of the immune system to AD pathology. In particular, genetic association studies in AD have robustly identified several genetic risk variants in immune-related genes^{2,59}. Using the ADNI and RS cohorts, we investigated the association of BA profiles of CN subjects with genetic variants in nine AD-related and innate immunity genes. Eight genetic variants were associated with selected BA levels at nominal significance (Supplementary Table 10). Three of these associations were significant after Bonferroni-correction, with rs616338 (*ABI3*) and rs190982 (*MEF2C*) associated with the DCA:CA ratio, and rs11771145 (*EPHA1*) linked to both DCA and TDCA. The association of the BAs to AD genes suggests that these

immune-related genes may influence the risk of AD through BA metabolism or changes in the gut microbiome. Interestingly, both *ABI3* and *MEF2C* are thought to be involved in immune reactions to pro-inflammatory stimuli that are partially secreted by microbes^{64,65}. The link to the DCA:CA ratio may thus mirror differences in gut microbiome composition due to altered immune response in AD, providing a mechanistic hypothesis for our findings. The function of *EPHA1* is not well understood but, it has been hypothesized that when activated, this receptor may affect the integrity of the blood-brain barrier (BBB)⁶⁶. Its association with levels of DCA is intriguing as DCA is known to be cytotoxic and can disrupt the BBB and then enter the brain²⁸. rs11771145 is associated with gene expression levels of *EPHA1*⁵⁵, and as DCA is not known to be produced by human metabolism, changed expression and activity of *EPHA1* may be related to DCA-mediated cytotoxic effects.

Using an established atlas of genetic influences on human blood metabolites⁴⁵, we further investigated a potential cytotoxic role of DCA. For almost half of the 13 identified loci, we found genetic evidence for involvement in AD-linked complex traits (Supplementary Table 11). In particular, *ABCA7* is an AD risk gene replicated in several genetic studies^{67,68}. Five additional genes (*LRRC7*, *CYCS*, *GPC6*, *FOXN3*, and *CNTNAP4*) genetically influence AD phenotypes, including cognitive decline and CSF markers. While it remains speculative if and how these genes interact with DCA to contribute to AD risk, it is intriguing that we identified *ABCA7* by screening for associations with DCA levels. *ABCA7* is highly expressed in the brain, and functions in the efflux of lipids, including cholesterol, from cells. Because of the structural similarity of DCA and cholesterol, we hypothesize that *ABCA7* may be able to also transport this BA, reconciling metabolomics findings via a functional hypothesis to a risk gene for AD. The findings that BA levels are regulated by AD-related genes might provide new mechanistic insights.

There is growing support for strong connections between the intestinal environment, with its diverse microbial composition and activity, and the functions of the central nervous system. The “gut-brain metabolic axis” facilitates bidirectional chemical communication between the central and enteric nervous systems through mechanisms just starting to be defined⁷⁻⁹. Such a metabolic axis is thought to be involved in the regulation of multiple host metabolic pathways in which levels of hormones, neurotransmitters, amines, GABA, short-chain fatty acids (SCFA), lipid metabolites, and others are regulated by gut microbiome activity¹². Changes in the composition of intestinal bacterial populations are associated with a wide array of neurological and neurodevelopmental disorders such as multiple sclerosis, autism, depression, schizophrenia, and Parkinson’s disease⁶⁹⁻⁷¹. In addition, increasing evidence suggests that liver disease may impact cognitive functions and contribute to AD⁷².

Our findings suggest novel metabolic links in AD where BAs represent a component of the gut-liver-brain axis that relates to cognition. We hypothesize that interconnected immune and gut

Chapter 5

microbiome dysregulation leads to increase in production of cytotoxic secondary BAs like DCA and its derivatives and these can modulate the BBB and build up in the

brain leading to impaired metabolic functions mediated by their receptors and targets. Such dysregulation includes cholesterol and glucose homeostasis.

It is of interest that BAs are ligands for nuclear receptors including FXR, LXRs among others and they act synergistically as metabolic sensors to regulate energy homeostasis^{73,74} peripherally and might also propagate their effects to the brain. Interestingly, levels of four BAs produced by the gut microbiome and those we show to be significantly correlated with disease status and cognition (DCA, GLCA, TLCA, TDCA) are hydrophobic and cytotoxic^{34,35,75,76}. Cell lines, animal models, and human studies suggest that levels of such BAs, particularly DCA, lead to a disruption of mitochondrial membranes resulting in increased reactive oxygen species, markers of inflammation, and apoptosis as well as decreases in cell viability and DNA synthesis^{34,35,77}. Studies in rodents with deuterium-labeled DCA demonstrated that DCA crosses the BBB and increases its permeability^{27,29}. Increased amounts of secondary BAs in blood may enter the brain through induced permeability of the BBB, affecting brain physiology and metabolism²⁸. Several studies in human and animal brains also revealed that the full panel of BAs is found in the brain²⁴⁻²⁷, but it is unclear whether this is due to transport from the periphery, from local synthesis, or both. The function of these BAs in the brain remains poorly defined with some support for them acting as neurosteroids⁷⁸.

BA levels and the gut microbiome influence each other, where bile salt hydrolase-rich bacteria readily modify the BA profile while, on the other hand, intestinal BAs control the growth and maintenance of commensal bacteria, maintain barrier integrity, and modulate the immune system⁷⁹⁻⁸². Such changes might impact brain functions. Significant data support a role for cholesterol metabolism in the pathogenesis of AD including large genetic studies. Cholesterol homeostasis is regulated in part by the gut microbiome suggesting that cholesterol intermediates including those produced by gut might present as one gut-brain axis of communication that needs to be further investigated in human and animal studies.

Limitations

This is an observational study, the results of which may contain confounding biases. For example, diet, lifestyle, exposome, and other factors may contribute to changes in the gut. It remains unclear how these important factors are related to AD pathogenesis and whether the observed differences we note are causes or consequences of disease. Further studies of metabolic changes in normal aging are required to help define which aspects of BA metabolism might be related to disease versus normal aging. Fecal material was not collected in the ADNI cohorts or other large studies therefore precluding a direct analysis of microbiota changes across the trajectory of disease. Such studies have just been initiated. Use of medications was extensively evaluated as a

possible confound (Supplementary Methods and Tables 7–9), and our key findings remained after controlling for medication use but larger studies need to further evaluate the effect of these medications. Additional experimental studies are needed to more fully define the expression of BAs and their receptors in the brain and the mechanistic roles of BAs in the development of AD. The impact of BAs on FXR, TGR5, vitamin, and hormone receptors in the brain and the signaling pathways impacted are currently unclear. It is important to evaluate in other large community studies the generalizability of our findings. The genetic links need to be tested in large populations.

Longitudinal studies covering presymptomatic stages are needed to establish the influence of immune changes on gut microbiome composition and activity in AD patients and the impact of this on BAs and cholesterol homeostasis. Tracking earliest changes in BA and other gut-derived metabolites might provide insights into causality. Labeling studies are needed to evaluate if BAs cross the BBB and build up in brain with further elucidation of their signaling and regulatory functions centrally. However, we cannot exclude the possibility that changes in the brain during disease can also impact the gut and liver, and hence, some of our findings might be brain derived.

Conclusions

In summary, there is evidence of a relationship among the intestinal BA profile, gut microbial composition and/or activity, innate immunity, and genetic variants implicated in AD. When disrupted, BAs may contribute to cognitive changes, highlighting the importance of cholesterol clearance and its regulation in AD. Disorders in BA metabolism cause cholestatic liver diseases, dyslipidemia, fatty liver diseases, cardiovascular diseases, and diabetes, which are all associated with risk of cognitive decline, directly or indirectly. Our results lend support to this relationship in the context of AD and cohorts at risk for AD. Our evolving understanding of the gut microbiome's role in aging and in central nervous system diseases and their progression could open potential new hypotheses in the field, regardless of whether the role is ultimately found to be causative, consequence, or contributory. The role of the gut microbiome in AD needs to be further investigated along with the emerging links between central and peripheral metabolic failures that might contribute to brain health and disease during aging.

Acknowledgments

The Alzheimer's Disease Metabolomics Consortium (ADMC): A complete listing of ADCMC investigators can be found at: <https://sites.duke.edu/adnimetab/who-we-are/>

The Alzheimer's Disease Neuroimaging Initiative (ADNI): Data used in the preparation of this article were obtained from the ADNI database (<http://adni.loni.usc.edu>). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf.

Funding for ADCMC (Alzheimer's Disease Metabolomics Consortium, led by Rima Kaddurah-Daouk at Duke University) was provided by the National Institute on Aging grant R01AG046171, a component of the Accelerated Medicines Partnership for AD (AMP-AD) Target Discovery and Preclinical Validation Project (<https://www.nia.nih.gov/research/dn/amp-ad-target-discovery-and-preclinical-validation-project>) and the National Institute on Aging grant RF1 AG0151550, a component of the M²OVE-AD Consortium (Molecular Mechanisms of the Vascular Etiology of AD – Consortium <https://www.nia.nih.gov/news/decoding-molecular-ties-between-vascular-disease-and-alzheimers>).

Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD A.D.N.I. (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support A.D.N.I. clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. A.D.N.I. data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

The Religious Orders and the Rush Memory and Aging studies were supported by the National Institute on Aging grants P30AG10161, R01AG15819, R01AG17917, and U01AG46152.

The work of various Consortium Investigators is also supported by various NIA grants (U01AG024904-09S4, P50NS053488, R01AG19771, P30AG10133, P30AG10124, K01AG049050, R03AG054936), the National Library of Medicine (R01LM011360, R00LM011384, R01 LM0112535), and the National Institute of Biomedical Imaging and Bioengineering (R01EB022574). Additional support came from Helmholtz Zentrum, the Alzheimer's Association, the Indiana Clinical and Translational Science Institute, and the Indiana University-IU Health Strategic Neuroscience Research Initiative.

Role of the Funder/Sponsor: [Funders listed above] had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Additional Contributions: The authors are grateful to Lisa Howerton for administrative support and the numerous ADNI study volunteers and their families.

Disclosures

J.B.T. reports investigator-initiated research support from Eli Lilly unrelated to the work reported here. S.S., S.K., and T.K. are employed by Biocrates Life Sciences AG. These authors have no other financial relationships relevant to this article to disclose. J.Q.T. may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is a co-inventor and he received revenue from the sale of Avid to Eli Lilly as a co-inventor on imaging-related patents submitted by the University of Pennsylvania. L.M.S. receives research funding from NIH (U01 AG024904; R01 MH 098260; R01 AG 046171; 1RF AG 051550) and MJFox Foundation for PD Research and is a consultant for Eli Lilly, Novartis, and Roche; he provides QC oversight for the Roche Elecsys immunoassay as part of responsibilities for the ADNI3 study. A.J.S. reports investigator-initiated research support from Eli Lilly unrelated to the work reported here. He has received consulting fees and travel expenses from Eli Lilly and Siemens Healthcare and is a consultant to Arkley BioTek. He also receives support from Springer publishing as an editor in chief of Brain Imaging and Behavior. M.W.W. reports stock/stock options from Elan, Synarc, travel expenses from Novartis, Tohoku University, Fundacio Ace, Travel eDreams, MCI Group, NSAS, Danone Trading, ANT Congress, NeuroVigil, CHRU-Hopital Roger Salengro, Siemens, AstraZeneca, Geneva University Hospitals, Lilly, University of California, San Diego-ADNI, Paris University, Institut Catala de Neurociencies Aplicades, University of New Mexico School of Medicine, Ipsen, Clinical Trials on Alzheimer's Disease, Pfizer, AD PD meeting. P.M.D. has received research grants and advisory/speaking fees from several companies for other projects, and he owns stock in several companies. Full disclosures will be made through the IJCME

Chapter 5

form. R.K.D. is inventor on key patents in the field of metabolomics including applications for Alzheimer disease. All other authors report no disclosures.

An email with links to the Authorship Form will be sent to authors for completion after manuscripts have been submitted

References


1. Alzheimer's, A. 2017 Alzheimer's disease facts and figures. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* **13**, 325-373 (2017).
2. Lambert, J.C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-8 (2013).
3. Jones, L. *et al.* Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimer's & dementia: the journal of the Alzheimer's Association* **11**, 658-671 (2015).
4. Sampson, T.R. & Mazmanian, S.K. Control of brain development, function, and behavior by the microbiome. *Cell Host Microbe* **17**, 565-76 (2015).
5. Wu, S.-C., Cao, Z.-S., Chang, K.-M. & Juang, J.-L. Intestinal microbial dysbiosis aggravates the progression of Alzheimer's disease in Drosophila. *Nature Communications* **8**, 24 (2017).
6. Kumar, D.K. *et al.* Amyloid-beta peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. *Sci Transl Med* **8**, 340ra72 (2016).
7. Ghaisas, S., Maher, J. & Kanthasamy, A. Gut microbiome in health and disease: linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and neurodegenerative diseases. *Pharmacology & therapeutics* **158**, 52-62 (2016).
8. Yarandi, S.S., Peterson, D.A., Treisman, G.J., Moran, T.H. & Pasricha, P.J. Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases. *Journal of Neurogastroenterology and Motility* **22**, 201-212 (2016).
9. Tognini, P. Gut Microbiota: A Potential Regulator of Neurodevelopment. *Frontiers in Cellular Neuroscience* **11**, 25 (2017).
10. Tremlett, H., Bauer, K.C., Appel-Cresswell, S., Finlay, B.B. & Waubant, E. The gut microbiome in human neurological disease: A review. *Annals of Neurology* **81**, 369-382 (2017).
11. Holmes, E., Li, J.V., Marchesi, J.R. & Nicholson, J.K. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. *Cell Metab* **16**, 559-64 (2012).
12. Nicholson, J.K. *et al.* Host-gut microbiota metabolic interactions. *Science* **336**, 1262-7 (2012).
13. Sampson, T.R. *et al.* Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson's Disease. *Cell* **167**, 1469-1480 e12 (2016).
14. Minter, M.R. *et al.* Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APPSWE/PS1DeltaE9 murine model of Alzheimer's disease. *Sci Rep* **7**, 10411 (2017).
15. Harach, T. *et al.* Reduction of Abeta amyloid pathology in APPPS1 transgenic mice in the absence of gut microbiota. *Sci Rep* **7**, 41802 (2017).
16. Cattaneo, A. *et al.* Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. *Neurobiol Aging* **49**, 60-68 (2017).
17. Bester, J., Soma, P., Kell, D.B. & Pretorius, E. Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS). *Oncotarget* **6**, 35284-303 (2015).

18. Di Paolo, G. & Kim, T.W. Linking lipids to Alzheimer's disease: cholesterol and beyond. *Nat Rev Neurosci* **12**, 284-96 (2011).
19. Beecham, G.W. *et al.* Genome-Wide Association Meta-analysis of Neuropathologic Features of Alzheimer's Disease and Related Dementias. *PLoS Genetics* **10**, e1004606 (2014).
20. Ridlon, J.M., Kang, D.J. & Hylemon, P.B. Bile salt biotransformations by human intestinal bacteria. *J Lipid Res* **47**, 241-59 (2006).
21. Donova, M.V. [Transformation of steroids by actinobacteria: a review]. *Prikl Biokhim Mikrobiol* **43**, 5-18 (2007).
22. Islam, K.B.M.S. *et al.* Bile Acid Is a Host Factor That Regulates the Composition of the Cecal Microbiota in Rats. *Gastroenterology* **141**, 1773-1781 (2011).
23. Camilleri, M. & Gores, G.J. Therapeutic targeting of bile acids. *Am J Physiol Gastrointest Liver Physiol* **309**, G209-15 (2015).
24. Mano, N. *et al.* Presence of protein-bound unconjugated bile acids in the cytoplasmic fraction of rat brain. *J Lipid Res* **45**, 295-300 (2004).
25. Naqvi, S.H. *et al.* Detection of monohydroxy "bile" acids in the brains of guinea pigs afflicted with experimental allergic encephalomyelitis. *J Lipid Res* **10**, 115-20 (1969).
26. Pan, X. *et al.* Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. *Metabolites* **7**(2017).
27. Higashi, T. *et al.* Unconjugated bile acids in rat brain: Analytical method based on LC/ESI-MS/MS with chemical derivatization and estimation of their origin by comparison to serum levels. *Steroids* **125**, 107-113 (2017).
28. Quinn, M. *et al.* Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. *Digestive and Liver Disease* **46**, 527-534 (2014).
29. Lalic-Popovic, M. *et al.* Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. *J Diabetes Res* **2013**, 598603 (2013).
30. Cecilia, M.P.R. *et al.* Neuroprotection by a Bile Acid in an Acute Stroke Model in the Rat. *Journal of Cerebral Blood Flow & Metabolism* **22**, 463-471 (2002).
31. Dionisio, P.A. *et al.* Amyloid-beta pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. *Neurobiology of Aging* **36**, 228-240 (2015).
32. Nunes, A.F. *et al.* TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-beta deposition in APP/PS1 mice. *Mol Neurobiol* **45**, 440-54 (2012).
33. Paolini, M. *et al.* Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities. *Hepatology* **36**, 305-14 (2002).
34. Ignacio Barrasa, J. *et al.* Deoxycholic and chenodeoxycholic bile acids induce apoptosis via oxidative stress in human colon adenocarcinoma cells. *Apoptosis* **16**, 1054-67 (2011).
35. Martinez-Diez, M.C., Serrano, M.A., Monte, M.J. & Marin, J.J. Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. *Biochim Biophys Acta* **1500**, 153-60 (2000).

36. Ramalho, R.M., Viana, R.J.S., Low, W.C., Steer, C.J. & Rodrigues, C.M.P. Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. *Trends in Molecular Medicine* **14**, 54-62 (2008).
37. Schulz, S. *et al.* Progressive stages of mitochondrial destruction caused by cell toxic bile salts. *Biochimica et biophysica acta* **1828**, 2121-33 (2013).
38. Marksteiner, J., Blasko, I., Kemmler, G., Koal, T. & Humpel, C. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease. *Metabolomics* **14**, 1 (2018).
39. Mapstone, M. *et al.* Plasma phospholipids identify antecedent memory impairment in older adults. *Nat Med* **20**, 415-8 (2014).
40. Greenberg, N., Grassano, A., Thambisetty, M., Lovestone, S. & Legido-Quigley, C. A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. *Electrophoresis* **30**, 1235-9 (2009).
41. Olazaran, J. *et al.* A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. *J Alzheimers Dis* **45**, 1157-73 (2015).
42. Bennett, D.A., Schneider, J.A., Arvanitakis, Z. & Wilson, R.S. Overview and findings from the religious orders study. *Curr Alzheimer Res* **9**, 628-45 (2012).
43. Bennett, D.A. *et al.* Overview and findings from the rush Memory and Aging Project. *Curr Alzheimer Res* **9**, 646-63 (2012).
44. Adams, H.H. *et al.* Genetic risk of neurodegenerative diseases is associated with mild cognitive impairment and conversion to dementia. *Alzheimers Dement* **11**, 1277-85 (2015).
45. Shin, S.Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet* **46**, 543-550 (2014).
46. Xie, G. *et al.* Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. *The FASEB Journal* **27**, 3583-3593 (2013).
47. St John-Williams, L. *et al.* Targeted metabolomics and medication classification data from participants in the ADNI1 cohort. *Sci Data* **4**, 170140 (2017).
48. Wilson, R. *et al.* Proneness to psychological distress is associated with risk of Alzheimer's disease. *Neurology* **61**, 1479-1485 (2003).
49. Wilson, R.S. *et al.* Participation in cognitively stimulating activities and risk of incident Alzheimer disease. *Jama* **287**, 742-748 (2002).
50. Wilson, R.S., Bienias, J.L., Evans, D.A. & Bennett, D.A. Religious Orders Study: overview and change in cognitive and motor speed. *Aging Neuropsychology and Cognition* **11**, 280-303 (2004).
51. Wilson, R.S. *et al.* Early and late life cognitive activity and cognitive systems in old age. *Journal of the International Neuropsychological Society* **11**, 400-407 (2005).
52. Saykin, A.J. *et al.* Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. *Alzheimer's & dementia: the journal of the Alzheimer's Association* **11**, 792-814 (2015).
53. McCarthy, S. *et al.* A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* **48**, 1279-83 (2016).

54. Das, S. *et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-7 (2016).
55. Arnold, M., Raffler, J., Pfeufer, A., Suhre, K. & Kastenmuller, G. SNIIPA: an interactive, genetic variant-centered annotation browser. *Bioinformatics* **31**, 1334-6 (2015).
56. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide association studies (GWAS Catalog). *Nucleic Acids Res* **45**, D896-D901 (2017).
57. Guerreiro, R., Bras, J. & Hardy, J. SnapShot: genetics of Alzheimer's disease. *Cell* **155**, 968-968 e1 (2013).
58. Villegas-Llerena, C., Phillips, A., Garcia-Reitboeck, P., Hardy, J. & Pocock, J.M. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. *Curr Opin Neurobiol* **36**, 74-81 (2016).
59. Sims, R. *et al.* Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat Genet* **49**, 1373-1384 (2017).
60. Rolo, A.P., Palmeira, C.M. & Wallace, K.B. Mitochondrially mediated synergistic cell killing by bile acids. *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease* **1637**, 127-132 (2003).
61. Shivaram, K.N. *et al.* The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile acid toxicity to isolated rat hepatocytes and hepatic mitochondria. *Free Radic Biol Med* **25**, 480-92 (1998).
62. Rodrigues, C.M., Fan, G., Ma, X., Kren, B.T. & Steer, C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. *J Clin Invest* **101**, 2790-9 (1998).
63. Hall, A.B., Tolonen, A.C. & Xavier, R.J. Human genetic variation and the gut microbiome in disease. *Nature Reviews Genetics* **18**, 690 (2017).
64. Han, J., Jiang, Y., Li, Z., Kravchenko, V.V. & Ulevitch, R.J. Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation. *Nature* **386**, 296-9 (1997).
65. Fairfax, B.P. *et al.* Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. *Science* **343**, 1246949 (2014).
66. Shoemark, D.K. & Allen, S.J. The microbiome and disease: reviewing the links between the oral microbiome, aging, and Alzheimer's disease. *J Alzheimers Dis* **43**, 725-38 (2015).
67. Hollingworth, P. *et al.* Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* **43**, 429-35 (2011).
68. Le Guennec, K. *et al.* ABCA7 rare variants and Alzheimer disease risk. *Neurology* **86**, 2134-7 (2016).
69. Holmqvist, S. *et al.* Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. *Acta Neuropathol* **128**, 805-20 (2014).
70. Jangi, S. *et al.* Alterations of the human gut microbiome in multiple sclerosis. *Nat Commun* **7**, 12015 (2016).
71. Dinan, T.G. & Cryan, J.F. Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. *J Physiol* **595**, 489-503 (2017).

72. Kim, D.G. *et al.* Non-alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. *J Neuroinflammation* **13**, 1 (2016).
73. Calkin, A.C. & Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. *Nat Rev Mol Cell Biol* **13**, 213-224 (2012).
74. Schaap, F.G., Trauner, M. & Jansen, P.L.M. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol* **11**, 55-67 (2014).
75. Faubian, W.A. *et al.* Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. *J Clin Invest* **103**, 137-45 (1999).
76. Perez, M.J. & Briz, O. Bile-acid-induced cell injury and protection. *World J Gastroenterol* **15**, 1677-89 (2009).
77. Sousa, T. *et al.* Deoxycholic acid modulates cell death signaling through changes in mitochondrial membrane properties. *Journal of Lipid Research* **56**, 2158-2171 (2015).
78. Keitel, V. *et al.* The bile acid receptor TGR5 (Gpbar-1) acts as a neurosteroid receptor in brain. *Glia* **58**, 1794-805 (2010).
79. Stenman, L.K., Holma, R., Eggert, A. & Korpela, R. A novel mechanism for gut barrier dysfunction by dietary fat: epithelial disruption by hydrophobic bile acids. *Am J Physiol Gastrointest Liver Physiol* **304**, 29 (2013).
80. Shapiro, H., Thaïss, C.A., Levy, M. & Elinav, E. The cross talk between microbiota and the immune system: metabolites take center stage. *Current Opinion in Immunology* **30**, 54-62 (2014).
81. Baptissart, M. *et al.* Bile acids: from digestion to cancers. *Biochimie* **95**, 504-17 (2013).
82. Allegretti, J.R. *et al.* Recurrent *Clostridium difficile* infection associates with distinct bile acid and microbiome profiles. *Aliment Pharmacol Ther* **43**, 1142-53 (2016).



Chapter 6

General Discussion



In this thesis, I aim to identify the genetic, metabolomic, and proteomic determinants of Alzheimer's disease (AD) risk and pathophysiology using integrated multi-omics and epidemiological approaches. Furthermore, I investigate the interaction of lifestyle factors with genetic risk factors in AD. The general discussion that follows will highlight the main findings of this thesis, their possible implications in understanding the AD pathophysiology, challenges, and opportunities for future research.

Genetics of Alzheimer's disease

In Chapter 2 of this thesis, I performed linkage analysis coupled with whole-genome sequencing to identify rare genetic variants. Genetic linkage analysis is a powerful approach to identify rare genetic variants, particularly when coupled with deep genomic sequencing¹. The study described in this chapter was performed as part of the Alzheimer's disease Sequencing Project (ADSP) and is based on multi-generational families from the Genetic Research in Isolated Populations (GRIP), a highly inbred Dutch isolate². Shared genetic and environmental factors in isolated family-based studies increase the power to detect rare variants³. I identified a genomic region, 5p14.3 (logarithm of odds (LOD) score = 3.3) linked to late-onset AD, and a haplotype region spanning over 9.1 cM shared by ten individuals contributing to the linkage signal at 5p14.3 region. With whole-genome sequencing of the affected family members, I identified a number of candidate single nucleotide polymorphisms (SNPs) in the *CDH18* gene, which may explain the identified genetic linkage region. *CDH18* encodes a type II cadherin protein, which is highly expressed in brain⁴ and is involved in neuronal development and synaptic function⁵.

In a separate study, A large GWAS of short-term verbal memory from The Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) has identified a genome-wide significant variant ($P = 5 \times 10^{-8}$) in the *CDH18* gene (Jari *et al.* 2019 [unpublished]). It is of note that loss of short-term memory is considered one of the early clinical symptoms of AD⁶ and is associated with an increased risk of AD^{7,8}, thus relevant to our finding. Further evidence from earlier studies have shown the association of various members of the cadherin gene family in neuropsychiatric disorders^{9,10}, CSF levels of A β -42¹¹, cognition, and education attainment^{12,13,14,15}. Taken together, findings from our study and those of others highlight the importance of a genomic region, i.e., 5p14.3, in the central nervous system, but its precise role in AD is yet to be explored. Due to the highly variable frequencies of rare variants, population specificity, and unstable genomic region, I did not find a specific variant associated with AD in our identified genomic region based on the statistical analysis. Future functional studies, in cellular models or transgenic animals, aims at deciphering the role of various cadherin genes in AD pathology are needed to validate our findings, and to identify the pathways contributing to our observation.




Figure 1: Biomarkers of AD trajectory over time, presenting three stages of AD, presymptomatic stage, MCI and eventually AD dementia. Reprinted from Leclerc *et al.*²⁷ Abbreviations: MCI, mild cognitive impairment; MRI, magnetic resonance imaging; CSF, cerebrospinal fluid.

Pathways implicated in Alzheimer's disease and lifestyle factors

A primary goal of genetic knowledge of a disease is to gain insight into novel pathways implicated in the etiology. Integrating genome-wide association study (GWAS) findings in AD with differential gene expression showed the role of eight biological pathways in AD¹⁶ and, more recently also of A β processing¹⁷. In chapter 3.1, I showed that *endocytosis* pathway-based risk score associates to AD, mild cognitive impairment (MCI) and progression from normal (dementia-free) to AD. This observation is in line with earlier studies reporting the *endocytosis* pathway as the earliest manifestation of AD¹⁸⁻²⁰. The *endocytosis* pathway is involved in neuronal uptake of cholesterol as well as excretion of secretory vesicles, thus crucial for synaptic function and axonal elongation²¹. Evidence from other studies also suggests a role of *endocytosis* dysfunction in A β aggregation²², impaired synaptic function, and release of neurotransmitters²³. Findings from this chapter indicate that the *endocytosis* pathway is shared between MCI and AD, thus may serve as a target for early AD risk assessment (Figure 1). I also showed that the increased genetic risk burden of risk variants in *clathrin/AP2 adaptor complex pathways* and *immune response* may play a role in early AD pathogenesis through white matter pathology. Among two genes clustered in *clathrin/AP2 adaptor complex* pathway (*PICALM*, *CLU*), *PICALM* is mainly expressed in the blood vessel walls and brain tissues²⁴ and is also expressed in the white matter, whereas *CLU* plays a role in the efflux of free insoluble amyloid-beta (A β) peptide through blood-brain barrier²⁵. Moreover, increased plasma levels of *CLU* were found to be associated with decreased integrity of white matter at a young age²⁶. Thus, the combined genetic risk of these two genes (*PICALM*,

CLU) may explain changes in white matter hyperintensities at MRI. Interestingly, a combined genetic risk score based on all genome-wide significant variants did not show association with any of the early features of AD pathophysiology, which suggest that aggregating multiple variants into a single score may dilute meaningful biological relevance of specific sets of genes belonging to a particular pathway. Findings from this study advances our understanding about the role of AD implicated pathways in early phase of AD and this also open avenues for research in pathway based genetic risk stratification of AD patients. Future studies are needed to explore the role of pathways in AD based on recent meta-analysis of AD GWAS¹⁷ which first time showed the enrichment of genetic variants related to the A β processing pathway.

Chapter 3.2 of this thesis addressed the question of whether adherence to a healthy lifestyle can attenuate or even offset the genetic risk of dementia contributed by *APOE* in the Rotterdam study, a prospective population-based study. To study the healthy lifestyle pattern, a composite profile was constructed based on six lifestyle factors including abstaining from smoking, avoiding social isolation, absence of depression, absence of diabetes, regular physical activity and healthy diet including limited alcohol consumption. Findings from this chapter showed that modifiable risk factors lower the risk of dementia in individuals with low (*APOE* $\epsilon 2\epsilon 3$, $\epsilon 2\epsilon 2$ genotypes) and intermediate (*APOE* $\epsilon 3\epsilon 3$) genetic risk of dementia but not in the high genetic risk group (*APOE* $\epsilon 2\epsilon 4$, $\epsilon 3\epsilon 4$ or $\epsilon 4\epsilon 4$ genotype carriers). If replicated in an independent cohort, the clinical implication of our findings may be that adopting a healthy lifestyle could potentially prevent or postpone the onset of dementia in individuals at low and intermediate genetic risk. However, in contrast to our findings, a recent study based on the UK Biobank data showed that the association of lifestyle and genetic risk factors with AD risk is independent and additive in nature²⁸. There may be several explanations of why our findings did not replicate. Although the UK Biobank-based study used a similar set of lifestyle factors, the study lacks deep dementia phenotyping in the cohort. Secondly, the use of polygenic risk score based on non-genome-wide significant loci by the UK Biobank study to account for the genetic component may explain the differences in both investigations. However, more extensive studies on the interaction of lifestyle factors with genetic factors in AD are needed to overcome the conflicting results.

Proteomics and Metabolomics of Alzheimer's disease

An increasing number of studies are focusing on identifying proteomic and metabolic determinants of AD during the preclinical and prodromal phase of the disease (Figure 1). In chapter 4.1, I studied the association of proteins profiled in blood with AD in the overall population and stratified by *APOE*. In this study, brain-related proteins were profiled in pre-symptomatic subjects from a prospective population-based study, the Rotterdam Study. In this chapter, I reported the association of CDH6 and HAGH protein levels in blood with AD in *APOE* $\epsilon 4$ carriers. The findings of this study were replicated in an independent Swedish BioFINDER cohort.

Furthermore, a genome-wide association study of protein levels in blood identified a genetic variant (rs111283466) that is also associated with the expression levels of *CDH6* transcripts. In an additional analysis, I showed a significant positive correlation of *CDH6* levels in CSF with p-tau and total-tau in Amsterdam Dementia Cohort (ADC), which suggests that *CDH6* levels in CSF may act as a biomarker of neurodegeneration. *CDH6* is a cell surface glycoprotein that is highly expressed in blood and is involved in synaptic functions²⁹⁻³¹, synaptogenesis³², TGF- β signaling³³, neural crest differentiation³⁴, presenilin-mediated signaling, and integrity of blood-brain barrier³⁵. *CDH6* protein-coding gene is part of a larger cadherin (CDH) gene cluster including *CDH8*, *CDH9*, *CDH10*, *CDH12*, *CDH13*, *CDH15*, and *CDH18*. It is of note that most of the cadherin genes including *CDH6*, *CDH9*, *CDH10*, *CDH12*, and *CDH18* are located in chromosome 5p14.3 region which I identified to be linked with AD in the genetic linkage analysis reported in Chapter 2. Positive associations of CSF levels of *CDH6* protein with p-tau and total-tau levels in the ADC cohort suggest the role of *CDH6* in the molecular process of neuronal and axonal cell injury, which begins years before the symptomatic phase of AD^{36,37}. I also find elevated levels of HAGH protein in *APOE* $\epsilon 4$ carriers. The HAGH protein (glyoxalase-2) is involved in the glyoxalase system along with glyoxalase-1, a key player in oxidative stress control^{38,39}. The glyoxalase system plays a role in detoxification of cytotoxic metabolite, methylglyoxal⁴⁰. In plasma, higher levels of methylglyoxal are observed in hyperglycemia, which aids in the production of reactive oxygen species (ROS) and causes oxidative stress. Moreover, methylglyoxal is also a precursor of glycation end products (AGEs) and are implicated in neurodegeneration and AD^{41,42}. Moreover, AGEs and glyoxalase system is involved in the regulation of amyloid precursor protein (*APP*) expression^{43,44}. Findings from this chapter reiterate observations from earlier studies that suggest the role of oxidative stress during the prodromal stage of AD⁴⁵⁻⁴⁷. Additionally, findings from this study suggest that the oxidative stress-related protein marker (glyoxalase-2 or HAGH) can be observed in the blood of the presymptomatic phase of AD carrying *APOE* $\epsilon 4$ allele.

In chapter 4.2, I set out to investigate the role of signaling lipids in AD pathophysiology and MCI to AD progression. Among signaling lipids, I focused on lysophosphatidic acids (LPAs) which are bioactive phospholipids and known to regulate several key physiological processes including brain immune response⁴⁸, myelination⁴⁹, synaptic transmission⁵⁰ as well as having a role in endothelial cells and neurovascular function⁵¹. In this study, I observed the significant positive association of five LPAs (C16:0, C16:1, C22:4, C22:6, and isomer-LPA C22:5) to all three AD biomarkers, i.e., $A\beta$ -42, p-tau and total tau levels in CSF. LPA C14:0 and C20:1 showed association to $A\beta$ -42 and alkyl-LPA C18:1, LPA C20:1 to tau pathology biomarkers (p-tau and total tau) in CSF. The positive association between various LPA and $A\beta$ -42 levels in CSF is concordant with an earlier finding, which suggested a role of LPAs in the upregulation of β -secretase (*BACE1*)⁵², a key enzyme involved in $A\beta$ production. Accumulation of $A\beta$ is an early event in the pathogenesis of AD⁵³, which may lead to synaptic failure, tau pathology, and neuronal death (see Chapter 1)⁵⁴. In the *APOE* stratified analysis, LPA C16:1 associated to $A\beta$ -42 levels in both *APOE* $\epsilon 4$ and *APOE* $\epsilon 33$ carriers but LPA C16:0 showed significant

association only in the *APOE* $\epsilon 3$ stratum, which implies that the *APOE* genotype may influence the association of LPAs with $A\beta$ -42 levels. I also found that decreased CSF levels of LPA C16:0 and C16:1 were associated with MCI to AD progression. Inverse relation of LPA levels to MCI to AD conversion may be due to their correlation with CSF $A\beta$ -42 levels, which is associated with a higher risk for MCI to AD progression⁵⁵. In line with these findings, an earlier study also showed decreased levels of LPA C16:0 in frontal cortex tissue of Lewy body disease patients with AD compared to controls⁵⁶. The fact that the association of LPAs to MCI to AD progression loses significance and the regression coefficient reducing to half after adjusting for $A\beta$ -42 levels suggests the role of LPA 16:0 and 16:1 is dependent on $A\beta$ -42. This study suggests a relationship between LPAs and $A\beta$ metabolism; thus, future research should focus on investigating the nature of this relationship. Our study provides evidence for the role of an important class of signaling lipids in the pathophysiology of AD, but there is an open question whether these signalling lipids triggers the biological cascade of events leading to AD pathology or are products of neurodegeneration.

Gut-Liver-Brain axis

The study described in chapter 5.1 of this thesis presents the association of liver function biomarkers with AD, cognition, neuroimaging, and CSF biomarkers of AD in participants of the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. This study has provided evidence for the association between lower levels of alanine aminotransferase (ALT) enzyme and elevated liver enzyme ratio (aspartate aminotransferase [AST] to ALT ratio) with AD and reduced cognitive performance, which is concordant with findings in an earlier study⁵⁷. Moreover, an increased AST to ALT ratio and lower levels of ALT were associated with increased $A\beta$ deposition, and reduced brain glucose metabolism and atrophy. The observation that the increased AST to ALT ratio associated with reduced brain glucose metabolism may explain the disturbed energy metabolism in AD and cognition^{58,59} and brain hypometabolism during the prodromal phase of AD^{60,61}. Findings from this chapter are concordant with a large number of studies that suggested the association of disturbed liver enzymes with altered levels of branched-chain amino acids, ether-linked phosphatidylcholines⁶², which relate to AD⁶³⁻⁶⁶ and its pathophysiology⁶⁷. AST and ALT enzymes also play a crucial role in gluconeogenesis in liver and neurotransmitter (glutamate) production in brain⁶⁸. In neuronal synapses, glutamate acts as a neurotransmitter and plays a role in long-term potentiation⁶⁹. Earlier studies have shown a positive correlation between plasma levels of liver enzymes and glutamate in blood^{58,70}, which indicates that reduced levels of ALT enzyme may downregulate glutamate levels. It is of note that plasma levels of glutamate correlate positively with CSF glutamate levels⁷¹, and lower levels of glutamate in plasma⁷² and brain tissues are reported in AD patients compared to controls⁷³⁻⁷⁶. This study relates liver function biomarkers in blood to various features of AD pathophysiology (Figure 2). One of the limitations of our study is that we cannot account for medication use in ADNI, which can potentially confound our results. Our study implicates the role of liver enzymes in the connection between




Figure 2: Gut-Liver-Brain axis. Abbreviations: BBB, blood-brain barrier; SCFA, Short-chain fatty acids; ASAT, Aspartate aminotransferase; ALAT, Alanine aminotransferase. Source: Adapted from Tripathi *et al*⁹⁶.

peripheral circulation and pathophysiological biomarkers of neurodegeneration. Our findings also raise questions about whether medications and lifestyle factors influence the link between peripheral circulation and brain. In future studies, other measures of liver function and non-alcoholic fatty liver disease should be investigated in addition to the effects of medication. Furthermore, Mendelian randomization may help to determine the causal relationships between the associations of liver function biomarkers and AD.

Chapter 5.2 describes the results from an association study of plasma levels of bile acids with AD diagnosis, cognition, and AD-associated genetic variants. Bile acids are products of cholesterol metabolism in the liver and further metabolized by gut microbiota^{77,78}. Bile acids play a role in various signaling and regulatory functions and may be relevant in the gut-liver-brain axis⁷⁹ (Figure 2). In AD patients, we observed significantly lower serum levels of primary bile acid (cholic acid CA) and increased levels of the microbial product, secondary bile acid, deoxycholic acid (DCA), and its glycine and taurine conjugated forms. Moreover, an increased ratio of DCA:CA was associated with cognitive decline which was replicated in serum and brain samples in the Rush Religious Orders and Memory and Aging Project. Analyzing the MCI to AD progression analysis showed that lower levels of CA and a higher ratio of secondary to primary BAs, GDCA:CA, and TDCA:CA were significantly associated with the risk of developing AD. Findings from

this chapter suggest a unique metabolic link of the gut-liver-brain axis and AD. Bile acids can act as ligands for the nuclear transcription factor FXR, which is involved in energy homeostasis pathways^{80,81}. It is of note that gut microbial derived bile acids (DCA, GLCA, TLCA, TDCA) which showed association with AD and cognition are hydrophobic and cytotoxic in nature⁸²⁻⁸⁵. DCA can disrupt mitochondrial membranes to produce reactive oxygen species and may thus influence cell viability via apoptotic and inflammatory pathways^{82,83,86}. Moreover, studies have shown that DCA can cross the BBB, affecting brain physiology and metabolism⁸⁷⁻⁸⁹. As AD is a genetic disease, we studied the association of AD implicated immune-related genetic variants with bile acid levels. We found that *ABI3* and *MEF2C* showed association with the DCA:CA ratio, and *EPHA1* with DCA and TDCA levels. These findings are compatible with the hypothesis that immune-related genes may influence the risk of AD in part through the bile acid metabolism or changes in the gut microbiome. Additional lookups in the atlas of genetic influences on human blood metabolites⁹⁰, showed that six genes (*ABCA7*, *LRRC7*, *CYCS*, *GPC6*, *FOXN3*, and *CNTNAP4*) are related to cognition and CSF AD biomarkers as well as levels of DCA levels in serum. Of the identified genes, *ABCA7* is among highly replicated risk loci for AD^{91,92}, which is highly expressed in the brain and plays a role in cholesterol transport^{93,94} and amyloid- β clearance⁹⁵. Overall, this study contributed to the understanding of the complex interconnection between gut microbiota, liver function, and genetics of AD, where bile acids as the product of liver and gut microbiota may act as a biochemical signal in the gut-brain metabolic axis. Furthermore, altered levels of bile acids highlight the importance of cholesterol clearance and its regulation in AD. Bile acids are the product of cholesterol metabolism, which highlights the need to investigate the relationship between bile acids and cholesterol sub-fractions in circulation. Future studies should focus on investigating the relationship between bile acids and gut microbiota and on identifying the microbial taxa whose abundance may derive the bile acids related to AD pathology.

In chapter 5.3, I further explored the connection between gut microbiota and genetics of AD and their relation with metabolites implicated in AD and cognition. I found an association of the risk (G) allele of *ABCA7* genetic variant with a lower abundance of phylum Firmicutes, class Clostridia, order Clostridiales and, a higher abundance of order Enterobacteriales and family Enterobacteriaceae. The findings related to Firmicutes, Clostridia, and Clostridiales are in line with earlier studies, which showed the decreased abundance of Firmicutes in AD patients compared to controls⁹⁷ and in *APP* transgenic mice⁹⁸. Additionally, I found evidence of an association between the higher abundance of class Clostridia and order Clostridiales with higher cognition levels. I also observed an association of the *ABCA7* genetic risk with higher abundance of order Enterobacteriales and family Enterobacteriaceae, which belong to phylum Proteobacteria ($P = 2.30 \times 10^{-3}$, $FDR = 5.42 \times 10^{-2}$). Although we did not find an association of these microbial taxa with cognitive function, an increased abundance of Proteobacteria is known earlier in AD patients⁹⁹. An increased abundance of Enterobacteriaceae has also been found in Parkinson's disease¹⁰⁰. In our study, integration of findings with earlier studies on the

association of cholesterol sub-fractions and gut microbiota¹⁰¹, suggest that HDL sub-fractions may play a role in the cross-talk between the gut microbiome and the brain. Of the 28 tested AD genetic risk variants, only the variant in the *ABCA7* gene showed association with gut microbial taxa. The *ABCA7* gene is highly expressed in the brain and microglia¹⁰² and plays a role in cholesterol transport^{93,94} and amyloid- β clearance⁹⁵. This gene is also implicated in microglial proinflammatory response in elderly individuals¹⁰³. One possible mechanism of the *ABCA7* gene association with gut microbial taxa may be the hyper-activated inflammatory response, which may result in an increased abundance of order Enterobacteriales and family Enterobacteriaceae. *ABCA7* gene may also influence gut microbiota through bile acid metabolism (Chapter 5.2). The variants in the *ABCA7* gene may alter blood levels of deoxycholic acid (DCA), a secondary bile acid. DCA is associated with gut microbiota⁷⁷ as well as to AD and cognition¹⁰⁴. It is also known that secondary bile acids may absorb into bloodstream and can modulate lipid metabolism through G-proteins coupled receptors such as FXR¹⁰⁵. Functional studies are required to validate these findings. Transgenic animal studies, aiming to unravel the role of *ABCA7* genetic variant in modulating gut microbiota, can also help to understand the mechanism. The integration of identified microbial taxa with measures of AD neuropathology and other endophenotypes of AD is of interest in future studies.

Future research

In this section, I describe the future directions of the AD research in multi-omics, which may open new avenues for understanding the risk and pathophysiology of AD. One of the large whole-exome and whole-genome sequencing in AD gene discovery efforts, ADSP discovered few rare variants due to inadequate sample size (AD cases = 2,778 and control = 7,262), which warrants the need for exome sequencing studies in a larger sample such as in the UK Biobank¹⁰⁶. Recent developments in the discovery of rare genetic variants of AD with large effect estimates¹⁰⁷⁻¹⁰⁹ may improve our understanding about the AD genetic risk. Rare genetic variants may also help to decipher functional pathways in disease pathophysiology. Future genetic research should utilize long read sequencing techniques to overcome the problems encountered in sequence depth, which are otherwise difficult to characterize using traditional next-generation sequencing¹¹⁰. At present, this is feasible at small scale studies. Moreover, research is needed to assess the functional aspects of genetic variants on AD pathology. Discovery of more disease-relevant genetic variants among known genetic loci of the disease may guide drug target studies¹¹¹. A recent study showed that most of the pleiotropic SNPs are located in intergenic regions, while the majority of the lead or causal genetic variants are located in the coding or flanking region of genes¹¹². Future genomic studies should also focus on even other types of genomic fingerprints (short repeats, other sequencing methods)^{113,114}, which may explain unexplained linkage findings as in Chapter 2 but also may elucidate causal variants in GWAS.

One of the several challenges in AD research is to assess the functional impact of known genetic variants with small effect sizes on the molecular pathways implicated in AD pathophysiology^{115,116}. Future research should expand beyond the highly researched amyloid hypothesis. Pathway-specific genetic risk scores, as developed in Chapter 3.1, open opportunities to evaluate the pathway-specific genetic risk score interaction with lifestyle factors such as education, alcohol intake, physical activity in longitudinal cohorts, which would help to identify the relevant pathways interacting with lifestyle factors in AD risk. It is of note that prior biological pathway information, which was used in our study, was based on the integration of gene expression data with available AD GWAS information published in 2013^{16,117}. A new pathway enrichment analysis based on a larger GWAS has expanded pathways including amyloid precursor protein metabolism and tau binding protein pathways that were not included in the analysis of Chapter 3.1¹⁷, which warrants the need for a new evaluation. GWAS based on Haplotype Reference Consortium (HRC) and TOPMed imputation panels such as European Alzheimer's Disease DNA BioBank (EADB) is uncovering more insight into biological pathways implicated in AD. Complex systems biology approaches to integrate multi-omics layers with genetic risk variants of AD would lead to more complex molecular pathways relevant to AD and may help to identify disease targets for drug research.

In this thesis, we identified the role of lysophosphatidic acids (LPAs) in AD pathophysiology. LPAs are bioactive signaling phospholipids whose receptors are highly expressed on astrocytes, and also on neurons¹¹⁸. LPAs are known to be involved in neuronal cell survival and outgrowth^{119,120}, but there is a need to explore their precise molecular mechanism in AD pathophysiology. One way to unravel their mechanism of action is through using the multi-omics approach in neuronal and astrocyte cell cultures and their co-cultures to identify the influence of LPAs on cell metabolism, expression of the gene, and various proteins involved in AD pathogenesis.

Metabolomics and proteomics of preclinical and predementia stages of AD have provided useful insight into the molecular mechanism of AD and yielded biomarkers of disease risk and progression (A β 42/40, p-tau, and total-tau). However, since metabolomics and proteomics are more sensitive to deviation in analysis approaches, there is a need to harmonize and standardize the global efforts to address study power issues¹²¹. Variability in study design, selection, storage and processing of samples, instrumental analysis, data analysis and most importantly, the inclusion of potential confounders such as medication use can lead to inconsistent and conflicting results¹²². Future research should focus on standardizing workflow in large metabolomics investigations in order to improve the generalizability of findings and their ultimate use in clinical diagnosis¹²³. Moreover, metabolomics studies in AD and dementia should be extended and focus on the interactions between the metabolome and proteomics with sex, lifestyle, and genetic risk factors. Variation in AD risk across genetic risk strata¹²⁴ may also be explained by variation in circulating metabolites. Thus, efforts should focus on integrated genetic and metabolomics information to identifying personalized signatures (unique metabolic fingerprint) of disease. There are growing

opportunities to incorporate advance machine learning and network analysis approach in large studies to address the challenges of data integration, which will improve the discovery of biomarkers of early disease assessment, allow patient stratification and lead to discovery of novel drug targets.

Conclusions

In the thesis, I study genetics, metabolomics, and proteomics to elucidate the pathophysiology of AD and the interaction of lifestyle factors with genetics, which determine the risk of AD. The research described in this thesis contributes to our understanding of the pathophysiology and molecular mechanism of AD in the prodromal and predementia phase of AD. In particular, the findings in the area of the gut-liver-brain axis may shed new light on potential new modifiable risk factors in AD.

References

1. Ott, J., Wang, J. & Leal, S.M. Genetic linkage analysis in the age of whole-genome sequencing. *Nat Rev Genet* **16**, 275-84 (2015).
2. Liu, F. *et al.* A genomewide screen for late-onset Alzheimer disease in a genetically isolated Dutch population. *The American Journal of Human Genetics* **81**, 17-31 (2007).
3. Zeggini, E. Using genetically isolated populations to understand the genomic basis of disease. *Genome Medicine* **6**, 83 (2014).
4. Thal, D.R., Rüb, U., Orantes, M. & Braak, H. Phases of A β -deposition in the human brain and its relevance for the development of AD. *Neurology* **58**, 1791-1800 (2002).
5. Seong, E., Yuan, L. & Arikath, J. Cadherins and catenins in dendrite and synapse morphogenesis. *Cell adhesion & migration* **9**, 202-213 (2015).
6. Peters, F. *et al.* The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study. *Brain* **132**, 1833-46 (2009).
7. Sullivan, E.V., Corkin, S. & Growdon, J.H. Verbal and nonverbal short-term memory in patients with Alzheimer's disease and in healthy elderly subjects. *Developmental Neuropsychology* **2**, 387-400 (1986).
8. Peters, F. *et al.* The neural correlates of verbal short-term memory in Alzheimer's disease: an fMRI study. *Brain* **132**, 1833-1846 (2009).
9. Wang, K. *et al.* Common genetic variants on 5p14.1 associate with autism spectrum disorders. *Nature* **459**, 528-33 (2009).
10. Singh, S.M., Castellani, C. & O'Reilly, R. Autism meets schizophrenia via cadherin pathway. *Schizophr Res* **116**, 293-4 (2010).
11. Deming, Y. *et al.* Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers. *Acta Neuropathol* **133**, 839-856 (2017).
12. Davies, G. *et al.* Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun* **9**, 2098 (2018).
13. Kichaev, G. *et al.* Leveraging Polygenic Functional Enrichment to Improve GWAS Power. *Am J Hum Genet* **104**, 65-75 (2019).
14. Lee, J.J. *et al.* Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet* **50**, 1112-1121 (2018).
15. Savage, J.E. *et al.* Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. *Nat Genet* **50**, 912-919 (2018).
16. International Genomics of Alzheimer's Disease, C. Convergent genetic and expression data implicate immunity in Alzheimer's disease. *Alzheimers Dement* **11**, 658-71 (2015).
17. Kunkle, B.W. *et al.* Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet* **51**, 414-430 (2019).
18. Funderburk, S.F., Marcellino, B.K. & Yue, Z. Cell "self-eating" (autophagy) mechanism in Alzheimer's disease. *Mt Sinai J Med* **77**, 59-68 (2010).

19. Ginsberg, S.D. *et al.* Upregulation of select rab GTPases in cholinergic basal forebrain neurons in mild cognitive impairment and Alzheimer's disease. *J Chem Neuroanat* **42**, 102-10 (2011).
20. Cataldo, A.M. *et al.* Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. *Am J Pathol* **157**, 277-86 (2000).
21. Vance, J.E., Campenot, R.B. & Vance, D.E. The synthesis and transport of lipids for axonal growth and nerve regeneration. *Biochim Biophys Acta* **1486**, 84-96 (2000).
22. Maxfield, F.R. Role of endosomes and lysosomes in human disease. *Cold Spring Harb Perspect Biol* **6**, a016931 (2014).
23. Woodruff, G. *et al.* Defective Transcytosis of APP and Lipoproteins in Human iPSC-Derived Neurons with Familial Alzheimer's Disease Mutations. *Cell Reports* **17**, 759-773 (2016).
24. Baig, S. *et al.* Distribution and expression of picalm in Alzheimer disease. *J Neuropathol Exp Neurol* **69**, 1071-7 (2010).
25. Zlokovic, B.V. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. *Nat Rev Neurosci* **12**, 723-38 (2011).
26. Braskie, M.N. *et al.* Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. *J Neurosci* **31**, 6764-70 (2011).
27. Leclerc, B. & Abulrob, A. Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. *ScientificWorldJournal* **2013**, 589308 (2013).
28. Lourida, I. *et al.* Association of lifestyle and genetic risk with incidence of dementia. *Jama* **322**, 430-437 (2019).
29. Fannon, A.M. & Colman, D.R. A model for central synaptic junctional complex formation based on the differential adhesive specificities of the cadherins. *Neuron* **17**, 423-34 (1996).
30. Obst-Pernberg, K. & Redies, C. Cadherins and synaptic specificity. *J Neurosci Res* **58**, 130-8 (1999).
31. Yamagata, M., Duan, X. & Sanes, J.R. Cadherins Interact With Synaptic Organizers to Promote Synaptic Differentiation. *Front Mol Neurosci* **11**, 142 (2018).
32. Arikath, J. & Reichardt, L.F. Cadherins and catenins at synapses: roles in synaptogenesis and synaptic plasticity. *Trends Neurosci* **31**, 487-94 (2008).
33. Sancisi, V. *et al.* Cadherin 6 is a new RUNX2 target in TGF-beta signalling pathway. *PLoS One* **8**, e75489 (2013).
34. Clay, M.R. & Halloran, M.C. Cadherin 6 promotes neural crest cell detachment via F-actin regulation and influences active Rho distribution during epithelial-to-mesenchymal transition. *Development* **141**, 2506-15 (2014).
35. Montagne, A. *et al.* Blood-brain barrier breakdown in the aging human hippocampus. *Neuron* **85**, 296-302 (2015).
36. Sutphen, C.L. *et al.* Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. *Alzheimers Dement* **14**, 869-879 (2018).
37. Hesse, C. *et al.* Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. *Neuroscience letters* **297**, 187-190 (2001).


38. Chen, F. *et al.* Role for glyoxalase I in Alzheimer's disease. *Proc Natl Acad Sci U S A* **101**, 7687-92 (2004).
39. Thornalley, P.J. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. *Biochem J* **269**, 1-11 (1990).
40. Xu, Y. & Chen, X. Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family. *J Biol Chem* **281**, 26702-13 (2006).
41. Desai, K.M. *et al.* Oxidative stress and aging: is methylglyoxal the hidden enemy? *Can J Physiol Pharmacol* **88**, 273-84 (2010).
42. Takeuchi, M. *et al.* Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. *Curr Alzheimer Res* **1**, 39-46 (2004).
43. Ko, S.Y., Lin, Y.P., Lin, Y.S. & Chang, S.S. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species. *Free Radic Biol Med* **49**, 474-80 (2010).
44. Wang, J.Z., Wang, Z.H. & Tian, Q. Tau hyperphosphorylation induces apoptotic escape and triggers neurodegeneration in Alzheimer's disease. *Neurosci Bull* **30**, 359-66 (2014).
45. Shea, T.B., Rogers, E., Ashline, D., Ortiz, D. & Sheu, M.S. Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. *Free Radic Biol Med* **33**, 1115-20 (2002).
46. Baldeiras, I. *et al.* Peripheral oxidative damage in mild cognitive impairment and mild Alzheimer's disease. *J Alzheimers Dis* **15**, 117-28 (2008).
47. Guidi, I. *et al.* Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. *Neurobiol Aging* **27**, 262-9 (2006).
48. Schilling, T., Stock, C., Schwab, A. & Eder, C. Functional importance of Ca²⁺-activated K⁺ channels for lysophosphatidic acid-induced microglial migration. *European Journal of Neuroscience* **19**, 1469-1474 (2004).
49. Anliker, B. *et al.* Lysophosphatidic acid (LPA) and its receptor, LPA1, influence embryonic schwann cell migration, myelination, and cell-to-axon segregation. *Glia* **61**, 2009-2022 (2013).
50. Armati, P.J. & Mathey, E.K. An update on Schwann cell biology—immunomodulation, neural regulation and other surprises. *Journal of the neurological sciences* **333**, 68-72 (2013).
51. Yukiura, H. *et al.* Autotaxin regulates vascular development via multiple lysophosphatidic acid (LPA) receptors in zebrafish. *Journal of Biological Chemistry* **286**, 43972-43983 (2011).
52. Shi, J., Dong, Y., Cui, M.-Z. & Xu, X. Lysophosphatidic acid induces increased BACE1 expression and A β formation. *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* **1832**, 29-38 (2013).
53. Walsh, D., Klyubin, I., Fadeeva, J., Rowan, M. & Selkoe, D. Amyloid- β oligomers: their production, toxicity and therapeutic inhibition. (Portland Press Limited, 2002).
54. Hardy, J. & Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *science* **297**, 353-356 (2002).
55. Hampel, H. *et al.* Value of CSF β -amyloid 1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. *Molecular psychiatry* **9**, 705 (2004).

56. Wood, P.L., Tippireddy, S., Feriante, J. & Woltjer, R.L. Augmented frontal cortex diacylglycerol levels in Parkinson's disease and Lewy Body Disease. *PLoS one* **13**, e0191815 (2018).
57. Giambattistelli, F. *et al.* Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. *Neurobiol Aging* **33**, 1633-41 (2012).
58. Sookoian, S. *et al.* Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level, 2. *The American journal of clinical nutrition* **103**, 422-434 (2016).
59. Kapogiannis, D. & Mattson, M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. *Lancet Neurol* **10**, 187-98 (2011).
60. Mosconi, L. *et al.* Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. *J Nucl Med* **47**, 1778-86 (2006).
61. Drzezga, A. *et al.* Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. *Eur J Nucl Med Mol Imaging* **30**, 1104-13 (2003).
62. Pietzner, M. *et al.* Hepatic steatosis associates with adverse molecular signatures in subjects without diabetes. *J Clin Endocrinol Metab* (2018).
63. Toledo, J.B. *et al.* Metabolic network failures in Alzheimer's disease: A biochemical road map. *Alzheimers Dement* **13**, 965-984 (2017).
64. Varma, V.R. *et al.* Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study. *PLoS Med* **15**, e1002482 (2018).
65. Kaddurah-Daouk, R. *et al.* Alterations in metabolic pathways and networks in mild cognitive impairment and early Alzheimer's disease. *Alzheimer's & Dementia: The Journal of the Alzheimer's Association* **9**, P571 (2013).
66. Kaddurah-Daouk, R. *et al.* Metabolomic changes in autopsy-confirmed Alzheimer's disease. *Alzheimers Dement* **7**, 309-17 (2011).
67. Botros, M. & Sikaris, K.A. The de ritis ratio: the test of time. *Clin Biochem Rev* **34**, 117-30 (2013).
68. Rui, L. Energy metabolism in the liver. *Compr Physiol* **4**, 177-97 (2014).
69. Francis, P.T. Glutamatergic systems in Alzheimer's disease. *Int J Geriatr Psychiatry* **18**, S15-21 (2003).
70. Kamada, Y. *et al.* Impact of plasma transaminase levels on the peripheral blood glutamate levels and memory functions in healthy subjects. *BBA Clin* **5**, 101-7 (2016).
71. Alfredsson, G., Wiesel, F.A. & Tylec, A. Relationships between glutamate and monoamine metabolites in cerebrospinal fluid and serum in healthy volunteers. *Biol Psychiatry* **23**, 689-97 (1988).
72. Wang, G. *et al.* Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. *J Proteome Res* **13**, 2649-58 (2014).
73. Hayasaka, S., Phan, K.L., Liberzon, I., Worsley, K.J. & Nichols, T.E. Nonstationary cluster-size inference with random field and permutation methods. *Neuroimage* **22**, 676-87 (2004).

74. Lowe, S.L., Bowen, D.M., Francis, P.T. & Neary, D. Ante mortem cerebral amino acid concentrations indicate selective degeneration of glutamate-enriched neurons in Alzheimer's disease. *Neuroscience* **38**, 571-7 (1990).
75. Fayed, N., Modrego, P.J., Rojas-Salinas, G. & Aguilar, K. Brain glutamate levels are decreased in Alzheimer's disease: a magnetic resonance spectroscopy study. *Am J Alzheimers Dis Other Demen* **26**, 450-6 (2011).
76. Procter, A.W. *et al.* Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer's disease. *J Neurochem* **50**, 790-802 (1988).
77. Kakiyama, G. *et al.* Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. *Journal of hepatology* **58**, 949-955 (2013).
78. Frimmer, M. & Ziegler, K. The transport of bile acids in liver cells. *Biochimica et Biophysica Acta (BBA)-Reviews on Biomembranes* **947**, 75-99 (1988).
79. Chiang, J.Y. Bile acid metabolism and signaling. *Compr Physiol* **3**, 1191-212 (2013).
80. Calkin, A.C. & Tontonoz, P. Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. *Nat Rev Mol Cell Biol* **13**, 213-224 (2012).
81. Schaap, F.G., Trauner, M. & Jansen, P.L.M. Bile acid receptors as targets for drug development. *Nat Rev Gastroenterol Hepatol* **11**, 55-67 (2014).
82. Martinez-Diez, M.C., Serrano, M.A., Monte, M.J. & Marin, J.J. Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. *Biochim Biophys Acta* **1500**, 153-60 (2000).
83. Ignacio Barrasa, J. *et al.* Deoxycholic and chenodeoxycholic bile acids induce apoptosis via oxidative stress in human colon adenocarcinoma cells. *Apoptosis* **16**, 1054-67 (2011).
84. Faubion, W.A. *et al.* Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas. *J Clin Invest* **103**, 137-45 (1999).
85. Perez, M.J. & Briz, O. Bile-acid-induced cell injury and protection. *World J Gastroenterol* **15**, 1677-89 (2009).
86. Sousa, T. *et al.* Deoxycholic acid modulates cell death signaling through changes in mitochondrial membrane properties. *Journal of Lipid Research* **56**, 2158-2171 (2015).
87. Quinn, M. *et al.* Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. *Digestive and Liver Disease* **46**, 527-534 (2014).
88. Higashi, T. *et al.* Unconjugated bile acids in rat brain: Analytical method based on LC/ESI-MS/MS with chemical derivatization and estimation of their origin by comparison to serum levels. *Steroids* **125**, 107-113 (2017).
89. Lalic-Popovic, M. *et al.* Deoxycholic Acid as a Modifier of the Permeation of Gliclazide through the Blood Brain Barrier of a Rat. *J Diabetes Res* **2013**, 598603 (2013).
90. Shin, S.Y. *et al.* An atlas of genetic influences on human blood metabolites. *Nat Genet* **46**, 543-550 (2014).
91. Hollingworth, P. *et al.* Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat Genet* **43**, 429-35 (2011).


92. Le Guennec, K. *et al.* ABCA7 rare variants and Alzheimer disease risk. *Neurology* **86**, 2134-7 (2016).
93. Hollingworth, P. *et al.* Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nature genetics* **43**, 429 (2011).
94. Le Guennec, K. *et al.* ABCA7 rare variants and Alzheimer disease risk. *Neurology* **86**, 2134-2137 (2016).
95. Satoh, K., Abe-Dohmae, S., Yokoyama, S., St George-Hyslop, P. & Fraser, P.E. ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer amyloid processing. *Journal of Biological Chemistry* **290**, 24152-24165 (2015).
96. Tripathi, A. *et al.* The gut-liver axis and the intersection with the microbiome. *Nat Rev Gastroenterol Hepatol* **15**, 397-411 (2018).
97. Vogt, N.M. *et al.* Gut microbiome alterations in Alzheimer's disease. *Scientific reports* **7**, 13537 (2017).
98. Harach, T. *et al.* Reduction of Alzheimer's disease beta-amyloid pathology in the absence of gut microbiota. *arXiv preprint arXiv:1509.02273* (2015).
99. Li, Z., Zhu, H., Zhang, L. & Qin, C. The intestinal microbiome and Alzheimer's disease: A review. *Animal models and experimental medicine* **1**, 180-188 (2018).
100. Scheperjans, F. *et al.* Gut microbiota are related to Parkinson's disease and clinical phenotype. *Mov Disord* **30**, 350-8 (2015).
101. Vojinovic, D. *et al.* Relationship between gut microbiota and circulating metabolites in population-based cohorts. *bioRxiv*, 617431 (2019).
102. Karch, C.M. & Goate, A.M. Alzheimer's disease risk genes and mechanisms of disease pathogenesis. *Biological psychiatry* **77**, 43-51 (2015).
103. Efthymiou, A.G. & Goate, A.M. Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. *Molecular neurodegeneration* **12**, 43 (2017).
104. MahmoudianDehkordi, S. *et al.* Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. *Alzheimers Dement* **15**, 76-92 (2019).
105. Fu, J. *et al.* The gut microbiome contributes to a substantial proportion of the variation in blood lipids. *Circulation research* **117**, 817-824 (2015).
106. Bis, J.C. *et al.* Whole exome sequencing study identifies novel rare and common Alzheimer's-associated variants involved in immune response and transcriptional regulation. *Molecular psychiatry*, 1 (2018).
107. Sims, R. *et al.* Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. *Nature genetics* **49**, 1373 (2017).
108. Guerreiro, R. *et al.* TREM2 variants in Alzheimer's disease. *N Engl J Med* **368**, 117-27 (2013).
109. Cruchaga, C. *et al.* Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. *Nature* **505**, 550-4 (2014).
110. Mantere, T., Kersten, S. & Hoischen, A. Long-Read Sequencing Emerging in Medical Genetics. *Front Genet* **10**, 426 (2019).

111. Watanabe, K., Taskesen, E., Van Bochoven, A. & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nature communications* **8**, 1826 (2017).
112. Watanabe, K. *et al.* A global overview of pleiotropy and genetic architecture in complex traits. *Nature genetics* **51**, 1339-1348 (2019).
113. Bertram, L. & Tanzi, R.E. Alzheimer disease risk genes: 29 and counting. *Nature Reviews Neurology* **15**, 191 (2019).
114. Zuk, O., Hechter, E., Sunyaev, S.R. & Lander, E.S. The mystery of missing heritability: Genetic interactions create phantom heritability. *Proceedings of the National Academy of Sciences* **109**, 1193-1198 (2012).
115. Katsumata, Y., Nelson, P.T., Estus, S., Fardo, D.W. & Initiative, A.s.D.N. Translating Alzheimer's disease-associated polymorphisms into functional candidates: a survey of IGAP genes and SNPs. *Neurobiology of aging* **74**, 135-146 (2019).
116. Rossin, E.J. *et al.* Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. *PLoS genetics* **7**, e1001273 (2011).
117. Lambert, J.C. *et al.* Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-8 (2013).
118. Mutoh, T., Rivera, R. & Chun, J. Insights into the pharmacological relevance of lysophospholipid receptors. *British journal of pharmacology* **165**, 829-844 (2012).
119. Spohr, T.C., Dezonne, R.S., Rehen, S.K. & Gomes, F.C. LPA-primed astrocytes induce axonal outgrowth of cortical progenitors by activating PKA signaling pathways and modulating extracellular matrix proteins. *Front Cell Neurosci* **8**, 296 (2014).
120. TC, E.S., Dezonne, R.S., Rehen, S.K. & Gomes, F.C. Astrocytes treated by lysophosphatidic acid induce axonal outgrowth of cortical progenitors through extracellular matrix protein and epidermal growth factor signaling pathway. *J Neurochem* **119**, 113-23 (2011).
121. Yi, L., Liu, W., Wang, Z., Ren, D. & Peng, W. Characterizing Alzheimer's disease through metabolomics and investigating anti-Alzheimer's disease effects of natural products. *Annals of the New York Academy of Sciences* **1398**, 130-141 (2017).
122. Jiang, Y. *et al.* Metabolomics in the development and progression of dementia: A systematic review. *Frontiers in Neuroscience* **13**, 343 (2019).
123. Lindon, J.C. *et al.* Summary recommendations for standardization and reporting of metabolic analyses. *Nature biotechnology* **23**, 833 (2005).
124. van der Lee, S.J. *et al.* The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *The Lancet Neurology* **17**, 434-444 (2018).



Chapter 7

Summary / Samenvatting



Summary

Alzheimer's disease (AD) is a complex neurodegenerative disorder that accounts for more than 70% of worldwide dementia cases. With no treatment available, the rising AD prevalence in aging populations is posing a serious economic and health challenge. Advances in multi-omics technology in recent decade enables us to disentangle the molecular mechanism underlying AD pathophysiology to guide drug and preventive treatment research. I used several layers of omics in highly characterized epidemiological cohorts to understand the pathophysiology, molecular mechanism and the risk of AD dementia.

Chapter 2 focused on identifying rare genetic variants in Erasmus Rucphen Family Study using linkage analysis and whole genome-sequencing approach under the Alzheimer's disease sequencing project (ADSP). Our study identified a genomic region 5p14.3 linked with AD. Functional bioinformatics analysis of the genetic variants in the AD linked region identified few rare genetic variants in *CDH18* and *CDH12* genes shared by the individuals contributing to the linkage signal at 5p14.3 regions.

Chapter 3 studied the role of AD implicated biological pathways in the prodromal phase of AD and the interaction of genetic risk factors with modifiable risk factors in AD. In Chapter 3.1, I identified the association of *endocytosis* pathway-based genetic risk score with mild cognitive impairment (MCI). Further, this study identified a relevance between the *immune response* and *clathrin/AP2 adaptor complex* pathways with white matter lesions at magnetic resonance imaging in predementia individuals. In Chapter 3.2, we studied the interaction of lifestyle factors with *APOE ε4* and polygenic risk score in the Rotterdam Study. We reported that the healthy lifestyle factors may lower the risk of dementia in individuals with low and intermediate genetic risk of dementia, while healthy lifestyle did not offset the dementia risk in high genetic risk group.

In Chapter 4, I studied the role of proteins and metabolites in AD risk and pathophysiology. Chapter 4.1, I studied the association of plasma levels of brain-related proteins with AD in overall sample and stratified by *APOE* genotype in the Rotterdam Study. I discovered the association of higher plasma levels of CDH6 and HAGH proteins with AD in *APOE ε4* carriers. The findings of this study were also replicated in the BioFINDER study. We further showed significant positive correlation between CDH6 protein levels and both phosphorylated tau and total tau in cerebrospinal fluid (CSF) in the Amsterdam Dementia Cohort. In Chapter 4.2, I studied the association of CSF and plasma levels of signaling lipids (lysophosphatidic acids (LPAs)) with CSF biomarkers of AD pathology including amyloid-beta 42, phosphorylated tau and total tau.

In Chapter 5, I studied the genetic and metabolic determinants of gut-liver-brain axis. In Chapter 5.1, we studied the association of liver function biomarkers with cognition, AD and imaging biomarkers of brain atrophy in The Alzheimer's Disease Neuroimaging Initiative (ADNI). In

this chapter, we identified that lower levels of alanine aminotransferase (ALT) enzyme and elevated liver enzyme ratio (aspartate aminotransferase (AST):ALT) were associated with AD and lower cognitive measure. Moreover, lower levels of ALT and increased ratio (AST:ALT) were associated with increased A β deposition, and reduced brain glucose metabolism and atrophy. In the next Chapter 5.2, we showed significant association of lower levels of primary bile acids (cholic acid) and increased levels of secondary bile acids (deoxycholic acid and its glycine and taurine conjugates) with AD while lower levels of cholic acid also showed association with faster progression from MCI to AD. In the next step (Chapter 5.3), I further investigated the association of AD-associated genetic variants with the abundance of gut microbiota and integrated the identified microbiota with metabolomics. I identified association of risk allele of a genetic variant of *ABCA7* gene with lower abundance of phylum Firmicutes, class Clostridia, order Clostridiales and, higher abundance of order Enterobacteriales and family Enterobacteriaceae.

Samenvatting

De ziekte van Alzheimer is een complexe neurodegeneratieve aandoening, meer dan 70% van alle wereldwijde gevallen van dementie betreft de ziekte van Alzheimer. Omdat er geen behandeling beschikbaar is, vormt de stijgende prevalentie van de ziekte van Alzheimer in de steeds ouder wordende populatie een ernstige economische- en gezondheidsuitdaging. Vooruitgang in multi-omics-technologie in het afgelopen decennium stelt ons in staat om het moleculaire mechanisme achter de pathofysiologie van de ziekte van Alzheimer te ontrafelen om onderzoek naar geneesmiddelen en preventieve behandelingen te begeleiden. Ik gebruikte verschillende lagen omics in zeer gekarakteriseerde epidemiologische cohorten om de pathofysiologie, het moleculaire mechanisme en het risico op ziekte van Alzheimer te begrijpen.


Hoofdstuk 2 richtte zich op het ontdekken van zeldzame genetische varianten in de Erasmus Rucphen Familie Studie met behulp van linkage-analyse en een whole genom-sequencing-aanpak in het kader van het Alzheimer's disease sequencing project (ADSP). Onze studie ontdekte een genomisch gebied, 5p14.3, gekoppeld aan de ziekte van Alzheimer. Met functionele bioinformatica-analyse van de genetische varianten in het ziekte van Alzheimer gekoppelde gebied, ontdekte we enkele zeldzame genetische varianten in *CDH18*- en *CDH12*-genen die worden gedeeld door de individuen die bijdragen aan het linkage signaal op 5p14.3-regio's.

Hoofdstuk 3 bestudeerde de rol van de bij de ziekte van Alzheimer betrokken biologische paden in de prodromale fase van de ziekte en de interactie van genetische risicofactoren met aanpasbare risicofactoren bij de ziekte van Alzheimer. In hoofdstuk 3.1 ontdekte ik de associatie van op endocytose pathway gebaseerde genetische risicoscore met milde cognitieve stoornis (MCI). Verder toonde deze studie een relevantie tussen de immuunrespons en clathrin/AP2-adaptor complexe paden met witte stoflaesies bij MRI-beeldvorming bij pre-dementie individuen. In

hoofdstuk 3.2 hebben we de interactie van leefstijlfactoren met *APOE* $\epsilon 4$ en polygene risicoscore onderzocht in de Rotterdam Studie. We hebben gevonden dat gezonde levensstijlfactoren het risico op dementie kunnen verlagen bij personen met een laag en gemiddeld genetisch risico op dementie, terwijl een gezonde levensstijl het dementierisico in de hoge genetische risicogroep niet compenseerde.


In hoofdstuk 4 heb ik de rol van eiwitten en metaboliëten op het risico op de ziekte van Alzheimer en pathofysiologie bestudeerd. In hoofdstuk 4.1 bestudeerde ik de associatie van plasmaconcentraties van hersen gerelateerde eiwitten met de ziekte van Alzheimer in het totale sample en gestratificeerd naar *APOE*-genotype in de Rotterdam Studie. Ik ontdekte de associatie van hogere plasmaspiegels van CDH6- en HAGA-eiwitten met de ziekte van Alzheimer in *APOE* $\epsilon 4$ -dragers. De bevindingen van deze studie werden ook gerepliceerd in de BioFINDER-studie. We toonden verder een significante positieve correlatie tussen CDH6-eiwitlevels en zowel gefosforyleerde tau als totale tau in hersenvocht (CSF) in het Amsterdam Dementia Cohort. In hoofdstuk 4.2 bestudeerde ik de associatie van CSF en plasmaspiegels van signaalipiden (lysofosfatidinezuren (LPA's)) met CSF biomarkers van ziekte van Alzheimer pathologie waaronder amyloïde beta-42, gefosforyleerde tau en totale tau.

In hoofdstuk 5 heb ik de genetische en metabole determinanten van de darm-lever-hersenen as bestudeerd. In hoofdstuk 5.1 bestudeerden we de associatie van biomarkers van leverfunctie met cognitie, ziekte van Alzheimer en beeldvormende biomarkers van hersenatrofie in The Alzheimer's Disease Neuroimaging Initiative (ADNI). In dit hoofdstuk hebben we een rol vastgesteld dat lagere levels van alanine aminotransferase (ALAT)-enzym en verhoogde leverenzymverhouding (aspartaataminotransferase (ASAT): ALAT) met ziekte van Alzheimer en lagere cognitie. Bovendien werden lagere ALAT-waarden en een verhoogde ratio (ASAT: ALAT) geassocieerd met verhoogde $A\beta$ -afzetting en verminderd hersenglucosemetabolisme en atrofie. In de volgende studie, in hoofdstuk 5.2, toonden we een significante associatie tussen lagere levels van primaire galzuren en verhoogde levels van secundaire galzuren (deoxycholzuur en de glycine- en taurine-conjugaten) en de ziekte van Alzheimer. Terwijl lagere levels van galzuur ook geassocieerd waren met snellere progressie van MCI naar ziekte van Alzheimer. In de volgende stap (hoofdstuk 5.3) heb ik de associatie onderzocht van de ziekte van Alzheimer geassocieerde genetische varianten met de overvloed aan darmmicrobiota en ik heb de ontdekte microbiota geïntegreerd met metabolomics. Ik ontdekte een associatie van het risico-allel van een genetische variant van het *ABCA7*-gen met een lagere overvloed aan phylum Firmicutes, klasse Clostridia, orde Clostridiales en hogere overvloed aan orde Enterobacteriales en familie Enterobacteriaceae.



Chapter 8

Appendix



Chapter 8.2

PhD Portfolio

PhD Portfolio

Name PhD student:	Shahzad Ahmad
Erasmus MC department:	Epidemiology
Research school:	Netherlands Institute of Health Sciences (NIHES)
PhD Period:	August 2014 – September 2019
Promotor:	Prof. C.M. van Duijn
Co-promotor:	Dr. N. Amin

Education	Year	ECTS*
Master of Science in Health Sciences, Genetic epidemiology		
<i>Core Courses</i>		
Study Design	2016	4.3
Biostatistical Methods I: Basic Principles	2015	5.7
Biostatistical Methods II: Classical Regression Models	2015	4.3
Genetic-Epidemiologic Research Methods	2014	5.1
SNP's and Human Diseases	2014	1.4
<i>Advance short courses</i>		
Linux for Scientist	2014	0.6
Advances in Genome-Wide Association Studies	2015	1.4
Family-based Genetic Analysis	2015	1.4
Psychiatric Epidemiology	2015	1.1
Principals of Epidemiologic Data analysis	2015	0.7
An introduction to the next-generation sequencing data	2015	1.4
Courses for the quantitative Researchers	2017	1.4
<i>Erasmus Summer Programme</i>		
Principles of Research in Medicine	2014	0.7
Genome-Wide Association Analysis	2014	1.4
Principles of Genetic Epidemiology	2014	0.7
Genomics in Molecular Medicine	2014	1.4
Advances in Genomics Research	2015	0.4
Human Epigenomics	2017	0.7

Chapter 8

(Inter) National conferences, meetings and presentations	Year	ECTS*
AAIC, Los Angeles, USA – (poster)	2019	1.2
ADAPTED consortium meeting Madrid, Spain	2019	0.6
Co-STREAM consortium meeting Stockholm, Sweden – (oral)	2018	1
ADAPTED consortium meeting Seville, Spain – (oral)	2018	1.2
AAIC, Chicago, USA (oral, poster and a media talk)	2018	1.2
ADES meeting, Amsterdam, The Netherlands	2018	0.6
Society for CSF analysis and clinical neurochemistry meeting, Amsterdam, The Netherlands – (poster)	2018	0.9
ADAPTED consortium meeting, Edinburg, UK	2018	0.6
CHARGE consortium meeting, Rotterdam, The Netherlands – (oral)	2018	0.9
ADES and EADB meeting, Barcelona, Spain	2018	0.9
Health RI conference, Utrecht, The Netherlands (poster)	2017	0.9
Co-STREAM consortium meeting, Cambridge, UK (oral)	2017	1
AAIC, London, UK (poster)	2017	1.2
EABD meeting, Rotterdam, The Netherlands	2017	0.6
CHARGE consortium meeting, Charlottesville, USA	2016	0.9
AAIC, Toronto, Canada (oral)	2016	1.2
Co-STREAM consortium meeting, Rotterdam, The Netherlands	2015	0.6
EADB meeting, Lille, France	2015	0.6
Seminars and workshops		
Seminars at the Department of Epidemiology	2014-2019	3
Genetic epidemiology working group meetings	2014-2019	2
BBMRI-OMICS: Introduction and Hands on application, Leiden, The Netherlands	2017	0.6
Applying data science to accelerate precision medicine, Uppsala Sweden	2018	0.6
Teaching		
Genetic Analysis of Family-Based Studies (GE05) – Coordinator	2019	1.5
An Introduction to the analysis of the Next Generation Sequencing Data (GE13) -Lecturing	2017-2019	3
Genome-wide Association Analysis (ESP29) – Teaching Assistant	2015-2018	3
Principles of Genetic Epidemiology (ESP43) – Teaching Assistant	2017-2018	3
Supervising Master's thesis		
María Fernanda Vinueza Veloz, Topic: Genetic risk for Alzheimer's disease and child brain white-matter microstructure	2016-2017	3
Others		
Genetic Epidemiology biweekly working group meeting organization	2015-2018	3
Reviewing assignments		1
· Alzheimer's & Dementia: The Journal of the Alzheimer's Association		
· Neurobiology of Aging		

*ECTS (European Credit Transfer System) equals a workload of 28 hours

List of Publications

Ahmad S, Bannister C, van der Lee SJ, Vojinovic D, Adams HHH, Ramirez A, et al. Disentangling the biological pathways involved in early features of Alzheimer's disease in the Rotterdam Study. *Alzheimers Dement.* 2018;14(7):848-57.

Ahmad S, Milan MDC, Hansson O, Demirkan A, Agustin R, Saez ME, et al. CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in *APOE* epsilon4 carriers. *Sci Rep.* 2020;10(1):8233.

Nho K*, Kueider-Paisley A*, Ahmad S*, MahmoudianDehkordi S, Arnold M, Risacher SL, et al. Association of Altered Liver Enzymes With Alzheimer Disease Diagnosis, Cognition, Neuroimaging Measures, and Cerebrospinal Fluid Biomarkers. *JAMA Netw Open.* 2019;2(7):e197978.

Licher S, Ahmad S, Karamujic-Comic H, Voortman T, Leening MJG, Ikram MA, et al. Genetic predisposition, modifiable-risk-factor profile and long-term dementia risk in the general population. *Nat Med.* 2019;25(9):1364-9.

MahmoudianDehkordi S*, Arnold M*, Nho K*, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. *Alzheimers Dement.* 2019;15(1):76-92.

Karamujić-Čomić H, Ahmad S, Lysen TS, Heshmatollah A, Roshchupkin GV, Vernooij MW, et al. Prion protein codon 129 polymorphism in mild cognitive impairment and dementia: the Rotterdam Study. *Brain Communications.* 2020;2(1):fcaa030.

van der Spek A, Warner SC, Broer L, Nelson CP, Vojinovic D, Ahmad S, et al. Exome Sequencing Analysis Identifies Rare Variants in ATM and RPL8 That Are Associated With Shorter Telomere Length. *Front Genet.* 2020;11:337.

Vojinovic D, Brison N, Ahmad S, Noens I, Pappa I, Karssen LC, et al. Variants in TTC25 affect autistic trait in patients with autism spectrum disorder and general population. *Eur J Hum Genet.* 2017;25(8):982-7.

Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. *Nat Genet.* 2019;51(3):414-30.

Chapter 8

Rueda-Ochoa OL, Rojas LZ, Ahmad S, van Duijn CM, Ikram MA, Deckers JW, et al. Impact of cumulative SBP and serious adverse events on efficacy of intensive blood pressure treatment: a randomized clinical trial. *J Hypertens*. 2019;37(5):1058-69.

Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. *Alzheimers Dement*. 2019;15(2):232-44.

Colijn JM, den Hollander AI, Demirkan A, Cougnard-Gregoire A, Verzijden T, Kersten E, et al. Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia. *Ophthalmology*. 2019;126(3):393-406.

Vojinovic D, Adams HH, Jian X, Yang Q, Smith AV, Bis JC, et al. Genome-wide association study of 23,500 individuals identifies 7 loci associated with brain ventricular volume. *Nat Commun*. 2018;9(1):3945.

Bis JC, Jian X, Kunkle BW, Chen Y, Hamilton-Nelson KL, Bush WS, et al. Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. *Mol Psychiatry*. 2018.

Hofer E, Roshchupkin GV, Adams H, Knol M, Lin H, Li S, et al. Genetic Determinants of Cortical Structure (Thickness, Surface Area and Volumes) among Disease Free Adults in the CHARGE Consortium. *bioRxiv*. 2018:409649.

Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding variants in *PLCG2*, *ABI3*, and *TREM2* implicate microglial-mediated innate immunity in Alzheimer's disease. *Nat Genet*. 2017;49(9):1373-84.

Leeuw FA*, Karamujić-Čomić H*, Tijms B.M., Peeters CFW, Kester MI, Scheltens P, Ahmad S, et al. Circulating metabolites are associated with brain atrophy and white matter hyperintensities. (Accepted for publication in the *Journal of Alzheimer's and Dementia*)

Ahmad S, Rafael A. Nafikov Rafael A, Blue E, Navas Patrick A, Karamujić-Čomić H, et al. Variation in cadherin genes in the 5p14.3 genomic region is implicated in Alzheimer's disease in an extended ADSP pedigree. (Submitted for publication)

Ahmad S, Orellana A, Kohler I, Frölich L, Rojas I, Gil S, et al. Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease. (Under review for publication in *Alzheimer's research and Therapy*)

Ahmad S*, Karamujic-Comić H*, Radjabzadeh D*, Bonnechere B, Vojinovic D, Hankemier T, et al. The Alzheimer's disease genetic risk variant in ABCA7 is associated to the gut microbiome. (In preparation)

**shared first authors*

Chapter 8.3

About the author

Shahzad Ahmad was born on 3rd of February 1988 in Kasur, Pakistan. After completing his higher secondary school education from Government College Kot Radha Kishan, Kasur (2005), he started his bachelors in Microbiology at Government College University, Lahore, Pakistan. After finishing his bachelor studies, he started working in a pharmaceutical company as a microbiologist. In 2011, he received a foreign study scholarship from Punjab Education Endowment Fund Pakistan for master in Life Science Informatics from the Bonn-Aachen International Center for Information technology, Bonn, Germany. During his master studies in Germany, he performed an internship at the Leipzig institute for plant biochemistry. He carried out his master thesis research at the Department of Translational Oncology, German Cancer Research Center (DKFZ) Heidelberg, Germany, during 2013-2014. In the same years, he also worked as a student research assistant in the same department. In 2014, he started his doctoral degree in the department of Epidemiology under the supervision of Professor Cornelia M. Van Duijn. During his PhD, he was also enrolled in master in Health Sciences (Genetic Epidemiology) from the Netherlands Institute for Health Sciences, Rotterdam. During his Ph.D, he worked in international consortia, including the Alzheimer's disease sequencing project (ADSP), the Alzheimer's Disease Metabolomics Consortium (ADMC), the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) and the International Genomics of Alzheimer's Project (IGAP). He had presented his research work at multiple international conferences and meetings. In August 2019, he started working as a postdoctoral researcher at the Leiden Academic Centre for Drug Research (LACDR). Since April 2020, he moved back to Erasmus MC, Rotterdam and is working as a joint postdoctoral researcher in the department of Epidemiology, Erasmus MC, Rotterdam and the LACDR, Leiden.



